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Thesis Abstract  
 
Introduction. Keratoconus and related corneal ectatic disorders are conditions characterised 
by a misshapen cornea. Keratoconus is typically managed with corneal rigid gas permeable 
contact lenses (CRGPcl) and when these are unsuccessful patients may be fitted with the much 
larger scleral rigid gas permeable contact lenses (SRGPcl). It has been hypothesised that due 
to their superior performance, SRGPcl might be considered as the first option for management 
of keratoconus and the present research investigates this hypothesis. 
Purpose.  To assess the visual performance, vision related quality of life (Qol) and subjective 
perception of vision (SPV) and the subjective perception of comfort (SPC) in two contact lens 
types: CRGPcl and SRGPcl, in successful CRGPcl wearers with keratoconus (and related 
ectatic corneal disorders). 
Methods. Thirty-four successful CRGPcl wearers, with keratoconus or related disorders, 
participated in a crossover randomised control trial (RCT). This research was approved by the 
National Research Ethics Service (NRES) of London-Camden and King’s Cross as well as the 
research ethics committees of London South Bank University (LSBU) and the Institute of 
Optometry. Participants were randomised into two groups, group 1 (sequence AB) were fitted 
with new CRGPcl and after a washout period, in which habitual CRGPcl were worn, were 
fitted with and crossed-over to SRGPcl. Group 2 were first fitted with SRGPcl and after a 
washout period were fitted with and crossed-over to new CRGPcl (sequence BA). Data for 
experimental outcome measures were collected three times: first on recruitment in habitual 
CRGPcl, and once after each period in experimental CRGPcl and SRGPcl. The outcome 
measures were: The Early Treatment Diabetic Retinopathy (ETDRS) log of minimum angle of 
resolution (logMAR) best corrected visual acuity (BCVA); the VectorVision 1000E contrast 
sensitivity function (CSF), expressed in both numeric and log contrast sensitivity (logCS); the 
National Eye Institute Visual Function Questioannaire-25 (NEI-VFQ) to assess the visual Qol; 
and the reported SPV and SPC, recorded on a Likert-like scale from 1–10. The final measure 
was at the end of the second period, each participant selected the preferred lens type, out of the 
two experimental lenses, for future habitual use.  
Results. Thirty participants completed the trial, 13 in group 1 and 17 in group 2. 
Randomisation demographics revealed no significant differences between the two 
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randomised groups except in corneal pachymetry (thickness): group 1[Mean 423.2 (±45.1)], 
group 2 [Mean 462.8 (±44.7)] (p= 0.002).  
The SPC in the experimental lenses and the SPC in the experimental CRGPcl in participants 
who selected CRGPcl as the habitual lens for future use, were the only measures, which 
exhibited significant differences. The SPC was not-normally distributed in SRGPcl, 
[Median=9.0, IQR=2.0, Mean=8.85, (±1.10)] and normally distributed in CRGPcl 
[Mean=7.78, (±1.45), Median=8.0, IQR=2.0]. The intra-subject period differences in SPC 
between group 1 (Median=1.0) and group 2 (Median=-1.0), revealed significantly higher 
scores in SRGPcl (p=0.002), rejecting H0. The preferred habitual lens choice outcome was: 
14 participants (47%) chose SRGPcl and 16 (52%) chose CRGPcl. Higher SPC scores in the 
experimental CRGPcl, were found in participants who chose CRGPcl, (p=0.006) and 
(p=0.009) by independent samples t-test and Mann-Whitney U test respectively, rejecting H0. 
The only significant carryover effect was found in the logCS scores (p=0.019), no other 
outcome was found to have significant carryover or period effects.  
No other outcome was found to have significant differences between the two lens types, 
supporting H0, with respect to: the ETDRS logMAR BCVA, the CSF numeric and logCS, the 
specific logCS at 6 cycles per degree (CPD), the 12 domains of the NEI-VFQ, the specific 
ocular pain domain of the NEI-VFQ and the SPV.  
Conclusion. The research population exhibited significantly better comfort in SRGPcl 
compared with CRGPcl, as measured by the Levit Subjective Comfort Scale (LSCS). 
Furthermore, participants who chose to remain in CRGPcl had significantly higher LSCS 
scores in CRGPcl than those who chose SRGPcl. Successful CRGPcl wearers whose LSCS in 
CRGPcl is < 7 are likely to achieve better comfort / tolerance with SRGPcl. No significant 
differences were found in this research population between the two experimental lens types, in 
the visual outcomes of logMAR, logCS and SPV and no significant difference was found in 
the visual Qol outcomes in the 12 domains of the NIE-VFQ. This research indicates that on 
average, successful CRGPcl wearers find SRGPcl more comfortable and there should be no 
visual and visual Qol advantage or disadvantage in refitting successful keratoconic CRGPcl 
wearers with SRGPcl and vice versa.  
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Research purpose statement 
 
The purpose of this research was to determine whether significant differences in a number of 
outcome measures could be established, when comparing the performance of CRGPcl versus 
the performance of SRGPcl in participants with keratoconus, who are successfully managed 
with habitual CRGPcl wear. It was hoped that the findings of this research may help to 
formulate the scope of application of SRGPcl in the management of keratoconus and other 
ectatic corneal disorders. 
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Chapter 1: Introduction 
 
Background overview 
 
The purpose of this chapter is to provide an overview for non-eye care professionals, of the 
structure of the anterior part of the eye and its optical properties. The cornea is the ocular (eye) 
tissue affected by corneal ectatic disorders such as keratoconus, the structure and function of 
the cornea will therefore be emphasised. This chapter also includes a summary of the main 
methods of assessing visual function and visual quality of life (Qol), both of which are highly 
relevant to the thesis. 
 
 
The structure and function of the human cornea and sclera 
 
 
Introduction 
 
The cornea and the sclera consist of dense connective tissue and form the outer shell of the 
eyeball (Figure 1.1). The cornea forms the transparent ocular ‘window’, which refracts* the 
light entering the eye [*refraction is the change in the direction and speed of a light when light 
passes from one medium such as air to another, such as a lens or an eye]. The corneal physical 
curvature and optical regularity* determine its optical properties, which vary between 
individuals, due to normal variation and / or disease [*optical regularity is a measure of the 
amount of physical and optical distortions present in the cornea]. The transition from the clear 
cornea to the opaque sclera, the limbus, contains a reservoir of corneal stem cells (Nishida and 
Saika, 2011).  
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The sclera is an opaque protective outer layer of the eye. Interwoven collagen fibres provide 
the mechanical strength of the cornea and sclera, protecting the inner eye from physical injury 
and maintaining ocular contour (Figure 1.1)  (Birk and Trelstad, 1984). The regular corneal 
collagen fibres facilitate corneal transparency, the lack of transparency of the sclera is due to 
the non-uniformity in the arrangement of its collagen fibres (Watson and Young, 2004). 
The cornea, covered by a thin layer of tear film is exposed to the environment, whereas the 
sclera is covered with the semi-transparent mucous membrane the conjunctiva and has no direct 
exposure to the environment. The conjunctiva is critical to maintaining the integrity of the eye, 
it protects the soft tissues of the eyelid and orbit and is the main site for the production of the 
mucous components of the tear film (Figure 1.2). Abnormalities of the conjunctiva may lead 
to restriction of ocular movement (loss of elasticity), deficiency of the tear film (deficient 
production of tear components), and decreased resistance to infection (deficient production of 
immune components), which also adversely affect the cornea (Nelson and Cameron, 2011). 
 
 
Figure 1.1 Major Ocular Structures + multilayer structure of the cornea 
https://www.flickr.com (licence type: all creative commons). 
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The cornea is approximately 500µm (0.5mm) thick and has a multilayer structure comprised 
of precisely arranged component layers (Figures 1.2), which interact with each other to 
maintain corneal function, transparency and structural integrity.  
These layers are (Nishida and Saika, 2011): 
1. Six layers of epithelial cells, to which the tear film complex is attached. 
2. The Basement membrane to which the epithelial cells are anchored.  
3. Thin collagen layer of the anterior stroma: Bowman’s layer. 
4. A thick central collagen fibrous structure called the substantia propria or stroma 
5.  Discovered in 2013, a tough, well-defined, acellular lining of 10μm-15μm between the 
corneal stroma and Descemet's membrane: Dua’s layer (Dua et al., 2013). 
6. A thin homogeneous elastic lamina called Descemet’s membrane  
7. A single, non-regenerating layer of endothelial cells forming part of the lining membrane    
of the anterior chamber of the eye (Nishida and Saika, 2011). 
 
 
Figure 1.2. The anterior Cornea: tear film, epithelium and epithelial basement membrane 
(https://www.researchgate.net). 
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Tear film 
 
The tear film is a complex composite structure which is a mixture of components from multiple 
sources (Nishida and Saika, 2011), it consists of three layers: a superficial lipid layer 
approximately 0.1µm thick, an aqueous layer 7µm thick comprising 98% of the tear volume 
and a mucinous layer 0.02µm–0.05µm (Holly and Lemp, 1977). Normal tear volume and 
production rates are about 6µL and 1.2µL / minute respectively, with a turnover rate of about 
16% per minute (Mishima et al., 1966). The base of the tear film is in contact with the outer 
surface membrane of the corneal and conjunctival epithelial cells, which incorporates elaborate 
folds and filaments, which increase the corneal surface area of contact, aiding adherence with 
the tear film (Lemp and Beuerman, 2011).  
The tear film protects the cornea from dehydration, it acts as a lubricant, a source of nutrients 
and a source of regulatory factors required for corneal epithelial cell maintenance and repair. 
Optimal physiology and immunology are maintained by biologically important ions and 
molecules, including electrolytes, glucose, immunoglobulins, lactoferrin, lysozyme, albumin, 
and oxygen as well as a wide range of active substances such as histamine, prostaglandins, 
growth factors, and cytokines (Nishida and Saika, 2011).  
Apart from lubrication, protection from disease and provision of nutrition to the cornea, the 
tear film is critical for the maintenance of the optical properties of the eye. The pre-corneal tear 
film stability between blinks allows clear vision; this limited stability is compromised in dry 
eye disease (DED), leading to optical image degradation between blinks (Goto et al., 2006). 
 
 
Corneal epithelium 
 
The corneal epithelium thickness is approximately 50µm. It forms an effective mechanical 
barrier and together with the cellular and chemical components of the conjunctiva and tear film, 
protects against potential pathological agents and microorganisms. The epithelial cells on the 
base layer of the cornea constantly divide to produce new cells. The superficial epithelial cells 
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differentiate and gradually emerge at the corneal surface. The differentiation process requires 
7-14 days to complete, after which the superficial cells are desquamated (shed) (Hanna et al., 
1961). Ultraviolet radiation, hypoxia [deprivation of oxygen] and mechanical stress induce 
apoptosis (cell death) and desquamation of corneal epithelial cells (Estil et al., 2000; Ma and 
Bazan, 2001; Esco et al., 2001). 
 
 
Corneal stroma 
 
The smooth surface of the cornea is essential for visual clarity. The regular arrangement of 
collagen fibres in the corneal stroma accounts for corneal transparency (Freegard, 1997). The 
size of and the distance between the collagen fibres in the corneal stroma are relatively 
homogeneous and are less than half of the wavelength of visible light (400–700nm). This 
anatomic arrangement generates a cancelling interference of scattered light rays allowing light 
to pass through the cornea (Maurice, 1984). If the diameter of or the distance between collagen 
fibres becomes heterogeneous, as in fibrosis (scarring), injury or oedema, incident rays are 
scattered randomly and the cornea loses its transparency (Nishida and Saika, 2011).  
 
 
Corneal endothelium 
 
The corneal endothelium contributes to the maintenance of corneal stromal transparency by the 
regulation of corneal hydration (Nishida and Saika, 2011). The healthy cornea is maintained at 
a relatively dehydrated state by the endothelial ion-pump, which maintains corneal 
transparency (Schmedt et al., 2012). Impaired endothelial function due to disease process or 
physiological endothelial insult may allow water to accumulate in the cornea causing corneal 
oedema and impair its transparency (Schmedt et al., 2012). 
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Innervation 
 
Tissue sensory innervation is required for pain sensation as well as for tissue repair. Most of 
the sensory nerves in the cornea are derived from the ciliary nerves of the ophthalmic branch 
of the trigeminal nerve (cranial nerve V). The density of nerve endings in the cornea is about 
300-400 times greater than that in the skin (Muller et al., 2003). It is one of the most innervated 
and therefore most sensitive tissues in the body.  
Damage or loss of the corneal epithelium results in severe ocular pain due to exposure of the 
nerve endings. Two of the 5th nerve branches, short and long posterior ciliary nerves, penetrate 
the sclera and provide fine sensory branches to the scleral stroma. Scleral innervation and 
sensitivity are significantly reduced compared to the cornea due to reduced tissue innervation.  
 
 
Wound healing 
 
Smooth corneal epithelium, transparent stroma, and a functioning endothelium are all essential 
for clear vision. Wound healing in the human body is generally initiated by the exit of blood 
constituents as a result of disruption of blood vessels. The mechanism of wound healing in the 
cornea is different since the cornea is avascular. The surface epithelial cells renew continuously 
to maintain the normal layered structure of the corneal epithelium. The existence of corneal 
epithelial stem cells at the limbus (Cotsarelis et al., 1989) and their importance for corneal 
epithelial homeostasis has been established (Secker and Daniels, 2008). Corneal injury which 
results in an epithelial defect is normally repaired by a rapid epithelial cell migration, 
proliferation, and differentiation, resulting in restoration of the stratified structure of the 
epithelium (Ljubimov and Saghizadeh, 2015). These processes are controlled and regulated by 
complex immune, neural, chemical and biological mechanisms and interactions (Ljubimov and 
Saghizadeh, 2015). 
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Vasculature 
 
The normal cornea does not contain blood vessels (Nishida and Saika, 2011). However, factors 
derived from the vascular arcade at the corneal limbus are important for corneal metabolism 
and wound healing (Ljubimov and Saghizadeh, 2015). In certain pathological conditions, and 
due to hypoxia during contact lens wear, new vessels may enter the corneal stroma from the 
limbus and result in a loss of corneal transparency (Cohen, 2011; Schmedt et al., 2012). In 
contrast to the cornea the sclera contains rich vasculature. 
 
 
Metabolism 
 
Corneal epithelial and endothelial cells require a supply of glucose and oxygen to maintain 
their normal, high metabolic functions (Aguayo et al., 1988). The cornea is supplied with 
glucose by diffusion from the internal aqueous humour (Nishida and Saika, 2011).  
Corneal oxygen supply is by diffusion from the tear fluid, which absorbs oxygen from the 
atmosphere. Disruption of the direct exposure of the tear film to the atmosphere interferes with 
oxygen supply to the cornea and may lead to corneal hypoxia and consequent stromal oedema 
(Schmedt et al., 2012). This may result, for example, from wearing of contact lenses made of 
materials with reduced gas permeability (Holden et al., 1985; Thoft and Friend, 1975).  
 
 
Corneal refractive properties 
 
The average adult human cornea measures 11-12mm horizontally and 9-11mm vertically. It is 
approximately 0.5mm thick at the centre, with gradually increasing thickness toward the 
periphery, where it is about 0.7mm thick (Mishima, 1968). The central 3mm optical zone of 
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the normal cornea is almost perfectly spherical with an average, radius of curvature of 7.5mm 
to 8.0mm. Normal corneal curvature has shortest (steepest) radius of curvature at the centre, 
which gradually increases (flattens) towards the periphery giving it a prolate elliptical shape 
(flattening ellipse). The optical properties of the cornea are determined by its transparency, 
surface regularity, shape, and refractive properties (Maurice, 1984).  
The total refractive power of the cornea is determined by the sum of refraction at the anterior 
and posterior interfaces. The central corneal refractive power averages +43.0 dioptres (DS)*, 
being the sum of the air–tear fluid interface (+44.0DS), tear fluid–cornea interface (+5.0DS) 
and cornea–aqueous humour interface (−6.0DS), the cornea contributes about 2/3 of the total 
refractive power of the eye (Nishida and Saika, 2011). [*Dioptre is a unit of refractive power, 
which is equal to the reciprocal of the focal length (in metres) of a given optical element such 
as a lens]. 
The maintenance of regular corneal shape and transparency are critical for the regular refraction 
of light and the formation of clear retinal image. The cornea may lose its transparency due to 
changes in the physical properties as discussed above. Changes in corneal contour caused either 
by pathological conditions such as scarring, thinning, refractive surgery or keratoconus may 
significantly disrupt corneal surface regularity and render the corneal surface irregularly 
astigmatic (Feder and Gan, 2011) (see below for explanation of astigmatism). 
 
 
The refractive status of the eye 
 
The refractive status of the eye refers to the position of an optical image generated by the 
refracting elements of the eye of an object positioned at an optical infinity [optical infinity is 
often taken to be a distance further than 4meters (0.25 dioptres)]. Ametropia is a term used to 
indicate that an imperfect refractive status is present as opposed to a perfect refractive status, 
emmetropia. In emmetropia the object of regard is imaged perfectly on the retina by the 
refractive elements of the eye. In emmetropic, hyperopic (long-sighted) and myopic (short-
sighted) eyes incident parallel rays of light are brought to focus upon the retina, behind the 
retina and in-front of the retina respectively. Astigmatism which means “lacking” a “point” is 
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a form of ametropia in which incident parallel rays of light are not brought into a single focus. 
Astigmatism may be classified as regular or irregular, with respect to the contributing ocular 
component, by orientation or with respect to the refractive error. In regular astigmatism the 
optical meridians having the maximum and minimum refractive powers are orthogonal. In 
irregular astigmatism the maximum and the minimum refractive power meridians are separated 
by an angle other than 90°. Irregular astigmatism is a hallmark of diseases such as keratoconus 
and occurs due to the irregular shape of the cornea (Rosenfeld, 2006). 
Corneal power is normally distributed in the population of normal eyes (Steiger, 1913; 
Stenstrom, 1948), the cornea reaches its adult power at around age 3yrs with only minor 
changes between aged 3-13yrs (Zadnik et al., 1993). Changes in corneal power contribute only 
to a portion of all refractive errors and variations in corneal curvature may play a significant 
role in the development of refractive error in a limited number of individuals (Rosenfeld, 2006). 
The refractive power of the crystalline lens (Figure 1.1) is 15-20DS, less than 50% of the 
corneal power, (Zadnik et al., 1993).  
The axial length (eye length from cornea to retina) and anterior chamber depth of the eye reach 
adult levels around age 15yrs and are considered to have the greatest effect on the refractive 
status of the eye. The excessive prevalence of emmetropia has led to the proposal of an active 
emmetropizing process, in which the growth of one or more ocular components compensate 
for the changes in the dimensions of other components (Rosenfeld, 2006). 
 
 
Visual acuity (VA) 
 
The assessment of visual function is an essential part of any research involved in the evaluation 
and comparison of various methods of correcting and managing disorders which cause visual 
disability such as keratoconus. Visual acuity is the most widely used measure of visual function 
both in optometric clinical practice and research (see chapter 4). Other important diagnostic 
measures of visual performance, such as colour perception and contrast sensitivity are used in 
research but less frequently in clinical practice. Visual acuity measurement is routinely used 
for the assessment of refractive error, ocular health screening, following the course of eye 
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disease, evaluating the effectiveness of refractive, medical and surgical treatments, prescribing 
aids for the visually impaired, and setting vision standards for employment and driving. The 
British Standards Institution has published standards of visual acuity for the UK (British 
Standards Institution., BS 4274-1:2003). 
Visual acuity expresses the resolution which detects the threshold size of a spot or a line against 
its background or the smallest angular size of the detail that can be resolved and recognised by 
the observer. Most clinical tests of visual acuity are based on the visual system’s ability to 
correctly recognise the smallest optotypes [figures or letters of different sizes used in testing 
visual acuity] (Bailey, 2006). 
The minimum angle of resolution (MAR) is typically expressed in minutes of arc and specifies 
the angular size of the critical detail within the just-resolvable optotype. For visual targets 
comprised of letters the critical detail is taken as 1/5 of the letter height (Figure 1.4b). The 
MAR of 1 minute of arc (1´) represents visual acuity of 6/6 (metric notation) or 20/20 (imperial 
notation). For a letter twice, the size of a 6/6 letter: 6/12 (20/40) the MAR is 2´. The MAR in 
minutes of arc is equal to the reciprocal of the metric or imperial decimal acuity value (Table 
1.1) (Bailey, 2006). The logarithm of MAR (logMAR) is a measure of visual acuity represented 
by the common logarithm of the MAR (Bailey and Lovie, 1976). For example, the logMAR of 
the MAR of 1´: Log101=0.00. The logMAR of 2´: log10 = 0.3. When the visual acuity score is 
better than 6/6 the logMAR value becomes negative, for example visual acuity of 6/4.8 in 
which the MAR=0.8´, the logMAR=- 0.1 (Table 1.1).                      
Until recently visual acuity was quite commonly scored in coarse, whole line steps when a 
criterion number of letters, e.g., 3 out of 5 letters in a line were identified correctly. 
Alternatively, the number of incorrectly identified letters would be designated by a negative 
sign e.g., 6/6-2, or a positive sign in front of the number of letters identified from the next line 
of optotypes, e.g., 6/6+2. Visual acuities are reported in what is known as the Snellen fraction, 
where the numerator indicates the test distance, and the denominator indicates the relative size 
of the letter, usually in terms of the distance at which the optotype width to be resolved would 
subtend a visual angle of 1´. Thus 20/40 or 6/12 indicate that the actual test distance was 20 
feet or 6m and that the strokes of the optotypes would subtend 1´ at 40 feet or 12 m, i.e. the 
size of the optotypes in this line is twice as large as in the 20/20 or the 6/6 line (Bailey, 2006).  
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Modern visual acuity chart design 
 
Bailey and Lovie (1976) improved the conventional Sloan (Sloan, 1959) visual acuity chart to 
include 5 letters per line, as opposed to 1-8 per row, with interline size progression of 0.1 log 
units and following it use in the ETDRS this chart became widely used (Ferris et al., 1982) 
(Figure 1.4a). The revised ETDRS 2000 series chart, better equates the letter recognition 
difficulty on all lines, and it is generally agreed that whilst gaining a role in clinical trials, its 
acceptance in the routine clinical use is limited (Shamir et al., 2016). 
  
 
 
Figure 1.4a. ETDRS LogMAR Optotype chart 
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Figure 1.4 b Snellen optotypes for visual acuity testing copied from https://www.flickr.com. 
 
Table 1.1. Visual Acuity Conversion Table 
Feet Metre Decimal LogMAR 
20/200 6/60 0.1 1 
20/160 6/48 0.125 0.9 
20/125 6/38 0.16 0.8 
20/100 6/30 0.2 0.7 
20/80 6/24 0.25 0.6 
20/63 6/19 0.32 0.5 
20/50 6/15 0.4 0.4 
20/40 6/12 0.5 0.3 
20/32 6/9.5 0.63 0.2 
20/25 6/7.5 0.8 0.1 
20/20 6/6 1 0 
20/16 6/4.8 1.25 −0.10 
20/12.5 6/3.8 1.6 −0.20 
20/10 6/3 2 −0.30 
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Visual acuity testing procedures  
 
The logarithmic progression of letter sizes in the ETDRS charts facilitates use at a variety of 
distances by the facility of accurate conversion of scores at different distances (VectorVision, 
2013). The standard test distance is 4 meters, with chart illumination standards vary from 100 
cd / m2 in the USA to 300 cd / m2 in Germany, in normal subjects a plateau in performance is 
reached at about 200 cd / m2 (Sheedy et al., 1984). 
It has been shown that criterion-dependent test procedures, in which patients decide when the 
letters become indistinguishable, lead to inaccurate and unreliable test results (Higgins et al., 
1984). Forced-choice procedures, which are criterion-free because the examiner, rather than 
the patient, determines whether the letter is correctly identified, are preferable (Ricci et al., 
1998). It has been shown that letter-by-letter scoring is more reproducible than line-by-line 
scoring (British Standards Institution., BS 4274-1:2003; Arditi and Cagenello, 1993).  
 
 
The physiological limits to visual acuity  
 
When the eye is in ideal focus a point object is imaged on the retina as a diffraction pattern, 
which is a small circular patch with faint surrounding rings called the Airy disc (Figure 1.5c 
top image). The limits to visual acuity are imposed by a combination of optical and neural 
factors (Bailey, 2006). The retinal image quality may be degraded by optical factors such as 
the various ametropias, which limit the resolution achieved by the visual system. Even with 
optimal refractive correction of ametropia, there still maybe image degradation as a result of 
chromatic (colour spectrum) optical aberrations, (as seen when light is refracted through a 
prism) (Figure 1.5a and b) and monochromatic (black and white) high order optical aberrations 
(HOA) degrade the retinal image (may be expressed by the point spread function, which is the 
appearance of a point of light due to a specific HOA distortion) (Figure 1.5c) (Thibos et al., 
2006).  
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Pupil size of the eye will also affect the retinal image quality, if the pupil is too small a 
diffraction pattern degrades the image formed, if too large increases the HOA, the ideal 
calculated pupil diameter for 1' resolution is 2.5mm (Bailey, 2006). Neural limitations relate to 
the anatomy and physiology of the retina and subsequent visual pathways. The calculated 
neural limit of resolution, is 0.82', which is similar in magnitude to the calculated optimal 
optical limit of resolution of 1' (Bailey, 2006). 
 
 
 
 
 
         
a.      b. 
Figure 1.5 a. Chromatic Aberrations visual spectrum, b. Chromatically aberrated reflected  
light https://www.flickr.com (licence type: all creative commons). 
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Figure 1.5 c. High Order Aberrations. Reprinted with permission from Optometric 
Management (http://www.optometricmanagement.com) 
                           
 
Contrast sensitivity (CS) 
 
Contrast sensitivity testing was originally developed as a research tool by vision scientists 
interested in characterizing normal visual function. Visual acuity measures the eye’s ability to 
resolve fine detail at 100% contrast; black optotypes on white background. In the real world, a 
range of contrasts present visual challenges, for example the challenge of seeing and 
recognising relatively large low-contrast objects such as faces, or important details in an 
environment affected by fog or glare (Figure 1.6d). Sine-wave grating stimuli are commonly 
used as visual targets in contrast sensitivity testing; these are patterns consisting of alternating 
light and dark bars, which have a sinusoidal luminance profile. The size variation in the sine-
wave gratings is generated by varying the spatial frequency of the grating bars by steps 
 
 
 
27 
 
measured by CPD (Sukha and Rubin, 2013). A CSF is derived by measuring the lowest 
detectable contrast across a range of spatial frequencies. A thorough assessment of contact 
sensitivity would involve establishing the minimum contrast that can be detected over a range 
of spatial frequencies (Elliott, 2006), (Figure 1.6a).  
Clinical CS testing provides a better understanding of the impact of visual impairment on visual 
function. Studies have shown that CS loss can lead to mobility problems and difficulty 
recognizing signs or faces even when adjusted for loss of acuity (Rubin et al., 2001; Rubin et 
al., 1994). Measuring both VA and CS as outcomes of a clinical trial may provide a more 
complete picture of the effects of treatment on the quality of vision than either measure alone 
(Rubin, 2013). CS tests in clinical use which employ sine-wave grating in a chart form include 
the Functional Acuity Contrast Test and the CSV-1000E.  
 
 
 
 
 
a.                                                                   b. 
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c.       d. 
Figure 1.6. a. CSF chart, with sine-wave grating. b. Sinusoidal grating pattern. c. CSF 
numeric scores curve. d. high and low contrast scene. With permission from VectorVision 
(http://www.vectorvision.com) 
 
The CSV-1000 CS test is a grating chart-based test, which has an internal illumination system. 
The chart presents 3, 6, 12, and 18 CPD spatial frequencies, with each row containing 17 
circular patches. CS levels in each row range from 0.70-2.08, 0.91-2.29, 0.61-1.99, and 0.17- 
1.55 logCS units for 3, 6, 12, and 18 CPD respectively (Table 1.2) (VectorVision, 2013). 
Contrast levels diminish in a logarithmic fashion. The CSV-1000 test was reported to be 
clinically reliable for monitoring visual changes in patients with glaucoma treated with beta-
blockers (Pomerance and Evans, 1994). 
The impact of the reduction in the quality of VA and CS depend on the task the individual is 
required to perform, which suggests that defining disability using a single threshold for VA or 
CS loss is arbitrary. Nevertheless, after many decades of acuity testing, a consensus has been 
reached, which states that a doubling of the MAR (increase of 0.3 logMAR or 15 ETDRS 
letters) represents significant loss in VA (Rubin et al., 2001). Data from large population-based 
studies suggest that a doubling of contrast threshold; reducing sensitivity by 0.30 logCS (Table 
1.2) has a comparable impact on task performance and Qol (Rubin et al., 2001; West et al., 
2002).  
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Table 1.2 Contrast Sensitivity Values for the CSV-1000E in Log Units 
Target No (reducing contrast) 
Row (CPD)  0 1 2 3 4 5 6   7 8 
A (3.0)  0.7 1 1.17 1.34 1.49 1.63 1.78 1.93 2.08 
B (6.0)  0.91 1.21 1.38 1.55 1.7 1.84 1.99 2.14 2.29 
C (12.0)  0.61 0.91 1.08 1.25 1.4 1.54 1.69 1.84 1.99 
D (18.0)  0.17 0.47 0.64 0.81 0.96 1.1 1.25 1.4 1.55 
 
 
When the VA scoring is performed letter by letter, Bailey et al., (1991) showed that for 
normally sighted subjects, a five letter change equivalent to a 0.10 logMAR difference, is 
sufficient evidence (95% confidence) that a significant change has occurred (Bailey et al., 
1991). The same difference of five letters in VA between the right and left eyes is considered 
clinically significant and requires further investigation to establish the cause for that difference 
(Brown and Yap, 1995). Most optometrist would recommend a change of glasses if a 0.10 
logMAR improvement is achieved compared with the habitual correction. 
 
 
Summary 
 
Chapter 1 has provided an overview of the structure and function of the eye with emphasis on 
important topics in this thesis: the cornea, sclera and the assessment of visual function. The 
next chapter is a review of keratoconus and other ectatic corneal disorders and their 
management with contact lenses. 
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Chapter 2: Literature review, keratoconus and its diagnosis and principles 
of management 
 
Methodology of literature search 
For chapters 2 and 3 the initial literature search was made for full articles in English, between 
Jan 1980 to February 2015 in PubMed employing the following terms: {Contact lenses} AND 
{keratoconus OR cornea ectasia} NOT {soft contact lenses} NOT {refractive surgery}, which 
yielded 326 articles. The purpose was to present a narrative review addressing the various 
aspects of corneal ectatic disorders with emphasis on keratoconus. In addition to these articles, 
appropriate, referenced textbooks in the fields of ophthalmology and optometry were referred 
to and where appropriate cited. Articles prior to 1980 that were identified in the reference list 
of publications found in the search were included if seminal work. In the PubMed search the 
command NOT excluded research which describes the use of soft contact lenses in keratoconus 
and research which describes iatrogenic keratoconus secondary to refractive surgery. 
In chapter 2 the literature from PubMed and referenced textbooks was used to present a 
narrative review of current knowledge of corneal ectatic disorders, with emphasis on 
keratoconus. The review includes definition, prevalence, incidence, demographics and 
aetiology of keratoconus and aspects of disease classification and diagnosis. Chapter 2 ends 
with a general outline of management and treatment of keratoconus.  
In chapter 3 the literature selection from PubMed and referenced textbooks is focused on 
contact lens management of keratoconus and related ectatic disorders. The research is selected 
to represent the current state of knowledge concerning contact lens management of 
keratoconus, concentrating on CRGPcl and SRGPcl. Research dealing with aspects of fitting 
methods and complications and morbidity associated with both lens types is critically appraised 
to highlight unresolved clinical questions and areas which require further research to improve 
the state of current knowledge and contact lens management of ectatic disorders. This chapter 
also includes research describing contact lens related outcomes such as visual acuity, contrast 
sensitivity, visual Qol and other objective and subjective measures important to contact lenses 
wearers.  
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Updated searches for newer relevant research were performed regularly and relevant new 
literature added. The searches were last updated in September 2018. 
 
 
Definition 
 
Keratoconus; conical cornea, is a clinical term used to describe a non-inflammatory ectatic 
corneal disorder, in which the cornea assumes a conical shape because of an inherent 
compromise in its structural integrity due to a naturally occurring, traumatic or iatrogenic 
corneal thinning and protrusion (Feder and Gan, 2011). It involves the central two thirds of the 
cornea with the apex [steepest and thinnest part of the cone] typically positioned inferiorly, 
infero-temporally, infero-nasally or centrally, although superior thinning has also been 
described (Weed et al., 2005), with mild to marked impairment of visual function (Feder and 
Gan, 2011) (Figure 2.1). The sclera in eyes with keratoconus remains normal, with no 
difference in thickness compared with healthy eyes (Schlatter et al., 2015). 
 
 
Figure 2.1. Keratoconus https://www.flickr.com all creative commons license 
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Keratoconus is the most common of a group of ectatic corneal disorders causing corneal 
irregularity, such as pellucid marginal degeneration (PMD), Terrien’s corneal marginal 
degeneration, keratoglobus and posterior keratoconus (Figures 2.2, 2.3, 2.4, Table 2.1). These 
conditions and corneal irregularity due to trauma or surgery generate a degraded retinal 
image due to induced HOA and therefore usually require optical management with specialty 
contact lenses (Feder and Gan, 2011). Eyes with keratoconus were shown to have 5.5 times 
more HOA than eyes with regular corneae (Pantanelli et al., 2007). In practice HOA in 
keratoconus result in reduced vision that, in moderate and severe cases, cannot be fully 
corrected with spectacles (Watts and Colby, 2017). 
 
     
   a. Keratoconus          b. PMD        c. Keratoglobus d. Posterior KC 
Fig 2.2 Cornea ectatic disorders (https://images.google.co.uk/) 
 
 
a.                                                         b. 
Figure 2.3 a. Keratoconus, side view, b. Keratoconus Munson’s sign 
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Table 2.1 Noninflammatory ectatic disorders – clinical presentation and appearance        
compared and contrasted (Feder and Gan, 2011). 
Condition  
Keratoconus 
(KC) 
Pellucid marginal 
degeneration (PMD) 
Keratoglobus 
Posterior 
keratoconus 
Features ↓         
Frequency 
Most 
common 
Less common Rare Least common 
Laterality 
Usually 
bilateral 
Bilateral Bilateral 
Usually 
unilateral 
Age at onset Puberty Age 20 to 40 years 
Usually at 
birth 
Birth 
Corneal 
thinning 
Inferior 
paracentral 
Inferior band 1-2 mm 
wide 
Greatest in 
periphery 
Paracentral 
posterior 
excavation 
Corneal 
protrusion 
Thinnest at 
apex 
Superior to band of 
thinning 
Generalized Usually none 
Iron line 
(Figure 
2.4c) 
Fleischer 
ring* 
Sometimes None Sometimes 
Scarring 
(Figure 
2.4a) Common Only after hydrops***  Mild Common 
Striae** 
(Figure 
2.4b) Common Sometimes Sometimes None 
 
 
     
  a.                                        b.                           c.                          d.  
Figure 2.4. a. Authors image, corneal scarring b. Vogt’s striae c.  Fleischer’s ring d. Stromal 
Scarring.  (https://images.google.co.uk/) 
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[*Fleischer's ring is not always found in keratoconus but when it is present it is pathognomonic 
of the condition and consists of a deposit of ferrous metal in the gutter created by the bulging 
protrusion of the cornea. It is a partial or complete annular line, commonly starts at the base 
of the cone. When identified, it provides a landmark for the peripheral edge of the cone. As the 
ectasia progresses, the ring tends to become more densely pigmented and narrower, and it may 
completely encircle the cone at its base. 
**Striae occur in the posterior stroma, just anterior to Descemet’s membrane. They disappear 
when intraocular pressure is raised, by exerting digital pressure on the globe. Striae are to be 
distinguished from the superficial linear scars, which may be seen in keratoconus at the corneal 
apex; scars do not disappear when pressure is applied. 
***Corneal Hydrops occurs in more advanced ectasiae, when aqueous humour penetrates into 
ruptures in Descemet’s membrane. This causes acute corneal oedema, which may persist for 
weeks or months, usually diminishing gradually. Eventually, it is replaced by scarring which 
in some cases may result in flattening of the cone].  
 
 
 
Prevalence, incidence, distribution and disease course 
 
Keratoconus occurs in all races with no clear gender predominance (Ramez et al., 2017). Due 
in part to varying diagnostic criteria the prevalence of keratoconus may vary significantly in 
different studies, on average from 50-200 per 100,000 (Feder and Gan, 2011). The prevalence 
of keratoconus exhibits significant demographic variations from the extremely low prevalence 
of 0.0003% in Russia to 2.3% in central India (Gorskova and Sevost'ianov, 1998; Jonas et al., 
2009). The role of ethnicity in the prevalence of keratoconus is demonstrated in the two survey 
reports from the United Kingdom; these indicate a 4.4–7.5 times greater prevalence of 
keratoconus in Asians (Indian, Pakistani and Bangladeshi) compared with Caucasians, 
suggesting a significant role of ethnicity (Georgiou et al., 2004; Pearson et al., 2000).  
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Ethnicity was also found to play an important role in the incidence of keratoconus, which 
exhibits a significant difference between the Asian: 25 per 100000 (1 in 4000) and white 3.3 
per 100000 (1 in 30000), per year respectively (p<0.001), with Asians presenting at 
significantly younger age (Georgiou et al., 2004). 
Unlike the displaced apex syndrome, where the off axis corneal apex appears like early 
keratoconus on corneal topography (Belin and Khachikian, 2011), keratoconus is a progressive 
disorder with an onset typically at puberty and a progression course of 10-20 years (Ramez et 
al., 2017). The rate of progression is variable and by the time it stops it may range from mild 
irregular astigmatism to severe protrusion, thinning and scarring, which may require 
keratoplasty (corneal transplant surgery) for restoration of reasonable vision (del Barrio et al., 
2017).  
 
 
Aetiology 
 
Heredity 
 
Heredity seems to play an important role in the aetiology of keratoconus as very high 
concordance is found in monozygotic twins (Edwards et al., 2001). Keratoconus prevalence of 
first-degree relatives was found to be 3.34% which is up to 68 times higher than in the general 
population (Wang et al., 2000). Gordon-Shaag et al., (2013) reported that in an Arab 
keratoconic population in Jerusalem, children of consanguineous parents had a fourfold risk of 
keratoconus compared with those of unrelated parents. Woodward (1981) found that 
keratoconus was maternally age related and was reflected in the social class (professional and 
intermediate class) of the patients attending the Moorfields contact lens clinic, were born at 
older maternal age compared with the general population (p<0.001) (Woodward, 1981). It is 
possible that some forms of keratoconus are under direct genetic control, other forms may 
require environmental stimuli to develop and progress (Gordon-Shaag et al., 2013).  
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Eye rubbing 
 
Despite the various associations with systemic disorders and ocular disease and the attempt of 
early theories to link the systemic and ocular disease associated with keratoconus, the aetiology 
of keratoconus remains unclear. Eye rubbing prevalence among keratoconus patients ranges 
from 66%-73% (Krachmer et al., 1984) and has been implicated as a causative and contributory 
factor in the development and progression of keratoconus (McMonnies, 2016; Gordon-
Shaag,Millodot,Kaiserman et al., 2015; Gasset et al., 1978; Rahi et al., 1977) by inducing a 
direct mechanical trauma and by increasing the protease tear film inflammatory mediators 
(Balasubramanian et al., 2013). The mechanical micro-trauma associated with eye rubbing may 
be the etiologic link between keratoconus and associated systemic and ocular diseases. Itching, 
ocular irritation, and eye rubbing are common features of vernal keratoconjunctivitis and atopic 
disease which are significantly more prevalent in keratoconus (Gasset et al., 1978). Vigorous 
eye rubbing is commonly observed in trisomy 21 (Down’s syndrome), which has a higher 
incidence of keratoconus and may explain the high incidence of associated corneal hydrops. 
Eye rubbing is also commonly seen in Leber’s tapeto-retinal degeneration and retinopathy of 
prematurity, both of which are associated with keratoconus (Feder and Gan, 2011). Regular 
repeated counselling against eye rubbing is indicated in patients with keratoconus and other 
corneal disorders to avoid corneal trauma associated with eye rubbing (McMonnies, 2016). 
 
 
Biomechanics 
 
The corneal biomechanics in keratoconus are thought to be abnormal; the keratoconic cornea 
is more fragile and has impaired capabilities to recover from chronic corneal epithelial trauma, 
which is considered a causative factor in the thinning of the corneal stroma and therefore 
associated with the pathogenesis and progression of keratoconus (Kim et al., 1999; Wojcik et 
al., 2014). Corneal thinning may be caused by weak stromal inter-lamellar attachments, which 
result in free lamellar sliding and the biomechanical instability of this tissue, which may be 
caused by the significant alterations in the orthogonal arrangement and the reduced number of 
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the collagen fibrils (Daxer and Fratzl, 1997). The reduced inter-lamellar collagen fibrils 
strength profile in the inferior compared with central stroma in the normal cornea, may explain 
the association of keratoconus with eye rubbing, which applies pressure gradient from top to 
bottom (Smolek and Beekhuis, 1997). 
 
 
Biochemistry 
 
Biochemical studies show that the total amount of corneal protein is decreased in keratoconus 
(Critchfield et al., 1988). The micro trauma caused to the keratoconic corneal epithelium by 
eye rubbing or interaction with the rigid surface of a contact lenses elevates the secretion levels 
of matrix metalloproteinase MMP-1 and MMP-13 (Mackiewicz et al., 2006) and inflammatory 
mediators such as IL-6 and TNF-𝛼 (Lema et al., 2009). The release of these factors by the 
corneal epithelium in response to the mechanical insult of eye rubbing or contact lens wear 
triggers an undesirable apoptosis of corneal stromal keratocytes and loss of stromal volume 
and may lead to scarring in individuals with heightened sensitivity to interleukin-1 such as 
occurs in keratoconus (Wilson et al., 1996). These processes suggest that keratoconus may 
have inflammatory aetiology. 
 
 
Pathology  
 
Every layer of the cornea may be involved in the pathologic process of keratoconus. 
Fragmentation of the Bowman's layer is an early change which leads to the progression of the 
disease and is specific to keratoconus (Sawaguchi et al., 1998). Z shaped interruptions, which 
are typical to keratoconus, are formed at the level of Bowman's layer allowing the corneal 
epithelium to grow backwards into the stroma and the stromal collagen to grow anteriorly into 
epithelium. The basal epithelium accumulates ferritin (iron) particles which eventually form 
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the Fleischer ring. The breaks in the Bowman’s layer are correlated to the clinically observed 
spaces within the thin stroma of the cone and are postulated to later fill with scar tissue and 
create the reticular branching opacities (Shapiro et al., 1986).  
Very early keratoconus may show small islands of corneal steepening, as keratoconus 
progresses, the conical area increases in size and decentration and may be classified into one 
of three shapes: nipple, oval (Perry et al., 1980) and globus (Feder and Gan, 2011) (Figure 2.5). 
Nipple cones typically display a central or infero-nasally decentred apex and are characterized 
by the presence of a 5mm steepened region surrounded by normal peripheral cornea. Oval 
cones, which are the most common, are larger than nipple cones. They are characterized by an 
inferior area of steepening with an infero-temporally displaced apex. In early stages of the 
disease superior cornea remains relatively normal. As the oval cone progresses, it proceeds in 
a radial fashion, with ectasia spreading into the temporal cornea, and in later stages it 
encompasses the superior cornea as well. Often a small island of normal cornea will persist in 
the superior nasal quadrant. Unlike nipple cones, oval cones show greater destruction of the 
underlying corneal layers (Perry et al., 1980). Globus cones are the largest in area and rarest of 
the three types. These cones generally involve at least 75% of the corneal surface (Robertson 
and Cavanagh, 2011). 
 
 
A. Nipple cone 
39 
 
 
B. Oval Cone 
 
 
C. Globus cone 
      
Figure 2.5. Corneal Topography of the 3 cone types, red indicates a steeper corneal 
curvature and blue flatter. 
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Diagnosis 
 
Presenting visual symptoms may range from a minor deterioration in vision to symptoms of 
considerable blur, photophobia [discomfort in bright light], glare, monocular diplopia [double 
vision] and ocular irritation (Feder and Gan, 2011). 
Age of presentation is typically during teens or twenties (Ramez et al., 2017). CS testing may 
uncover visual dysfunction before the more standard high contrast VA examination (Zadnik et 
al., 1987).  
Characteristic findings during slit lamp bio-microscopy examinations are prominent corneal 
nerves and fine parallel striae (Vogt’s striae) observed in the posterior stroma, anterior to 
Descemet's membrane, these striae disappear when gentle pressure is applied on the globe 
(Sherwin et al., 2017). Iron deposits at the base of the cone known as Fleischer ring, may be 
observed as incomplete initially, to complete rings at the demarcation of the base of the cone. 
As the disease progresses corneal thinning may be observed at the cone apex as well as 
superficial linear scars which result from ruptures in the Bowman's layer. In more advance 
keratoconus ruptures in Descemet's membrane create deeper opacities at the cone apex. 
Aqueous imbibition into the stroma through these defects in Descemet's membrane may cause 
corneal oedema (hydrops) also known as acute keratoconus, which may persist for weeks or 
months, eventually replaced by scar tissue (Feder and Gan, 2011). Intra-stromal cysts or clefts 
may occur as a result of corneal hydrops, which may lead to stromal neovascularisation 
(invasion of small blood vessels), which poses a higher risk of future corneal graft rejection 
(Parker et al., 2015).  
Corneal scarring due to keratoconus disease progression occurs in approximately 30% of eyes 
(Barr et al., 2000; Zadnik et al., 1998). Corneal scarring induces forward and backward scatter 
and absorption of light, which results in reduction of VA. Corneal scarring may occur as a 
natural disease progression in keratoconus or may be induced or accelerated by external factors 
such as CRGPcl flat fitting CRGPcl (Korb et al., 1982).  
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Keratometry and Topography 
 
The keratometer measures corneal curvature of the principal meridians only at a central 3-4mm, 
by superimposing fine images of projected mires (targets) reflected from the cornea. Inability 
to superimpose these images suggests irregular corneal astigmatism, a hallmark of keratoconus. 
There is no keratometric value beyond which the diagnosis of keratoconus is definite. 
Steepening of the inferior cornea compared to central cornea is typical in keratoconus and may 
be identified by keratometry (Feder and Gan, 2011).  
Corneal topographers were developed to enable accurate measurement of larger corneal surface 
area, originally introduced by Antonio Placido in 1880, consisted of circular, alternating black 
and white mire pattern, with a central aperture through which the clinician could view the 
reflected virtual image (Versaci and Vestri, 2017). Video capture of Placido disk images and 
the automatic detection of the mires facilitated calculation of corneal shape and power 
distribution, represented in modern topography with the color-coded contour maps introduced 
by Maguire and associates (Maguire et al., 1987). The ‘warmer’ colours represent higher 
dioptric powers and steeper curvatures, the ‘cooler’ colours represent the lower dioptric powers 
and flatter curvatures. Similar color-coded maps can be used to present changes in corneal 
elevation.  
The slit-based tomographers measure both the anterior and posterior corneal surface, which 
enables the measurement of corneal pachymetry (thickness), which greatly aids in the diagnosis 
of corneal ectasiae (Versaci and Vestri, 2017). Pachymetry measurements have become 
essential in the diagnosis of early keratoconus, grading disease severity and shown that the 
thinnest areas of the corneal stroma are generally infero-temporal to the line of sight (Ambrósio 
et al., 2017). 
The two topographical approaches in general use currently are the Placido disk or reflection-
based topographers, and the scanning slit-based tomographers. However, other methods to 
measure corneal shape have been developed and include scanning slit technology, raster 
stereography, scanning high-frequency ultrasound, holography, Fourier profilometry, and 
optical coherence tomography (OCT) (Martinez and Klyce, 2011; Versaci and Vestri, 2017; 
Cavas-Martínez et al., 2017).   
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  A.    B.       C.                            D.         
Figure 2.6. A Topographer with Placido rings B Rings reflected from cornea C color-coded 
contour map normal cornea. D color-coded contour map Keratoconus 
 
Computer-assisted corneal topographers have become an essential standard in the diagnosis of 
subclinical keratoconus and for tracking the progression of the disease (Wilson and Klyce, 
1991a; Duncan et al., 2016a). Various methods for the measurement and display of corneal 
topography have emerged. The original reflected Placido rings systems have evolved and are 
used in isolation or in conjunction with slit-scan systems; raster-stereography and scheimpflug 
photography in the analysis of corneal topography and keratoconus detection (Versaci and 
Vestri, 2017) (Fig 2.6). Corneae are radially asymmetric, aspheric, and may be irregular (Bogan 
et al., 1990). This is particularly true for corneae of patients who have corneal ectatic disorders 
(Martinez and Klyce, 2011). 
A number of statistical indices have been created from corneal topography data in order to 
derive corneal quantitative measurements, classification and screening algorithms, such as the 
simulated keratometry, which measure the power derived from the four points in the central 3–
4mm of the principal meridians and may be used for numerous tasks from diagnostics to contact 
lens fitting. Irregularity of the corneal topography over the pupil is represented with the Surface 
Regularity Index (SRI) (Wilson and Klyce, 1991b), which is correlated to potential visual 
acuity and is a measure of local fluctuations in central corneal power. It represents the regularity 
of the central corneal surface in front of the pupil; higher values suggest higher irregularity and 
a consequent reduction in visual acuity (Cavas-Martínez et al., 2017).  
Conversion of corneal topography to corneal wave-front may be used for the presentation and 
evaluation of corneal optics. Fourier transforms and Zernike polynomials are also quantitative 
descriptors of corneal surface optics and can be used to calculate the optical aberrations of the 
cornea (Figure 2.7) (Keller and van Saarloos, 1997; Oliveira et al., 2012). 
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Figure 2.7. Zernike Polynomials https://images.google.co.uk/ 
 
Other indices were developed to detect specific patterns seen in corneal ectatic conditions, and 
artificial intelligence techniques were used in the algorithms to recognize topographical 
appearances of keratoconus and other abnormal corneal conditions (Swartz et al., 2007; 
Duncan et al., 2016b; Lopes et al., 2016). 
 
 
Management and treatment of keratoconus 
 
When keratoconus is mild it may be successfully managed with spectacle and soft contact lens 
correction. If disease progression is detected, treatment to increase corneal rigidity, collagen 
cross-linking (CXL), may be considered to halt or slow the progression of keratoconus (Wittig-
Silva et al., 2008; Giacomin et al., 2016; O’Brart, 2017). CXL is achieved by corneal stromal 
saturation with riboflavin followed by irradiation with ultraviolet-A light, which induces cross-
links at the surface of collagen fibrils, with resultant overall increase in mechanical stiffness, 
which usually halts the progression keratoconus (Bao et al., 2017). 
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If spectacles and standard contact lenses fail to provide adequate visual function, specialist 
contact lenses are required to manage the visual disability caused by the corneal irregularity in 
keratoconus (Watts and Colby, 2017). Contact lens intolerance may result from epithelial 
breakdown over a sub-epithelial scar at the apex of the cone. This epithelial abnormality may 
be debrided by a special laser assisted procedure, phototherapeutic keratectomy and after the 
cornea has healed, contact lens wear may be resumed (Rapuano, 1997).  
Individuals with early to moderate keratoconus, without central scarring who are intolerant to 
contact lenses, may be candidates for intra-stromal ring segment (INTACS) insertion. This 
procedure flattens the central cornea when circular plastic implants are inserted into specially 
created tunnels in the peripheral corneal stroma aiming to reshape the cornea and reduce its 
irregularity (Alio et al., 2006; Kılıç et al., 2017). 
When stable and comfortable contact lens fit cannot be achieved or when contact lenses fail to 
provide adequate vision, surgical management may be considered. Keratoplasty (corneal 
transplantation) depend on the individual’s needs and the surgeon’s preferred technique. 
Traditionally full thickness corneal replacement, penetrating keratoplasty, which entails 
removing the entire thickness of the cornea and replacing with donor tissue, has been the 
surgery of choice (Bao et al., 2017). The partial removal and replacement of stromal tissue; 
lamellar keratoplasty may be considered for mild to moderate disease. A more recent 
alternative used is deep anterior lamellar keratoplasty, in which only the anterior corneal layers 
are removed and replaced with healthy donor tissue, leaving Descemet’s membrane and  
endothelium, with the advantage of preserving these tissues (Feder and Gan, 2011; del Barrio 
et al., 2017). 
 
Summary 
Chapter 2 outlines relevant aspects of corneal ectatic disorders, specifically keratoconus, the 
most commonly encountered corneal ectasia. The complex, multifactorial aetiology of 
keratoconus remains only partially understood, with inconclusive evidence regarding 
environmental and genetic influences. Recent research, which revealed evidence to 
overexpression of inflammatory mediators undermines the very definition of keratoconus as a 
non-inflammatory corneal disorder. The consensus regarding keratoconus is that it is a 
bilateral, progressive disorder, with highly variable prevalence and incidence, due in part to its 
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complex aetiology, but also the variability in diagnostic criteria. The significantly detrimental 
effect of keratoconus on the integrity of the retinal image and therefore on vision is universally 
accepted, and results from irregular astigmatism and high order aberrations and in many cases 
corneal scarring. The impact of keratoconus is exacerbated by young age at which the disease 
presents. When keratoconus progresses to levels which are not amenable to standard optical 
corrections with spectacles and soft contact lenses, the preferred mode of management is 
RGPcl, which neutralise the corneal irregularity and facilitate restoration of clear vision. 
Contact lens management of keratoconus will be discussed in the next chapter. 
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Chapter 3: Literature review: contact lenses in the management of 
keratoconus. 
 
 
In this chapter, key literature on the contact lens management of keratoconus and related 
disorders will be presented. Based on the literature presented, the rationale for the research 
described in successive chapters will be outlined. The methodology of literature search in this 
chapter is outlined in the section Methodology of literature search section at the beginning of 
chapter 2 page 30. 
 
 
 
Introduction 
 
Contact lenses have evolved since the 1900s when they were made from materials impervious 
to air such as glass or polymethylmethacrylate, to the modern highly gas permeable soft and 
rigid materials (Robertson and Cavanagh, 2011). Soft contact lenses became commercially 
available in 1965 and have improved considerably over the years, in design, manufacture, and 
material (e.g., improved oxygen permeability). 
Contact lenses are routinely used as the primary mode of vision correction and in 2007 were 
estimated to be used by 125million wearers worldwide (Key, 2007). They offer obvious 
cosmetic benefits and improvement in Qol (Plowright et al., 2015), compared with glasses 
(Ehsaei et al., 2011). Superior visual performance over spectacles is achieved by the 
elimination of the magnification effects, which degrade visual quality in individuals with high 
myopia / hyperopia, astigmatism or anisometropia [large difference in refractive error between 
the eyes] (Benjamin, 2006; Taylor Kulp et al., 2006). The well-centred optical zone of contact 
lenses, unlike the fixed optical zone of spectacles, moves with the eyes, providing improved 
optical alignment with the direction of gaze, thereby improving peripheral and binocular vision. 
For patients with uncorrected regular and irregular astigmatism, rigid lenses often provide 
superior to spectacle visual quality through the formation of an aqueous ‘lens’ in the post lens 
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tear film, which optically neutralizes regular and irregular corneal astigmatism (Robertson and 
Cavanagh, 2011; Watts and Colby, 2017). Modern contact lens designs can meet almost any 
individual optical requirement in both healthy and pathological eyes. These optical advantages 
of contact lenses may be offset in some cases by the contact lens interaction with the tear film, 
such as occur in ocular surface abnormalities associated with dry eyes and other tear film 
dysfunctions (Muntz et al., 2015). Other significant limitations of contact lenses are 
interruption of oxygen (O2) supply to the cornea, risk of infection and mechanical trauma.  
Contact lenses pose a barrier to natural corneal respiration since the cornea, which has no direct 
blood supply, relies on its contact with the atmosphere for supply of O2 and removal of carbon 
dioxide (CO2). The barrier that contact lenses pose to normal gas exchange between the cornea 
and the atmosphere was found to cause corneal warpage, vascularization, oedema, and 
susceptibility to infection (Robertson and Cavanagh, 2011). Contact lens materials have 
evolved continuously over the past several decades to improve O2 permeability, to maintain 
healthy corneal physiology.  
Contact lens material permeability to air is defined as Dk, where D is the diffusion coefficient 
of the material and k is the air solubility constant (Fatt, 1986). The O2 transmissibility of a 
specific lens is a measure of O2 permeability as a function of lens thickness, Dk/t (Fatt, 1986; 
Nicolson and Vogt, 2001). The higher the DK and the DK/t values the better the transmission 
of air through the contact lens matrix, leading to healthier the corneal physiology during contact 
lens wear (Fatt, 1996). 
Microbial keratitis is the most serious complication of contact lens use, and contact lenses are 
a major risk factor for corneal ulcers (Cohen, 2011). Corneal ulcers are usually caused by 
bacteria such as pseudomonas, other microorganisms such as fungi and amoeba may be 
involved in microbial keratitis in contact lens wearers.  
Mechanical corneal trauma from contact lenses such as corneal abrasion, can cause discomfort, 
compromise the physical barrier to resident and foreign microorganisms and can produce 
scarring that impairs visual function. Intensive antibiotic treatment may be required if the 
abrasion is associated with immune-mediated infiltrates because it may rapidly develop into a 
microbial keratitis (Cohen, 2011). In keratoconus mechanical trauma is associated with reduced 
contact lens tolerance, scarring and disease progression due to corneal scarring, which will be 
discussed in detail below. 
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Contact lens types 
 
Soft contact lenses  
 
Conventional soft, flexible lenses are composed of a HEMA (2-hydroxyethylmethacrylate) 
core polymer and a hydrophilic monomer which functions to absorb water. To reduce the rate 
of infection and other complications associated with contact lens wear, materials with better 
lens-cornea biocompatibility and oxygen transmissibility were developed to optimize corneal 
physiology during contact lens wear (Holden and Mertz, 1984).  
 
 
 
Corneal rigid gas permeable contact lenses (CRGPcl) 
 
In the early 1980s, newer Rigid Gas Permeable contact lens (RGPcl) materials and designs 
emerged replacing the original impermeable polymethylmethacrylate material. Compared with 
early soft contact lenses, CRGPcl offer significant physiological advantages as well as 
improved comfort and safety because they do not cover the entire corneal surface, feature high 
O2 permeability/transmissibility values and due to their mobility during blinks generate 
continuous tear exchange. Additional advantages of CRGPcl over soft lenses include increased 
durability, enhancement of visual acuity, due to neutralization of both regular and irregular 
corneal astigmatism (Benjamin, 2006) and a decrease in adverse reaction due to resistance to 
binding of tear film deposits and chemically preserved contact lens care solutions. Despite the 
advantages of RGP materials, the majority of contact lens wearers use soft lenses owing to 
greater comfort during adaptation (Morgan and Efron, 2006).  
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Scleral gas permeable contact lenses (SRGPcl) 
 
SRGPcl vault (bridge over) the cornea and limbus and are physically supported entirely by the 
conjunctival tissue overlying the sclera (van der Worp, 2015). The lack of widespread use of 
SRGPcl since their inception in the 1880s is attributable to limitations in corneal imaging 
systems, problems with contact lens manufacturing technology and products and skills required 
for fitting, cost and patient perceptions. The use of SRGPcl has recently increased due to 
availability of large-diameter RGP buttons, from which lenses are lathe cut, improvement in 
corneal and scleral contour assessment and computer-driven lathes, which are now able to 
accurately produce large-diameter lenses to precise specifications. The development of 
complex modern SRGPcl designs and availability of diagnostic fitting sets have recently 
facilitated a more widespread utilisation of these lenses (van der Worp et al., 2014). 
 
Contact lenses in corneal disease  
 
Common indications for therapeutic contact lenses include their use as a bandage to support 
and protect the cornea, manage pain, and aid in epithelial healing following abrasions or 
recurrent corneal erosions. Bandage contact lenses most commonly fitted are the soft highly 
O2 permeable, such as silicone hydrogel contact lenses, although large diameter CRGPcl and 
SRGPcl may occasionally be utilised in the rehabilitation of diseased ocular surface (Christie, 
1999).  
In eyes with keratoconus the visual distortions lead to significantly lower visual Qol scores 
compared to individuals with normal corneal health (Tatematsu-Ogawa et al., 2008; Aydin 
Kurna et al., 2014). Vision in eyes with keratoconus may be markedly improved by RGPcl, by 
the optical neutralisation of the corneal irregularity by the tear layer formed by the regular rigid 
contact lens surface (Benjamin, 2006). Due to the similarity in the refractive index of the cornea 
and the tear film under the RGPcl, 90% of the corneal irregularity is optically neutralised 
(Figure 3.1) (Szczotka-Flyn et al., 2006).  
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Figure 3.1. Neutralisation of corneal irregularity by tear film reservoir 
(https://images.google.co.uk/.) 
 
According to the Scleral lens education society, the classification of RGPcl is determined by 
the area of contact between the lens and the ocular surface (van der Worp, 2015). If a lens bears 
on the cornea only, it is called a CRGPcl (Figures 3.2. a, b). A lens which partly rests on the 
cornea and partly on the sclera is called a corneo-scleral lens. A lens which rests entirely on 
the sclera is classified as a SRGPcl (Figure 3.3) (van der Worp et al., 2014). Over the years a 
plethora of contact lens designs has emerged. 
 
 
 
Figure 3.2. CRGPcl on eyes with keratoconus 
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                                  Figure 3.3 SRGPcl on an eye with keratoconus 
The relatively smaller CRGPcl, which distribute their weight on the cornea, are currently 
considered the gold standard in the management of the visual disability caused by keratoconus 
(Robertson and Cavanagh, 2011). Until a few years ago SRGPcl were fitted by a handful of 
specialized contact lens practitioners around the world and manufactured by few manufacturers 
(van der Worp et al., 2014). Despite the recent resurgence in the use of SRGPcl, these lenses 
are used mainly for advanced disease, a problem solver in the more challenging cases, or where 
other contact lens management options fail. (Schornack, 2015; Visser et al., 2016). 
In the initial early stages of keratoconus spectacles and soft contact lenses may be sufficient to 
manage the ametropia. Corneae often become hypersensitive in the initial stages of the disease 
due to stretching of the corneal nerve fibres within the steepened corneal area, which may make 
adaptation to CRGPcl more difficult (Robertson and Cavanagh, 2011). 
Although soft contact lenses offer better initial comfort then CRGPcl, because of low modulus 
of elasticity soft contact lenses as a rule conform to the irregular corneal shape (Holden and 
Zantos, 1981) and therefore do not effectively neutralise the irregular astigmatism induced by 
keratoconus. Thicker than standard custom soft contact lenses are manufactured to reduce the 
cornea draping effect and similar to RGPcl generate a tear reservoir to neutralise the irregular 
corneal astigmatism. A study by Jinabhai et al. (2014) investigated the performance of such 
lenses in habitual CRGPcl wearers. They found that these soft lenses failed to match the 
superior visual performance achieved by the habitual CRGPcl (Jinabhai et al., 2014).  
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Management of keratoconus 
 
Contact lens types for the management of keratoconus are summarised in Table 3.1. CRGPcl 
are fitted directly onto the corneal surface to correct the corneal optical abnormalities, these 
lenses are relatively small and cover up to 80% of the corneal surface area, attached to it by 
surface tension forces. There is no standard fitting algorithm for every cornea with keratoconus, 
it is therefore imperative to employ a variety of lens designs to address individual cases. 
Although multiple CRGPcl designs are utilised in the management of keratoconus, there is to 
date a lack of high-quality evidence from controlled prospective clinical trials comparing the 
performance of different proprietary CRGPcl designs (Downie and Lindsay, 2015). 
Topographical assessment of corneal shape and curvature, revealing the shape, type, size and 
position of the cone, is an essential first step in CRGPcl fitting. Specialist designs of CRGPcl 
are available, such as the Rose-K design (Menicon USA, Clovis, CA), which was found to be 
successful for centrally positioned cones (Ozkurt et al., 2008). The Rose-K and other CRGPcl 
for keratoconus are designed with steeper than normal central lens curvature to fit the steep 
corneal cone, and flatter peripheral lens curvature to align the more normal corneal periphery 
and distribute the weight of the lens in that area, to avoid excessive mechanical pressure on the 
cone (Watts and Colby, 2017). These lenses are available in overall diameters of 7.9–10.2mm, 
with central curves ranging from 4.75mm (steep) to 8.0mm (relatively flat). Variable peripheral 
curves are designed for attaining the recommended peripheral corneal alignment and the 
desired lens edge lift of 0.8mm in order to facilitate good tear exchange. The newer Rose-K2 
lens design incorporates a posterior, central aspheric curve, for further optimisation of lens fit 
and vision and is advocated not only for centrally positioned nipple cones but also for oval 
cones (Romero-Jimenez et al., 2013). 
The stability of CRGPcl is affected by the lens cornea fitting relationship: eyelid forces (e.g., 
during blinking) and gravitational forces. These lenses therefore exhibit a level of inherent 
positional instability on the cornea, which is more pronounced when fitted to eyes with 
keratoconus. CRGPcl may display multidirectional movement, decentration, rotation, rocking, 
tilt and flexure, all of which may reduce comfort and cause retinal image degradation by 
inducing optical aberrations. Zadnik et al., (2000) reported in the Collaborative Longitudinal 
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Evaluation of Keratoconus (CLEK*) study, that CRGPcl fitted to unscarred keratoconic eyes 
achieved what is considered normal BCVA in only 34.6% of cases (Zadnik et al., 2000). 
*[The (CLEK) study is an eight-year, multi-centre, natural history study of 1,209 CRGPcl 
wearing patients with keratoconus who were examined annually for eight years. Its goals were 
to prospectively characterise changes in vision, corneal curvature, corneal status, and vision 
related Qol]. 
Large diameter RGPcl ranging from 10.4-12.0mm, the intra-limbal designs are also used in 
keratoconus fitting (Ozbek and Cohen, 2006). The resulting larger optic zone (circa 9.4 mm) 
may improve vision, especially in corneae with decentred cones, due to better lens centration 
(Watts and Colby, 2017). The drawbacks of these lenses relate to sub-optimal distribution of 
lens weight over the cone and peripheral cornea and more challenging lens handling. 
With advanced cones and significant irregular astigmatism, clinicians may not be able to 
achieve adequate lens centration and stability with CRGPcl, the semi-scleral and SRGPcl may 
be fitted. These lenses are designed to rest on the sclera and vault the entire cornea and limbus. 
The reduced lens movement and minimal lens edge interaction with the eyelids result in 
comfort similar to soft contact lenses (Visser et al., 2016). SRGPcl are currently available in 
advanced and varied designs with the aim of achieving better physical fit and optical 
performance. Fitting of modern SRGPcl is performed through diagnostic lens assessment using 
trial lenses (van der Worp et al., 2014).  
Patients intolerant of CRGPcl may also be fitted with hybrid lenses (Figure 3.4), which have a 
rigid centre of 8-8.5mm and a soft lens skirt reaching diameters of 14-15mm. In 2008, 
SynergEyes have developed hybrid lenses with skirts made of silicone hydrogel material, with 
good oxygen transmissibility, which makes these an ideal hybrid lens for keratoconus (Nau, 
2008). The commonly encountered problems of corneal hypoxia, oedema and 
neovascularization with the older hybrid lenses are less likely to occur with the newer materials 
(improved oxygen permeability) and designs. However, the occasional lens tightening may 
cause corneal abrasions and allergic reactions such as giant papillary conjunctivitis (Chung et 
al., 2001).  
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Figure 3.4. SynergEyes UltraHealth Hybrid lens for keratoconus (image kindly 
supplied by SynergEyes UK) 
Another alternative to CRGPcl are the piggyback lens combination (O'Donnell and 
Maldonado-Codina, 2004). Lens fit is accomplished by first fitting a low plus-power soft 
contact lens and on top of it a 9.0–9.5mm CRGPcl. Custom soft lens designs are available, such 
as the Flexlens with a cut-out or depression to hold the CRGPcl and maintain optimal centration 
(Watts and Colby, 2017) . My own impression is that the main drawbacks of the piggyback 
system are the cost of lenses, patient compliance with the complex cleaning regimen of soft 
and hard lenses and sub-optimal physiological performance due to reduced O2 transmission 
through the combination of two lenses.  
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Table 3.1 Contact lens options for keratoconus (Robertson and Cavanagh, 2011 P.1223) 
Contact lens type Indication 
Conventional hydrogels 
Early cones with little astigmatism, lenses will drape the 
cornea 
Silicone hydrogel Early cones, less lens drape due to higher modulus 
Toric hydrogels Early cones with regular astigmatism 
Soft keratoconic designs 
Early to moderate cones, increased central lens thickness to 
mask irregular astigmatism 
Corneal RGP standard design 
Early to moderate cones, individual lens parameters may be 
modified to enhance lens fit 
Aspheric corneal RGP 
Early to moderate cones, lens decentration may cause 
problems with vision 
RGP keratoconus designs 
Moderate to advanced cones, may add toric surfaces to 
enhance vision 
Semi-scleral and scleral RGP 
Advanced cones, vault the cornea, may use toric designs to 
enhance lens fit, bi-toric designs to enhance lens fit and vision 
Piggy-back and hybrid designs 
Moderate to advanced cones, comfort of soft lenses vision of 
RGP lenses. 
 
 
 
 
CRGPcl in the management of keratoconus 
 
In the following section key literature will be used to describe aspects related to the 
management of keratoconus with CRGPcl, their fitting approaches and effects on the visual 
Qol of the lens wearers and corneal pathophysiology.  
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Quality of life with CRGPcl 
 
Patients with keratoconus require prolonged daily contact lens wearing schedules because their 
visual wellbeing depends on contact lens correction of their corneal irregularity. The aim of 
the diagnostic fitting process, which utilises fluorescein* for the assessment of lens fitting 
patterns, is to achieve the optimal lens cornea fitting relationship. [*sodium fluorescein, NaFl, 
is a diagnostic dye used routinely in optometric practice for enhancing visualisation of the tear 
film, cornea and conjunctiva. In RGPcl fitting the NaFl enhanced tear film thickness is 
evaluated to achieve the desired lens cornea relationship]. 
CRGPcl are considered the gold standard in the management of keratoconus. However, their 
fitting, especially in the more advanced stages of the disease, is not as straight-forward as in 
normal corneae. Even well-fitting lenses may result in complications such as sub-optimal 
vision, reduced tolerance and exacerbation of the corneal disease.  
Kymes et al., (2004) validated the vision related Qol instrument, the NEI-VFQ for patients 
with keratoconus. They found that CRGPcl wearers with keratoconus had significantly lower 
scores in all domains of the NEI-VFQ compared with an age matched reference group from a 
study of Walline et al., (2000), of healthy CRGPcl wearers (Kymes et al., 2004; Walline et al., 
2000). It is therefore suggested that clinicians should carefully evaluate and address the full 
range of Qol issues that may affect patients with keratoconus (Tatematsu-Ogawa et al., 2008). 
Tatematsu-Ogawa et al., (2008) and Kurna et al., (2014) also found that vision related Qol was 
worse in individuals with keratoconus than in healthy individuals when assessed by NEI-VFQ 
and suggested that the maintenance of good BCVA with contact lens correction may improve 
vision related Qol (Tatematsu-Ogawa et al., 2008; Aydin Kurna et al., 2014).  
 
Wu et al., (2015) reported that CRGPcl do not improve the visual Qol of patients with the more 
advanced stages of keratoconus. They recommended that other contact lens modalities should 
be available for those patients to achieve better subjective outcomes (Wu et al., 2015).  
Jones-Jordan et al., (2013) reported on 961 subjects with keratoconus who completed the NEI 
VFQ. They found relatively small changes in the NEI-VFQ scores due to the maintenance 
adequate BCVA in CRGPcl. The authors found that larger ocular asymmetry; decreases in VA 
and increase in corneal steepness in the better eye were associated with decreasing Qol scores. 
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They concluded that the vision of the better eye typically has a more significant effect on visual 
Qol than the difference between the eyes (Jones-Jordan et al., 2013). 
 
 
Effects of CRGPcl on the keratoconic cornea 
 
Although the scarring of Bowman's layer and the anterior corneal stroma may occur as a natural 
disease process (Feder and Gan, 2011), the increased susceptibility of the keratoconic corneae 
to trauma (Wojcik et al., 2014) is thought to be associated with abnormal expression of genes 
responsible for the biochemical processes in wound healing. Chronic corneal epithelial trauma 
is therefore thought to be associated with the pathogenesis and progression of keratoconus 
(Kim et al., 1999; Wojcik et al., 2014). Corneal abrasions and scarring which arise as a result 
of chronic corneal injury by CRGPcl are therefore a major concern and led to critical reviews 
and refinements of CRGPcl fitting techniques (Ruben, 1975; McMonnies, 2005; Szczotka-Flyn 
et al., 2006).  
 
 
 
Fitting methods of CRGPcl 
 
There are three philosophies for fitting of CRGPcl in keratoconus (Loft and Wolffsohn, 2016; 
Szczotka-Flyn et al., 2006; Watts and Colby, 2017). 
 1. The apical bearing fitting method (Figure 3.5a) 
 2. The apical clearance or cone vaulting fitting method (Figure 3.5b) 
 3. Three-point-touch, or the divided-support fitting method (Figure 3.5c) 
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1. The apical bearing with primary lens support and bearing on the apex of the cornea and 
minimal peripheral stabilisation.  
 
 
 
Figure 3.5a. Examples NaFl patterns in flat central fitting with cone bearing. 
 
2. Apical clearance or cone vaulting, with lens support and bearing directed away  from the 
apex to the para-central cornea. 
 
 
 
Figure 3.5b. NaFl patterns in central clearance fitting with excessive (bubbles) to acceptable 
cone clearance 
 
3. Three-point-touch, or the divided-support method, with emphasis directed towards reducing 
or "feathering" the apical touch to minimise scarring of the fragile apical cone area. This is 
done by distributing the lens weight and spreading it over a larger area, including the central 
and peripheral cornea.  
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Figure 3.5c. NaFl patterns in divided support, three-point touch, fitting 
 
 
Currently the most widely accepted corneal lens fitting philosophy is the three point touch or 
the divided support method, in which the intention is to distribute the weight of the lens 
between the cone area and the normal peripheral cornea (Loft and Wolffsohn, 2016; Szczotka-
Flyn et al., 2006; Woodward, 1989; Watts and Colby, 2017), thus achieving good physical lens 
fit and minimal physiological corneal insult (Figure 3.5d). 
 
 
 
   Optimal centration                  lens centration side view     translation/movement in down gaze 
Figure 3.5d. Optimal physical CRGPcl fit. 
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Fitting methods and their relation to corneal pathology progression 
 
Corneal bearing fitting method of CRGPcl 
 
Mechanical interaction between the CRGPcl and cornea is inevitable, irrespective of the 
method of fitting. If as a result of these interactions the ectatic cornea fails to maintain an intact 
epithelium, its deficient wound healing mechanisms may contribute to stromal scarring and 
disease progression. 
Korb et al., (1982) suggested that the harsh contact between the CRGPcl and the fragile corneal 
apex in keratoconus is likely to be associated with corneal scarring (Korb et al., 1982). They 
investigated whether apical corneal insults such as corneal abrasion and scarring may be the 
consequence of the apical-bearing lens fitting method. They recruited 7 patients with 
keratoconus who had never worn contact lenses and fitted them with CRGPcl. The 
experimental eye was fitted with a lens bearing on the cone; the control eye was fitted with 
cone clearance. The authors postulated that this fitting difference between the eyes in the same 
individual would ensure that the primary variable would be the lens-cornea relationship. The 
intra-subject variability was minimised by selecting individuals fulfilling nine criteria of 
disease severity equivalence.  
Both lens fitting modalities were fitted to the better and worse eyes in equal numbers. Detailed 
examinations of the state of the cornea were performed at baseline and during follow up at 
intervals of 1, 2, 4, 8, and 12 weeks. Further follow-up was performed at 3-month intervals for 
the first year. After one year the authors found no significant or permanent changes in the 
corneae of any of the seven eyes fitted by apical clearance. In contrast, 4 of the 7 experimental 
eyes fitted with apical bearing, developed superficial opacities (scarring) after 3-12 months. A 
fifth eye wearing the apical bearing lens developed a moderate corneal fold after 12 months. 
The experimental, cone-bearing lenses were reported to be more comfortable than the control 
(apical clearance) in all 5 eyes, which exhibited the adverse findings (the better reported 
comfort was most likely due to better vision, normally achieved with cone bearing). The 
acquired corneal opacities in the four eyes remained permanent.  
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These results led to the conclusion that lenses fitted with apical bearing produced corneal 
scarring, whilst lenses fitted with apical clearance did not. Interestingly of the four corneae 
which developed scarring, two occurred with the more advanced and two with the less 
advanced level of keratoconus. This finding suggests that the fitting characteristics of CRGPcl 
may be more important in the development of scarring than differences in the degree of 
keratoconus.  
The authors recommended that attempts to achieve central apical clearance or at least a three-
point divided support fit should be attempted in eyes with keratoconus and heavy apical 
bearing of CRGPcl on the cornea should be avoided.  
Despite the small sample size and the selection of participants with early keratoconus, 
inexperienced in contact lens wear, this study supported the clinical impressions and reports of 
previous investigators (Bier and Lowther, 1977; Black and in Girard, 1967; Williams, 1960) 
who have advised against the fitting of CRGPcl by the apical bearing method. The authors did 
not address other important aspects of contact lens wear, such as differences in comfort and 
quality of vision between the two fitting methods, furthermore the lens designs used for the 
two methods of fitting were not identical; this introduces an additional variable which may 
have affected the results.  
Zadnik et al., (2005) compared the safety and efficacy of flat and steep fitting CRGPcl in 761 
keratoconic participants who completed an 8-year follow up in the CLEK study. At baseline 
they found that 41% of eyes with CRGPcl had a corneal scar compared with 24% corneal 
scarring in non-CRGPcl wearers (Zadnik et al., 2005). CRGPcl were fitted with apical bearing 
and apical clearance to 87% and 13% respectively. They found that 43% of the corneae fitted 
with apical bearing were scarred compared to 26% of those fitted with apical clearance. When 
the eyes with unscarred corneae at baseline were evaluated, they found that by year 8, 32% of 
these eyes developed scarring during wear of apical bearing lenses, compared with 14% 
scarring of corneae fitted with apical clearance (p=0.007).  
The authors postulated that despite the significant differences in corneal scarring between the 
two methods of fitting, only a randomised study would be able to assess the risk of corneal 
scarring due to a particular fitting method. The CLEK study is a natural history sample; 
therefore, the correlation of fitting method and corneal scarring is not necessarily causal. As 
more advanced disease presents higher risk for scarring and CRGPcl tend to fit flatter and bear 
on the corneal apex in advanced keratoconus, it is impossible to statistically discriminate 
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between the effects of flat fitting lenses and disease severity on the incidence of corneal 
scarring. This principle also applies to other CLEK studies such as measurement of VA in 
(Zadnik and Mutti, 1987), assessment of contact lens comfort (Edrington et al., 2004) and 
evaluation of ocular pain (Kymes et al., 2008).  
The difference between the divided support and apical bearing fitting methods is often difficult 
to establish, especially in a progressive disorder such as keratoconus. As the disease progresses, 
the divided support lens fit, with minimal bearing on the apex may alter into heavy bearing 
even when disease progression is relatively minor, as described by Edrington et al., (1999). 
The authors re-fitted the 808 patients according to a protocol of fitting from their previous 
study (Edrington et al., 1996) and analysed the lens-cornea fitting relationship of the habitual 
lenses worn by these patients. They found prior to refitting the participants, that despite the 
clinically established association between cone bearing and corneal scarring, 88% of eyes had 
their habitual CRGPcl bearing on the cone apex, and only 12% exhibited corneal clearance 
(Edrington et al., 1999).  
A report by Szczotka et al., (2001) in the CLEK study, evaluated corneal scarring, visual acuity, 
corneal curvature and Qol in 1209 CRGPcl wearers with keratoconus. They found that 88% 
wore CRGPcl with apical bearing, 53% had corneal scarring in one or both eyes, and that 
corneal scarring was associated with corneal staining, contact lens wear, age, the presence of a 
Fleischer's ring and a steeper cornea. All these parameters except age contributed to, or may 
have been the result of, CRGPcl bearing on the cornea (Szczotka et al., 2001).  
Since almost 90% of keratoconic CRGPcl in the CLEK study exhibited apical bearing 
(Edrington et al., 1999) and more than 50% had corneal scarring in one or both eyes (Szczotka 
et al., 2001), these findings appear to support the conclusions of Korb et al., (1982), which 
attributed a causal relationship between chronic CRGPcl bearing on cornea and corneal 
scarring. Furthermore, the CLEK study concluded that corneal scarring was associated with 
decreased measures of high and low-contrast visual acuity, and possibly the reduced visual Qol 
in keratoconic CRGPcl wearers. Since the nature of CRGPcl fit may be causal or contributory 
to the complications associated with corneal morbidity, reduced visual performance and visual 
Qol, it follows that practitioners should take measures to minimise contact lens wear related 
complications such as corneal scarring when managing corneal ectasiae with CRGPcl.  
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Apical clearance fitting of CRGPcl 
 
Clinical experience shows that the steep central curvature of CRGPcl required to achieve a 
vault of the corneal apex, may also cause problems such as: the trapping of air bubbles in the 
flatter areas adjacent to the corneal apex, which may disrupt vision by corneal deformation  
(Szczotka-Flyn et al., 2006). The small optic zone and lens diameters used in fitting 
keratoconus, may lead to discomfort and visual disturbances such as halos, ghosting and glare 
due to the encroachment of the peripheral (non-optical) part of CRGPcl into the pupil area. The 
steep lens curves required in this approach may reduce tear exchange and lens mobility 
resulting in tear stagnation, oedema, corneal insult and lens intolerance. The positively powered 
tear lens created by the steep central back curve, requires high negative optical powers, which 
may reduce retinal image quality and increase lens thickness (Szczotka-Flyn et al., 2006). Lens 
flexure resulting from the steep central fit will induce astigmatism and reduce vision (Sorbara 
et al., 2000).  
Gundel et al., (1996) investigated the feasibility of fitting keratoconic patients with apical 
clearance, as recommended by Korb et al. (1982). To achieve apical clearance, they used the 
lens design developed and validated by Edrington et al., (1996) (Gundel et al., 1996). Thirty 
eyes of 17 participants were randomly assigned to a steep lens-fitting protocol*; the lenses 
dispensed had on average a 0.6mm steeper central radius than their habitual CRGPcl *[Their 
fitting protocol stipulated that a 0.2 mm steeper radius than the diagnostic lens which exhibits 
a definite apical clearance (DFCL) is used]. The strict criteria for success were based on the 
measurement of VA, hours of daily lens wear and observable levels of corneal fluorescein 
staining, erosions, distortion from CRGPcl pressure, corneal oedema and scarring. All these 
changes were noted at different stages for some subjects, including central corneal scarring in 
one eye after 12 months. At 12 months the mean visual acuity was 6/7.5 (logMAR 0.10) and 
the average wearing time was 14 hours a day, both features are indicative of a successful result.  
As no control group was implemented in this study, no comparative results with alternative 
fitting approaches such as divided support or corneal bearing lenses are available. Nevertheless, 
the conclusion of this study was that fitting keratoconic corneae with apical clearance is a viable 
method.  
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An interesting finding in this study is the corneal steepening in 14 eyes (47%), the flat meridian 
increased by 2.29D, the steep meridian increased by 1.28D, which indicates corneal moulding. 
This effect was especially obvious in 5 of the 14 eyes that showed a mean increase of 5.9D 
(0.83mm) in the flattest meridian and 3.92D (0.56mm) mean increase in the steepest. These 
findings demonstrate a marked increase in the level of keratoconus in those eyes, which is 
known to be associated with increased risks of scarring (Zadnik and Mutti, 1987), reduced 
visual acuity (Zadnik et al., 2005) and a reduction in almost all aspects of NEI-VFQ scores 
(Kymes et al., 2004; Kymes et al., 2008; Aydin Kurna et al., 2014). 
McMonnies (2004) reported a case in which a keratoconic patient wore a substantially steeper 
lens in the right eye and flatter lens in the left eye due to accidental lens switching. The right 
eye required an alteration in contact lens fitting due to a progression in keratoconus at a higher 
rate than exhibited previously and more than the progression exhibited by the left eye. The 
author suggested that: It is possible that the adventitious apical clearance fitting on the right 
eye served to promote an increase in ectasia that might not have occurred if the intended apical 
support fitting had been worn (McMonnies, 2004). This case report is in agreement with the 
findings of Gundel et al., (1996) regarding the possible contribution / causation of disease 
progression by CRGPcl fitted to vault the cone apex.  
The corneal shape changes occurring in orthokeratology*, a method in which centrally flat 
fitting CRGPcl worn overnight, generate tear fluid pressure to alter the shape of the cornea in 
a controlled manner to achieve a desired optical change (Maseedupally et al., 2013), may be 
useful in understanding the tendency of even the healthy corneae to adopt the shape and 
curvature of the CRGPcl. These changes which affect corneal thickness and shape (Gifford et 
al., 2011) are reversible, the healthy cornea returns to its original shape and thickness, 
exhibiting no significant difference to controls in the frequency or severity of corneal NaFl 
staining during wear (Lui et al., 2000), no alteration in the corneal epithelial permeability and 
no clinically significant changes in corneal biomechanical properties on lens removal (Yeh et 
al., 2013).  
Hartstein and Becker (1970) examined the corneal rigidity in three groups of patients who were 
successful long-term wearers of CRGPcl. Despite the inability to perform statistical analysis 
due to the small numbers involved, the authors postulated that higher ocular rigidity is 
associated with a better maintenance of a normal corneal shape and that at least one type of 
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keratoconus may be related to the long-term wearing of CRGPcl in eyes with unusually low 
ocular rigidity (Hartstein and Becker, 1970) .  
Hill et al., (1974) found that even healthy corneae are susceptible to deformation by CRGPcl 
by showing that corneal steepening occurred in 85% with centrally steep lenses over a period 
of 1 to 6 years. (Hill and Rengstorff, 1974).  
In keratoconus the central cornea is abnormally thin, soft and pliable compared with the normal 
cornea, it exhibits reduced total protein, variable total collagen, and reduced levels of sulphate 
proteoglycans (Kenney and Brown, 2003). The pathological thinning in keratoconus may 
develop as a result of altered biomechanical properties (Bao et al., 2017) such as the loss of 
tensile strength and elasticity (Wojcik et al., 2014) or may be the primary change, which if 
associated with loss of elasticity and increased plasticity, may reduce the corneal ability to 
recover from trauma associated with external mechanical insult such as contact lens wear or 
eye rubbing (Gordon-Shaag et al., 2015). Kenney and Brown (2003) who examined the 
hypothesis of a cascade of events causing keratoconus and its progression, recommend that 
patients with keratoconus should minimize their exposure to oxidative stress by wearing 
ultraviolet protection, minimize the mechanical trauma like eye rubbing, poorly fitting contact 
lenses and keep eyes comfortable with artificial tears, non-steroidal anti-inflammatory drugs 
and/or allergy medications (Kenney and Brown, 2003). The recovery from deformation by a 
healthy cornea such as observed in orthokeratology and poorly fitting CRGPcl may not occur 
in keratoconus, in which corneal biomechanics are impaired (Wojcik et al., 2014; Kenney and 
Brown, 2003; Bao et al., 2017). This impaired recovery may predispose the cornea to 
permanent deformation by the mechanical pressure induced by sub optimally fitting CRGP and 
lead to progressive pathological changes as demonstrated by Gundel et al., (1996) and noted 
by McMonnies (2004, 2005).  
McMonnies (2005) analysed the possible influence of eyelid tonus, tear fluid pressure and 
intraocular pressure on the generation and progression of keratoconus during CRGPcl wear. 
He postulated that the lens bearing on the peripheral cornea and suction forces in the central 
area generated by lenses fitted with apical clearance are compounded by the rise in intraocular 
pressure due to eyelid squeeze forces during blinks, which may be pushing and stretching the 
softer central cornea and cause keratoconus progression by additional forward protrusion. This 
would occur due to strong sub-atmospheric fluid pressure forces under the lens that draw the 
lens to the cornea and the cornea to the lens, which flattens the mid peripheral cornea and 
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facilitates compensatory steepening of the apex. He concluded that the known risk of scarring 
responses to excessively flat fitting CRGPcl must be balanced against the possible risk of 
corneal moulding and keratoconus progression responses to CRGPcl fitted with apical 
clearance. He suggested that fittings by divided support, where there is minimal central bearing 
or clearance may be the most appropriate fitting approach. He stipulated that this is difficult to 
achieve in practice in view of the high level of accuracy required and the dynamic-progressive 
nature of keratoconus. The author further suggested that any large increases of intraocular 
pressure due to activities such as vigorous eye rubbing, strong squeeze blinks, inverted body 
positions, and strenuous muscular effort, should be recognised as risk factors in patients with, 
or at risk of keratoconus, glaucoma, or progressive myopia (McMonnies, 2005).  
McMonnies summarised the known risks associated with apical support fitting method. 
1. Chronic corneal epithelial changes, which may not be evident on bio-microscopy.  
2. Chronic, visible epithelial trauma caused by friction between CRGPcl and cornea. 
3. Acute or chronic epithelial trauma that results in permanent scarring of the corneal apex. 
4. Chronic epithelial trauma that may cause corneal stromal thinning. 
 
McMonnies summarised the known risks associated with the apical clearance fitting.  
1. Corneal moulding may be greater in keratoconus due to reduced tensile strength and 
elasticity, and/or greater plasticity of the softer and thinner cornea.  
2. Reduced oxygen tension caused by the thicker lens and post-lens tear layer, leading to 
corneal oedema and increased tendency to mould to the steeper lens curvature. 
3. Progression of ectasia if moulding to the steeper lens curvature becomes a permanent change. 
4. Tighter lenses with sharper transitions may reduce lens movement and cause imprinting 
insult of the corneal epithelium. 
5. Apical clearance may facilitate fine bubbles formation, increase light scatter and glare. 
6. Cornea moulding to a steeper shape during lens wear may cause a myopic shift and reduction 
in unaided visual acuity on lens removal. 
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7. Reduced acuity with contact lenses may result from residual astigmatism (McMonnies, 
2004; McMonnies, 2005).  
 
 
Summary of CRGPcl fitting methods and their effects on keratoconus progression 
 
The available evidence suggests that corneal changes associated with both CRGPcl fitting 
philosophies have significant negative effects on VA and disease status. The scarring 
associated with CRGPcl wear (Barr et al., 2000) is likely to be caused by apical support-cone 
bearing lenses, found in the majority (88%) of patients (Edrington et al., 1999). The cone 
clearance fitting philosophy recommended to safeguard against corneal scarring (Gundel et 
al., 1996; Korb et al., 1982) appears to negatively affect disease progression by inducing 
permanent corneal steepening (McMonnies, 2004; McMonnies, 2005). The theoretically 
desirable fitting method of divided support may not be achievable or sustained in many wearers 
(McMonnies, 2005). CRGPcl may therefore contribute to disease progression and adversely 
affect vision, corneal health, contact lens tolerance and subsequently all aspects of visual Qol, 
as demonstrated by Kymes et al. (2008), who found that a decline in visual acuity of 10 letters, 
and a disease progression equivalent to a corneal curvature increase of 3.00D, were associated 
with significant declines (10 points) in the NEI-VFQ scale scores (Kymes et al., 2008).   
 
 
Clinical implications of SRGPcl management of keratoconus 
 
CRGPcl provide better high and low contrast BCVA than spectacles and soft lenses in eyes 
with keratoconus (Griffiths et al., 1998) and are the most widely prescribed optical 
management in keratoconus (Zadnik et al., 1998; Mandathara et al., 2017). The conclusion 
from the discussion above is that irrespective of the fitting philosophy, CRGPcl may contribute 
to or cause pathological changes in keratoconic corneae. It is therefore understandable that 
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SRGPcl, which vault (bridge over) the cornea attracted considerable interest in the management 
of keratoconus. 
Both SRGPcl and CRGPcl, almost completely neutralise the anterior corneal surface 
irregularities caused by ectatic corneal disorders. Unlike CRGPcl, which distribute their weight 
and mass on the cornea, SRGPcl are fitted to bear on the sclera, without contact with any part 
of the cornea, which precludes mechanical interaction between the cornea and contact lens 
surface. The cornea is immersed in the tear and saline reservoir vaulted by SRGPcl (van der 
Worp et al., 2014; Visser et al., 2013; Visser et al., 2007a). The cornea is therefore protected 
not only from mechanical interaction with the rigid contact lens surface but also from the 
shearing forces of the eyelids, eye rubbing, exposure to ultraviolet radiation and external debris, 
all of which are recognised irritants with the potential to exacerbate keratoconus (Wojcik et al., 
2014; Kenney and Brown, 2003). However, SRGPcl are not prescribed as a first option but 
only when other lenses did not provide adequate management (van der Worp et al., 2014; 
Szczotka-Flyn et al., 2006). This view was supported by Rathi et al., (2013) who stipulated 
that contact lenses can improve the vision and delay or obviate the need for keratoplasty and 
that the lenses of choice are CRGPcl. They recommend that if discomfort with or intolerance 
to CRGPcl occur, then customized soft toric, piggyback combination or hybrid contact lenses 
should be fitted. SRGPcl in their opinion are only to be used when all other options fail, or if 
patients present with associated ocular allergic disease (Rathi et al., 2013). This reluctance to 
use SRGPcl remains, despite significant improvements in manufacturing techniques, wider 
availability of improved lens designs, systematisation of the fitting protocols, availability of 
preformed SRGPcl fitting sets and substantial reductions in costs (van der Worp et al., 2014).  
Other researchers suggest that long-term management with SRGPcl reduced the indication for 
corneal transplant surgery in severe keratoconus by more than 50% (Koppen et al., 2017) and  
was well accepted in patients with advanced ectasia who are intolerant to other contact lenses, 
or when surgery is not available or considered inappropriate (Maharana et al., 2016).  
Visser et al. (2007) performed a prospective study to evaluate the indications for modern 
SRGPcl and their clinical performance (Visser et al., 2007a). In part II: the authors have 
evaluated patient satisfaction with their SRGPcl (Visser et al., 2007b). All 178 participants 
(284 eyes) in these studies failed with other contact lens modalities, 143 (50.3%) eyes had 
keratoconus, 56 (19.7%) eyes had penetrating keratoplasty [full thickness central corneal graft 
surgery], the rest had irregular astigmatism due to various causes such as PMD and ocular 
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surface disorders such as keratitis sicca [severe dry eye disorder] and corneal dystrophies, 
totalling 25 eyes (8.8%). SRGPcl were fitted according to a strict fitting protocol which aimed 
to achieve the desired clearance of the cornea and the limbus, the peripheral-haptic zone of the 
lens was fitted precisely to align the sclera and distribute lens weight without causing undue 
local pressure. When required, custom made toric scleral lenses were used to achieve this. The 
authors claimed that optimal lens fitting characteristics were achieved with most eyes. Fifty-
nine eyes (20.8%) had to be refitted due to adverse clinical findings. Most patients showed no 
adverse clinical signs during their review appointments, with the exception of bulbar 
conjunctiva [the area which bears the weight of the lens] hyperaemia [redness due to local 
blood vessel dilation], which occurred in 20.8% of eyes. The authors stipulated that a well-
balanced scleral bearing area, gentle movement of the lens with digital push up testing, 
approximately 250μm of corneal clearance and 50μm-100μm of limbal clearance are all 
essential fitting attributes to avoid contact lens related complications. The authors claimed to 
achieve visual rehabilitation with SRGPcl for this group of patients by demonstrating 
significant increases in monocular and binocular visual acuities compared to glasses. This 
improvement was most apparent in participants with keratoconus and penetrating keratoplasty. 
No comparison was made between SRGPcl and CRGPcl with respect to visual acuity.  
Earlier studies by Kok and Visser (1992), Tan et al., (1995), Pullum and Buckley (1997), Segal 
et al., (2003), Pullum et al., (2005) and Rosenthal and Croteau (2005), all found similar 
favourable visual improvements and positive clinical performances of SRGPcl in cases of 
challenging diseased corneae, in eyes which could not be managed by other contact lens options 
(Kok and Visser, 1992; Tan et al., 1995; Pullum and Buckley, 1997; Segal et al., 2003; Pullum 
et al., 2005). 
Despite variations in study design, sample sizes, conditions managed, definition of diagnoses, 
fitting methods, scleral lens types, materials, and so forth their results highlight the usefulness 
of SRGPcl in clinical practice. As in the earlier studies the conclusions of Visser et al., (2007) 
were: “modern scleral lenses can be used successfully for visual rehabilitation and 
management of a wide range of corneal disorders that have not responded adequately to other 
treatment modalities” (Visser et al., 2007a).  
In a follow up publication Visser et al., (2007b) examined the satisfaction levels with SRGPcl 
in the same 178 participants. Fifty per cent were refitted from CRGPcl, 30% wore no lenses at 
all, and the rest had various other lens types. The participants were asked to state the number 
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of insertion attempts, lens wearing hours, number of breaks from wearing lenses and the 
previous correction before they had received SRGPcl. Scores from a Likert scale questionnaire; 
from 1 (very poor) to 5 (excellent) were obtained for the original lenses as well as for the 
SRGPcl fitted during the first phase of the study. The questionnaire covered 3 topics: comfort, 
visual quality and overall satisfaction as well as 7 aspects of contact lens wear: comfort, lens 
dryness, visual quality, air bubbles during lens wear, tear debris during lens wear, lens 
cleanliness and lens handling. Significantly higher scores were obtained with SRGPcl. Scores 
of 3 (out of 5) for comfort were given by 98.9%, for visual quality by 97.9% and overall 
satisfaction by 98.9% of participants. In comparison scores of 3 or more were given with the 
former correction by 54.6% for comfort, by 51.8% for visual quality, and by 50.4% for overall 
satisfaction. Significant increases were found in the scores with SRGPcl for all three topics 
(p<0.001). Higher scores for comfort, visual quality, and overall satisfaction were found in 
more than 75%, furthermore in the 99 eyes refitted from a spherical SRGPcl to toric design 
[for better scleral fit], significant increases in comfort, visual quality, and overall satisfaction 
were observed (Visser et al., 2007b). The authors suggested that this was because of better lens 
weight distribution on the naturally toric peripheral sclera, as found by other studies (Visser et 
al., 2006; Visser et al., 2013).  
High level of subjective satisfaction was confirmed in patients with keratoconus refitted with 
SRGPcl despite mid-day lens fogging, reported by 50% of them (Bergmanson et al., 2016). A 
retrospective cohort study by Baran et al., (2012) investigated the success rate of fitting 
SRGPcl in the management of corneal ectasia (Baran et al., 2012). They reviewed the records 
of 59 patients with corneal ectasia disorders, the majority of whom (74.6%) wore CRGPcl. 
SRGPcl were fitted to 89 eyes of 49 patients. Forty-three patients, 78 eyes (88%) with 
keratoconus completed the validated NEI-VFQ (Mangione et al., 2001; Aydin Kurna et al., 
2014) at six months. The authors measured an improvement of 27.6/100 points (p < 0.001). In 
the 10 patients who passed the selection criteria but were not dispensed with SRGPcl, no 
significant difference in the score was found at six months (p<0.697). The authors concluded 
that a satisfactory fit of SRGPcl in participants with ectasia results in a positive impact on 
visual acuity and continued successful contact lens wear. The authors further stipulated that 
SRGPcl treatment is an alternative to penetrating keratoplasty for patients with corneal ectasia 
who are contact lens intolerant.  
A retrospective study by Pecego et al., (2012) reported the results of fitting the Jupiter SRGPcl 
in 107 eyes of 63 participants with a variety of ocular conditions; the majority (63%) had 
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keratoconus. Eighty-six eyes (80%) were either unhappy with their visual acuity or intolerant 
to their previous contact lenses. The authors found that the SRGPcl were comfortable in 84% 
of eyes, but 23% of eyes abandoned wear after 3 months. Patients who abandoned SRGPcl 
exhibited significantly less subjective comfort and less improvement in BCVA compared to 
those who remained in SRGPcl. The BCVA was 20/30 (6/9.5) or better in 73% of eyes wearing 
SRGPcl with a mean improvement of 3.5 (±2.6) Snellen lines (Pecego et al., 2012).  
SRGPcl are fitted in alignment with the sclera and thus spread the weight of the lens evenly to 
avoid excessive local compression of the conjunctiva and sclera. The science and art of design 
and fitting of modern SRGPcl has benefited from research into the topography of the ocular 
surface obtained from the micron precise imaging of the cornea, the corneo-scleral junction 
and the sclera by Optical Coherence Tomography (OCT)  (Gemoules, 2008; van der Worp et 
al., 2010; Kojima et al., 2013).  
Researchers from the Pacific University suggest that the scleral shape around the limbus is 
tangential [a continuous straight-line] with the peripheral cornea and not a convex surface 
which continues to flatten as was previously assumed. The sclera was found to be of a non-
rotationally symmetrical shape around its four quadrants, with the nasal quadrant being the 
flattest, the temporal quadrant the steepest and the superior is somewhere between the inferior 
and the temporal quadrants (van der Worp et al., 2010). This rotational asymmetry is more 
pronounced further from the limbal area; from 15mm-20mm diameter away from the centre of 
the cornea. These researchers found that at approximately 15mm from the corneal apex, the 
scleral angles appear on average fairly similar in all four quadrants. Based on these results and 
past clinical experience with large diameter [over 18 mm in size] SRGPcl the authors suggested 
that rotationally asymmetrical, toric or quadrant specific, large diameter scleral lenses should 
be used to achieve optimal scleral alignment. Optimal scleral alignment should ensure even 
weight distribution, gentle lens positioning and balancing, which would result in better lens 
comfort and tolerance, better lens centration and stability as well as improved scleral and 
conjunctival health. This positional stability of SRGPcl facilitates the application of more 
complex optical correction such as front surface toric [correcting the residual ocular 
astigmatism] and wavefront HOA corrections [correcting the residual HOA], both of which 
often remain uncorrected with RGPcl. Both Sabesan et al., (2013) and Marsack et al., (2014) 
demonstrated that SRGPcl with customised wavefront optics are capable of fully or partly 
correcting the residual HOA in keratoconus. However, despite the improved retinal image 
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quality generated by these lenses, the improved high contrast visual acuity did not reach 
normal, age-matched levels (Sabesan et al., 2013). 
Visser et al., (2013) published an evaluation of the performance of a SRGPcl design which 
featured a non-rotationally symmetrical peripheral (haptic) lens area. This design differs from 
traditional SRGPcl in two ways. The first is the configuration of the peripheral haptic to match 
the non-rotationally symmetrical sclera at an area beyond 15mm from corneal centre. The 
second difference is that rather than having the customary curved spherical shape, these haptic 
lenses feature a tangential design. The authors postulated that the adjustable flat and steep 
meridian of this bi-tangential haptic would improve lens fit by the generation of a more even 
distribution of lens pressure over the sclera. A total of 213 eyes of 144 participants were fitted, 
keratoconus (n=121 eyes; 56.8%), ocular surface diseases (n=31eyes; 14.6%), penetrating 
keratoplasty (n=29 eyes; 13.6%), and other forms of irregular astigmatism (n=28 eyes; 13.1%). 
The most common lens diameter was 20.0 mm (162 lenses; 76.1%, range: 18.5-21.5 mm). The 
results revealed that 77% of participants (164 eyes) gave high ratings for comfort. Median 
BCVA was decimal 0.8 (Snellen 6/7.5, range: 0-1.5, Snellen equivalent 6/600-6/4). Most lenses 
were observed to have good fitting characteristics, optimal values were seen for lens movement 
(208 lenses; 97.7%) and lens position (208 lenses; 97.7%). Median central corneal clearance 
was 200µm. The lenses exhibited good rotational stability with an oblique median lens 
stabilization axis at 140° (range: 0°-180°) in the right eyes and 60° (range: 0°-180°) in the left 
eyes. The researchers concluded that the bi-tangential SRGPcl fitting and performance 
characteristics were beneficial for both the health professional and the patient (Visser et al., 
2013).  
Picot et al., (2015) conducted an observational retrospective study, evaluating quality of life 
with the French version of the NEI-VFQ before and after SRGPcl adaptation, of 47 patients 
(83 eyes, 56 eyes with keratoconus) all of whom failed to adapt to CRGPcl and were refitted 
with SRGPcl. The mean duration of wearing SRGPcl was 18 (±10) months and the mean daily 
wearing time was 14 (±3) hours. The average scores on the NEI-VFQ after six months were 
significantly higher than with CRGPcl, with a global score of 80.2/100 with SRGPcl versus 
48.1/100 with CRGPcl (p<0.0001). The authors concluded that because SRGPcl showed a 
significant improvement in quality of life for patients who failed to tolerate CRGPcl they 
represent a viable alternative prior to consideration of surgery (Picot et al., 2015). 
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A recent literature review of the complications and fitting challenges associated with SRGPcl 
(Walker et al., 2016) reveal that serious complications as a result of infection, inflammation 
and corneal hypoxia are rare with modern materials and designs. To prevent corneal hypoxia, 
the materials of SRGPcl need to feature high Dk values such as Boston EO (Dk 82), XO (Dk 
100) and Menicon Z (Dk 160), as well as having a tear lens thickness of not more than 200µm 
(Jaynes et al., 2015). They highlight the challenges of obtaining optimal fitting characteristics 
in view of the natural asymmetry of the sclera, such as lens seal-off, which may cause lens 
suction and reduced tear exchange. Lens bearing on the corneal limbus should be avoided due 
to the importance and sensitivity to mechanical lens pressure of this stem cell rich area (Figures 
3.6a. and b.).  
 
Figure 3.6a. NaFl fit of SRGPcl with dark area at 1 o’clock indicating heavy lens bearing on 
the cornea. Copied from Walker et al., (2016) with permission from Maria K. Walker, OD, 
MS, FAAO, FSLS. 
 
 
Figure 3.6b A. Circum-limbal bearing. B. Local epithelial breakdown staining. Copied from 
Walker et al., (2016) with permission from Maria K. Walker, OD, MS, FAAO, FSLS. 
74 
 
Other undesirable ocular side effects were highlighted, such as conjunctival prolapse (Figure 
3.7), epithelial bogging (Figure 3.8) and mid-day fogging (Figure 3.9) of lenses as limiting 
factors unique to SRGPcl, which at present have no known, clinically significant long-term 
consequences (Walker et al., 2016). 
 
 
Figure 3.7. Conjunctival prolapse under the lens edge, white arrows, corneal vascularisation 
due to chronic hypoxia caused by conjunctival adhesion to the cornea. Copied from Walker 
et al., (2016) with permission from Maria K. Walker, OD, MS, FAAO, FSLS. 
 
 
 
Figure 3.8. Epithelial bogging. Copied from Walker et al., (2016) with permission from 
Maria K. Walker, OD, MS, FAAO, FSLS. 
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Mid-day lens fogging was reported by 50% of satisfied keratoconic SRGPcl wearers, refitted 
from CRGPcl (Bergmanson et al., 2016). A study by Carracedo et al., (2016) evaluated the 
turbidity and thickness of the post lens tear layer and its effect on visual quality in 36 
participants with keratoconus. They found a x8 higher number of particles per mm2 after eight 
hours of SRGPcl wear compared to 5minutes after lens insertion (p < 0.05). A decrease in 
BCVA (p < 0.001) and contrast sensitivity (p < 0.05) after eight hours of SRGPcl wear was 
found, both of these visual outcome measures showed a significant correlation with post-lens 
tear turbidity: r=0.567 (p=0.002) for turbid tear layer area and r=0.469 (p=0.049) for the 
number of particles per mm². Tear layer thickness was considered to positively correlate with 
tear turbidity, no correlation between turbidity and post-lens tear layer thickness was found 
(p > 0.05) (Carracedo, Serramito-Blanco et al., 2017). 
 
 
Figure 3.9. Lens fogging due to accumulation of particular matter behind the lens. The 
arrows point to the post-lens tear film, which exhibits change in thickness and clarity. Copied 
from Walker et al., (2016) with permission from Maria K. Walker, OD, MS, FAAO, FSLS. 
 
In an earlier study exploring the utility of SRGPcl in the management of dry eye symptoms in 
patient with keratoconus Carracedo et al., (2016) found that despite a significant decrease in 
signs and symptoms of dry eyes, the MMP9 [inflammation bio-marker] increased significantly, 
most likely due to tear stagnation and the use of saline in lens cavity at insertion (Carracedo et 
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al., 2016). These researchers found in a later study that corneal and limbal temperatures are not 
affected by SRGPcl wear, which suggests that not enough inflammation occurs during SRGPcl 
wear to increase temperature, the researchers also found no effect on tear volume or tear break 
up time after lens removal (Carracedo,Wang et al., 2017). 
Nixon et al., (2017) published a case series report which highlighted an unintended contact 
lens related complication of corneal limbal bullae in all 14 participants fitted with small 
diameter SRGPcl. [Corneal epithelial bullae are oval, larger than 40µm in size, gas and / or 
fluid field lesions manifesting corneal epithelial oedema]. The authors concluded that due to 
the unique design of these lenses an unintended mechanical bearing on the corneal limbus, 
caused the undesirable local mechanical compression, which led to contact lens induced 
epithelial edema after only 6 hours of lens wear (Nixon et al., 2017).  
Weber et al., (2017) used conjunctival impression cytology to evaluate the changes in goblet 
cell density and the inflammatory mediator HLA-DR [Human Leukocyte Antigen – antigen D 
Related] after 12 months wear of SRGPcl in patients with moderate to severe dry eye disease. 
They found that the goblet cell density did not differ significantly (p>0.05) and the 
inflammatory mediator was also unchanged except in participants with Sjogren syndrome, in 
which there was an increase in HLA expression (Weber et al., 2017). 
Giasson et al., (2017) measured the in vivo oxygen tension available to the cornea and found 
that after 5minutes of wear, SRGPcl fitted with a 400μm corneal clearance reduces oxygen 
tension by 30% compared to a 200μm clearance (Giasson et al., 2017). Reduced oxygen to the 
cornea may cause undesirable complications such as corneal oedema and vascularisation. Rathi 
et al., (2017) described corneal vascularisation, which resolved on discontinuation of lens wear 
(Rathi et al., 2017). Esen and Toker (2016) examined the influence of SRGPcl settling and 
corneal clearance on clinical performance and hypoxia induced corneal changes. They found 
that the corneal swelling after 8 hours was 62.8μm (1.3%) (80% occurred during the first 4hrs) 
and wearers comfort scores were not significantly influenced by corneal clearance. They 
nevertheless recommended fitting according to the current guidelines of using high DK 
materials and minimising apical clearance and lens thickness, to facilitate long-term corneal 
health (Esen and Toker, 2017) 
The large size of SRGPcl may be challenging with respect to lens handling, in a retrospective 
review of 34 patients fitted with SRGPcl, 8 patients (25%) were unable to handle these lenses 
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(Barnett et al., 2016). Even in successful SRGPcl wearers Suarez et al., (2018) found that 40% 
of patients had persistent handling difficulties after 1 month of lens wear (Suarez et al., 2018). 
Optimal fitting characteristics of SRGPcl are achievable nowadays due to the advent of 
computerized lathe cutting technology, which enables manufacturing of very smooth lens 
surfaces and edges with sub-micron precision. Contact lens practitioners are now able to adjust 
individual lens parameters after assessing the lens fit during trials (Rathi et al., 2015). The 
fitting characteristics of complete corneal clearance, the maintenance of liquid lens and the 
physical protection from mechanical and other external irritants make SRGPcl useful in cases 
of ocular surface pathology (Pullum and Buckley, 1997; Romero-Rangel et al., 2000; Stason 
et al., 2010), corneal protection and aid in healing in cases of exposure keratitis (Chahal et al., 
2017; Zaki, 2017) and as a means in aiding management of oculo-plastic pathology such as 
exposure keratitis and pain after blepharo-ptosis (droopy eyelids) surgery (Scofield-Kaplan et 
al., 2017; Chahal et al., 2017). SRGPcl have demonstrated long term safety and efficacy in 
complex cases such as ocular rehabilitation after penetrating keratoplasty (Severinsky et al., 
2014) or long-term maintenance of visual acuity in cases of dry eyes, when the fluid reservoir 
between the cornea and SRGPcl needs to be increased (Sonsino and Mathe, 2013). In their 
review of modern scleral lenses Maharana et al., (2016) concluded that SRGPcl are extremely 
useful in patients with advanced ectasia intolerant to other contact lenses. (Maharana et al., 
2016). The majority of participants in the studies above were individuals whose management 
with CRGPcl failed to deliver adequate tolerance and/or visual performance. These studies 
conclude that SRGPcl are a viable management option where other correction modalities fail 
to deliver the required comfortable and safe contact lens wear and / or the desired visual 
outcome.  
The decision regarding the most appropriate contact lenses in individual cases must be based 
on the degree of corneal irregularity and on secondary factors, such as tear film deficiency and 
corneal scars. Visser et al., (2016) developed a contact lens selection algorithm, based on peer 
reviewed literature, which takes these primary and secondary factors into account. They 
identified sub-optimally fitting lenses in 58% of the participants in their study, who benefitted 
from a refitting (Visser et al., 2016).  
Schornack (2015) published a literature review of 184 publications selected from 899 peer-
reviewed scientific publications related to SRGPcl design, fabrication, prescription, and 
management. The author concluded that current literature provides little insight into the 
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potential effects of SRGPcl on anterior segment anatomy and physiology. The differences in 
the physical features as well as the fitting characteristics of the various available SRGPcl, 
precludes the assumption of consistency of their performance and effect on the anterior eye. 
The author suggested that before embracing the use of SRGPcl in healthy eyes it would be 
advisable to fully explore potential metabolic and mechanical challenges to anterior segment 
structures. Specific aspects which are characteristic to SRGPcl such as fluid reservoir 
thickness, may present a significant barrier to oxygen transmissibility and may lead to hypoxic 
complications, furthermore the rate and volume of tear exchange beneath the lens and its effects 
on the physiology of the anterior segment are not yet known. There are currently no evidence-
based guidelines for ideal scleral lens fitting characteristics and use of appropriate care 
products, or reports regarding incidence of complications and risk factors for complications. 
The author concluded that for patients with few other options for disease management, 
 ” we can be reasonably confident that the risks of inaction or surgical intervention 
 outweigh potential risks of scleral lens wear, but the exact placement of scleral lenses 
 within an overall management strategy has yet to be defined” (Schornack, 2015). 
 
After reviewing the literature my conclusion is that the current clinical approach in the 
management of keratoconus and other irregular corneal disorders is to fit SRGPcl in two 
circumstances. First for patients who are intolerant to CRGPcl, second when pathology is either 
adversely affected by CRGPcl or too advanced to be effectively managed by CRGPcl or other 
contact lens modalities such as soft, hybrid and piggyback combination lenses, with corneal 
transplant surgery remaining the only option. 
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Summary 
 
In the management of keratoconus and related conditions with CRGPcl, researchers highlight 
the importance of avoiding corneal trauma, chronic irritation, scarring and deformation through 
moulding, to preserve corneal integrity and protect against contact lens related exacerbation of 
pathology.  
Individuals with keratoconus may not only suffer from sub optimally fitting CRGPcl 
(Edrington et al., 1999) but also exhibit higher prevalence of atopic disease and therefore 
greater sensitivity to external irritants such as glare, dust, pollen and contact lens edges and 
movement (Feder and Gan, 2011). These factors may reduce their tolerance to the small 
diameter, highly mobile, sub-optimally fitted CRGPcl. The close proximity of CRGPcl to the 
fragile, bio-mechanically compromised keratoconic cornea has the potential to cause 
undesirable effects, exacerbating corneal pathology. Due to the progressive nature of 
keratoconus, the requirement to distribute the weight of the CRGPcl evenly over the fragile 
cone and the peripheral cornea is difficult to achieve and maintain. The most commonly 
encountered feature in CRGPcl fitting of a keratoconic cornea is lens bearing on the cone, 
which is considered by most researchers to lead to corneal scarring, with detrimental 
consequences on vision, comfort and Qol.  
When CRGPcl are fitted with corneal clearance to avoid corneal bearing, the resultant lens 
cornea interaction may result in compromised comfort, reduced vision and lens tolerance and 
most worryingly the exacerbation of pathology.  
Due to their size and large, 360° area of contact / alignment with the sclera, SRGPcl are 
minimally mobile and the thin and well-rounded lens edges are tucked-in under the eyelids, 
which facilitate eyelid gliding over the smooth lens surface without undue irritation during 
blinking. The complete vault of the entire cornea by the central portion of SRGPcl protects the 
cornea and surrounding tissue from direct mechanical insult by the lens and external irritants 
and debris. SRGPcl may therefore not only reduce or eliminate the adverse effects of direct 
mechanical lens / cornea interactions but also provide a barrier to other external irritants.  
SRGPcl may enable through utilisation of more complex optics improve the quality of the 
retinal image. The additional advantage of modern highly gas permeable contact lens materials 
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and customisation of SRGPcl with modern computerised manufacturing make the use of these 
lenses logical in the management of keratoconus and other irregular cornea disorders, not only 
as the last resort in patients who failed with other contact lenses, but also as suggested by 
(Bergmanson et al., 2016) as a lens of first choice. Despite these theoretical advantages of 
SRGPcl there has not been a marked shift from using these lenses as a problem solver to lens 
of first choice. Possible reasons for this may be greater costs, required fitting expertise, and 
lack of high-quality evidence-based research.  
In agreement with Mandathara et al., (2017), I found no randomised controlled trials evaluating 
the management of keratoconus with contact lenses, nor other clinical studies which compare 
the performance of SRGPcl on patients whose management with CRGPcl is satisfactory. A 
RCT comparing outcome measures of visual performance, vision related Qol and SPC and 
SPV, may be useful in the consideration of a wider use for modern SRGPcl in specialist contact 
lens practice, not just as a problem solver but as a management of choice to positively enhance 
the contact experience and potentially as first choice management option in patients with ectatic 
disorders.  
To address the issues raised above, a research question may be formulated as follows: Is there 
a significant difference in the visual performance, visual Qol, SPC and SPV between CRGPcl 
and SRGPcl in successful CRGPcl wearers with keratoconus. 
The null hypothesis (H0) of this RCT is that there will be no difference between CRGPcl and 
SRGPcl in any of the research outcome measures. 
The alternative hypothesis is that a significant difference between CRGPcl and SRGPcl would 
be found in one or more of the research outcomes.  
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Chapter 4: Methods 
 
 
 
Introduction  
 
 
In this section the research experimental design, interventions, outcome measures and 
statistical methods will be described. 
The chosen experimental design for this research is RCT with a crossover. The RCT when 
appropriately designed, conducted, and reported, represents the gold standard quantitative 
design for evaluating healthcare interventions (Schulz et al., 2010; Burns et al., 2011). The 
crossover is described in more detail below, compares intra-subject differences between the 
two groups, thus avoiding problems of comparability with regard to confounding variables 
such as gender and age, as participants are their own controls (Wellek and Blettner, 2012). 
RCT with a crossover was therefore considered the most appropriate experimental design to 
show if a difference existed between the performance of the two experimental lens types. The 
literature review showed to date no RCT researching contact lens management of keratoconus 
was performed, this was also confirmed by other researchers (Mandathara et al., 2017).  
 
 
Crossover design 
 
A crossover design is a repeated measurements design such that each participant receives 
different treatments during different time periods, by crossing over from one treatment to 
another during the course of the trial. This is in contrast to a parallel design in which 
participants are randomized to a treatment and remain on that treatment throughout the trial. In 
crossover clinical trials the disease/condition should ideally be chronic and stable, and 
the treatments should not result in total cures but only alleviate the disease / condition. 
Crossover design therefore works well for chronic conditions, where there is no cure and the 
treatments attempt to improve Qol. 
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Crossover design is considered appropriate in this experiment because, the condition 
investigated: corneal ectasiae generally and keratoconus specifically, are chronic in nature 
(Gordon-Shaag et al., 2015) and although progressive, tend to stabilise with time and are rarely 
diagnosed after age 50 (Ramez et al., 2017). The treatment investigated in this research are two 
different contact lens types, which both optimise VA by masking the irregular astigmatism and 
reducing the HOA. These lenses are not curative but a mode of management of the optical / 
visual disability caused by keratoconus (Feder and Gan, 2011; Watts and Colby, 2017). 
Furthermore, we were interested in comparing two contact lens management alternatives with 
respect to outcomes measures of visual quality, Qol and SPC and SPV, thus to control for 
individual confounds, it was desirable to administer both management options to each 
participant. 
In this experiment the 2×2 crossover design was used (Table 4.1), participants who were 
randomized to the sequence AB received treatment A in the first period and treatment B in the 
second period, those randomised to sequence BA receive treatment B in the first period and 
treatment A in the second period (Figure 4.1). 
 
 
Table 4.1 Crossover design sequences 
Period / Sequence Period 1 Period 2 
Sequence AB CRGPcl SRGPcl 
Sequence BA SRGPcl CRGPcl 
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Figure 4.1 sequence of randomisation and crossover 
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The main disadvantage of a crossover design is that carryover, period and sequence effects 
(see below) may be confounded with treatment effects and cannot be estimated separately, 
which may bias results [treatment effect is the effect of a treatment at the time of its 
application]. 
A carryover effect is defined as the effect of the treatment from the previous time period on the 
response at the current time period, i.e., measurements taken during the second period may be 
a result of the direct effect of the treatment in period 2 and/or the carryover or residual effect 
of the treatment applied in period 1, yielding statistical bias. The incorporation of 
appropriate washout periods in the experimental design can diminish the impact of carryover 
effects. The presence of a differential carryover effect must be tested for by an appropriate 
independent samples test comparing the sums of the treatments between the 2 groups (Wellek 
and Blettner (2012). If a differential carryover effect is significant, this must be appropriately 
accounted for in the statistical analysis (Jones and Kenward, 2015). 
A washout period is defined as the time between treatment periods, the rationale for this is that 
the previously administered treatment is “washed out” and therefore should not affect the 
measurements taken during the current period with the exception of permanent effects which 
alter the participant in some manner. Assuming that no significant permanent alteration of the 
participant occurs, it is important to identify if a differential carryover effect, (carryover effect 
due to [A] differs to carryover due to [B]), because if the carryover effects for [A] and [B] are 
equivalent, this common carryover effect is not confounded with the treatment difference.  
A sequence effect can result if participants assigned to one sequence are different from those 
assigned to the other sequence, but under a randomized design it is reasonable to assume that 
sequence effects are minimized (Diaz-Uriarte, 2002). 
A period is each occasion on which a treatment is applied, a period effect must be accounted 
for due to changes of the participants during the intervals between the measurements, or 
through habituation to the measurement itself (Diaz-Uriarte, 2002). To test for the presence of 
period effects, the crossover differences, which are equivalent to the differences in scores of 
treatments for all subjects (A-B), are computed and compared by an appropriate independent 
samples test (Diaz-Uriarte, 2002). The presence of a period effect must be accounted for in the 
statistical analysis of the results (Table 4.2).  
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Wellek and Blettner (2012) in agreement with Diaz-Uriarte (2002), stated that crossover trials 
are not typical matched-pairs designs, however are often analysed inappropriately, as if they 
were. The main problems with this approach according to Diaz-Uriarte (2002) are  
1. Not accounting for period effects, which may affect the results of measurements depending 
on the period these measurements occurred.  
2. Failure to consider carryover effects when comparing treatment effects. 
These errors may lead to questionable results, where the lack of significant treatment effects 
could be the consequence of inflated variances (type II error), and the significant effects 
reported could be the result of either period or carryover effects (type I error) (Diaz-Uriarte, 
2002). 
The AB/BA design employed in this research is considered to be balanced [each treatment 
precedes every other treatment the same number of times (once)], which means that if the 
carryover effects are equal, then carryover effects are not confounded with treatment 
differences.  
The AB/BA design is also uniform within sequences [each treatment appears the same number 
of times within each sequence], which means that sequence effects are not confounded with 
treatment differences and are uniform within periods [each treatment appears the same number 
of times within each period] minimising the confounding period effect.  
Due to the design being balanced, one approach for the statistical analysis of the 2×2 crossover 
is to conduct a preliminary test for differential carryover effects, if this is found to be not 
significant, then the data from both periods are analysed in the usual manner. If there is a 
differential carryover effect, then only the data from the first periods are analysed, where 
differences between participants in the two groups are compared as in a parallel RCT (Wellek 
and Blettner, 2012; Armitage and Hills, 1982).  
Because this experimental design involves repeated measurements on participants, the 
statistical modelling must account for between-participant variability [dispersion in 
measurements from one participant to another], and within-participant variability [dispersion 
in measurements from one time point to another within a patient]. The crucial variable for 
analysis in a crossover design is the within subject difference in outcome between the two study 
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periods. In order to assess the difference between treatment effects, a statistically valid test for 
independent samples has to be carried out with the values obtained for this variable. 
The statistical analysis of normally-distributed data from a 2×2 crossover trial, under the 
assumption that the carryover effects are equal is as follows: 
The statistical model we assumed for continuous data from the 2×2 crossover trial [(Table 4.2 
Jones and Kenward (2015)]: 
 
Table 4.2 Crossover design sequence by period statistics (Jones and Kenward, 2015) 
 
Sequence / Period Period 1  Period 2  
Sequence AB μA + ν + ρ μB + ν - ρ + λA 
Sequence BA μB - ν + ρ μA - ν - ρ + λB 
 
 
μA and μB represent population means for the direct effects of treatments A and B, respectively, 
ν represents a sequence effect, ρ represents a period effect, and λA and λB represent carryover 
effects of treatments A and B, respectively. For sequence AB, the Period 1 vs. Period 2 
difference has expectation μAB = μA - μB + 2ρ - λ. For sequence BA, the Period 1 vs. Period 2 
difference has expectation μBA = μB - μA + 2ρ - λ. Therefore, we construct these differences for 
every participant and compare the two sequences with respect to these differences using an 
appropriate independent samples test. Thus, we are testing: H0: μAB - μBA = 0 for each outcome 
measure (Jones and Kenward, 2015). 
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Study population recruitment 
 
 
Participant selection 
 
 
Most of the participants were recruited from the contact lens clinic in the ophthalmology 
department at the Central Middlesex Hospital (CMH) in North-West London. The CMH 
ophthalmology department provides specialist contact lens care to patients with corneal 
pathologies or other conditions, which require contact lens care beyond the scope of many 
community optometrists. Patients are usually referred to the department by community 
optometrists via their general practitioners. Three patients, who completed the study, were 
recruited from the chief investigator’s community practice. One patient approached the 
investigator by email but did not fulfil the selection criterion of being free of problems with his 
current CRGP contact lenses and therefore was rejected. 
The CMH contact lens clinic offers a single, weekly clinical session, during which up to twelve 
patients may be examined. Two optometrists provide specialist contact lens management to 
patients in this clinic; the chief investigator Mr A. Levit and the research coordinator Mr A. 
Stanton. Both optometrists are contact lens specialists with many years of experience of 
working in the NHS hospital eye service and private specialist contact lens clinics. Both 
optometrists achieved the Good Clinical Practice certification prior to starting this research 
(Appendix IIIA). 
 
 
Inclusion criteria  
 
1. Diagnosis of Keratoconus or related primary and secondary irregular cornea conditions [see 
chapter 2].  
2. Participants are successful CRGPcl wearers. 
88 
 
3. Age 18 to 69. These ages were decided upon since contact lens management of keratoconus 
rarely occurs before the age of 18, and additional eye morbidities which may affect vision are 
more common after the age of 70. 
 
 
Exclusion criteria  
 
1. Patients with keratoconus who are satisfied with their unaided vision in both eyes. 
2. Patients with keratoconus who have additional eye disease which affects their vision, such 
as significant cataract, glaucoma etc. 
 
Most participants were fitted with the experimental lenses in both eyes. For four participants 
only one eye was fitted with both experimental lenses recruited. This is because, although 
keratoconus is a bilateral disease (Gomes et al., 2015), there may be a significant asymmetry 
between the two eyes (Zadnik et al., 2002). It is not unusual for patients to require keratoconus 
management in one eye only, with the other eye having sub-clinical disease or having 
undergone a corneal graft due to severe disease. It was therefore considered appropriate not to 
exclude participants with eye asymmetry, who either required no treatment or wore contact 
lenses which could not be included in this research. Including these patients was considered an 
appropriate representation of the variety of patients with corneal ectasiae requiring contact lens 
management. 
 
 
Participants recruitment 
 
The recruitment process was performed during the regular contact lens clinics. At CMH, the 
research coordinator, would inform the prospective patients that they were eligible to 
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participate in the study and would provide them with written information about the study 
(Appendix IA). In community practice the chief investigator’s clinical assistant Mr Daniel 
Gorjian, would inform the prospective participants that they may be eligible to participate in 
this research and provide the written information. The recruitment started in January 2016, 
following ethical approvals in September 2015 and was completed in July 2018.  
No direct payments were made to participants. However, all contact lenses were supplied free 
of charge during the trial period. At the end of the trial participants could keep either of the 
contact lenses used in the trial, under the usual optometric supervision at the contact lens clinic.  
Confirmation of suitability was based on satisfactory performance of CRGPcl. The symptoms 
and history examination conducted during the standard, routine contact lens check-up 
established whether the prospective participant was experiencing any significant difficulties 
during their contact lens wear. Examination of contact lens fit and BCVA were performed 
subsequently to ensure that the habitual CRGPcl exhibited acceptable physical fit and enabled 
adequate visual performance (Appendix IIA). The integrity of the corneal surface and the rest 
of the ocular adnexa were checked to confirm that no significant adverse effects were caused 
by contact lens wear.  
Suitable candidates were given the research participant information document (Appendix IA 
and IB) to read and if interested were invited to participate in the research after the completion 
of the formal informed consent procedure (Appendix IC). 
 
 
Informed consent procedure 
 
After reading the participant information document the prospective candidates had an 
opportunity to ask questions and discuss these with the chief investigator during their regular 
follow up appointment or other appropriate time during the contact lens clinic. The chief 
investigator gave the informed consent document (Appendix IB) to the prospective candidates 
and discussed all aspects of the RCT, prior to signing the consent form within three months 
from the invitation to participate. All prospective participants had sufficient time to ask 
questions and to consider and decide whether they wished to participate. 
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After signing the consent form (Appendix IC), all participants were reminded that they were 
free to withdraw at any time without any explanation. It was made clear to them in writing and 
verbally that should they choose not to participate in the research or withdraw from the research 
prior to its completion their standard of care will not be affected. 
 
 
Communication of urgent and routine matters  
 
The participants were informed in their consent document that should an issue arise, which 
would influence their continued participation; it would be conveyed to them by e-mail, 
telephone or by a written letter depending on the urgency. Participants’ details were available 
to the chief investigator in the participants’ hospital records and the digital practice records 
kept on password protected computer. Routine information was conveyed to the participants 
during their routine check-ups. 
 
 
Loss of capacity  
 
Participants were informed during their consent procedure that in the unlikely event of a loss 
of capacity, the research team would retain research data collected and continue to use it 
confidentially for the purposes for which consent was sought. This could include further 
research after the current project has ended as this was made clear in the information for 
participants. 
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Access to research results  
 
At the completion of the study a lay summary of the anonymous results would be prepared and 
published on the Institute of Optometry website. The participant information highlighted this 
and any participants who did not have web access could contact the researchers for a paper 
version. 
 
 
Randomisation 
 
After the completion of the consent process the participants were randomised to group 1 
[sequence AB]and group 2 [sequence BA] according to the randomisation order generated by 
the online research randomiser http://www.randomizer.org/ (Figure 4.1 Appendix V.E). The 
online randomiser created a list of 30 numbers from 1-30 randomly allocated to the 2 groups. 
The participants were allocated their treatment arm in the order of their recruitment from 
participant 1 to participant 30 (Table 4.10). The protocol for replacing participants who were 
unable or unwilling to complete this study was to recruit additional, appropriate participants to 
replace the drop outs with treatment allocation by sequential alternation in participants 31-34. 
The length of participation in the study for most participants did not exceed 9-12 months during 
which they attended on 4-6 occasions. Study total length was from May 2015 to June 2018. 
The extra clinic attendance required by this study (compared with the normal 2 check-ups per 
year) was necessary because most participants were not familiar with SRGPcl and these lenses 
needed to be fitted in the same way as to a new patient, which requires both lens collection and 
lens handling instruction appointments as well as an early review to ensure that no adverse 
effects occurred with these lenses. These additional check-ups as well as the two appointments 
for outcome measures data collection were required in this study. All participants were 
informed about these additional requirements during the informed consent procedure. 
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Experimental contact lenses 
 
The experimental contact lens was the SRGPcl, Zenlens™ and the control contact lens was the 
CRGPcl Rose K2™. Both lens types were fitted to achieve optimal contact lens fit on the ocular 
surface according to recognised clinical criteria (see chapter 3) and manufacturers fitting 
instructions. The CRGPcl Rose K2 lenses were fitted with the aim to achieve the most widely 
recognised best fit of a divided support / three-point touch fitting relationship between the lens 
and the cornea (Loft and Wolffsohn, 2016; Szczotka-Flyn et al., 2006; Woodward, 1989; Watts 
and Colby, 2017).  
The desired lens cornea fitting relationship was achieved with the Rose K2 lenses by utilising 
a comprehensive fitting set, consisting of 26 lenses, with optical lens radius range 5.10 to 
7.60mm (full range 4.30-8.59mm), in a variable lens diameter from 8.50 to 9.20mm (full range 
7.90-10.40mm), with variable power to approximate the final lens power (range -2.00 to -
23.00DS). Lens adjustments were implemented following the recommended fitting guidelines 
(Art Optical, 2013). Central fitting of cone clearance or feather cone touch was achieved by 
selecting the appropriate central optic zone radius from the fitting set until the desired central 
fit was achieved. Modification of the central lens radius and or diameter was possible if 
required, when the fitting set lens central parameters did not achieve an acceptable fit. 
Peripheral lens fitting was optimised by utilising the flexible edge lift system, with 5 levels of 
symmetrical edge lift variation.  
When necessary central and / or peripheral toric lens designs or quadrant specific asymmetrical 
corneal technology were employed in moderate to high corneal asymmetry (Art Optical, 2013). 
The CRGPcl mean OZR was 7.05mm, Mean lens diameter was 9.11mm, mean lens power was 
-5.79DS, cylinder -1.92DC and axis 145°. Standard lens design was used in 32 lenses (57%). 
The 24 (43%) of non-standard lenses used were 6 (11%) toric (central and /or peripheral), 1 
(2%) was quadrant specific, the remaining 17 (30%) had adjusted, symmetrical, non-standard 
peripheral lens curves. The CRGPcl were manufactured and supplied by the CE approved 
British contact lens manufacturer Menicon David Thomas.  
The SRGPcl were initially manufactured by the CE approved Dutch contact lens manufacturer 
UCO-Lavec-BV and later by the Bausch and Lomb speciality contact lens manufacturing 
division in Hastings UK. The desired fitting relationship between the eye and the SRGPcl was 
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achieved by following the published manufacturer fitting guidelines (Alden Optical, 2016) and 
recognised standards of clinical experts (van der Worp, 2015). The lenses were fitted from 2 
comprehensive fitting sets (26 lenses in each set), one with symmetrical peripheral (haptic) 
design the other with a toric haptic design. The fitting sets contained lenses in 2 diameters, 
16mm [n=54 (96%)] and 17mm [n=2 (4%)] and in two designs, prolate (flattening ellipse) 
(n=56) and oblate (steepening ellipse, nil used in this research), with central SAG (lens height) 
increments of 300µm, range 4100-5800µm, with a total, customisable SAG range of 3200 - 
6700µm in 10µm micron steps. The customisable SAG range facilitated the achievement of 
the required 200-300µm corneal clearance after lens settling. This was achieved by allowing 
the best fitting trial lens to settle for a minimum of 60min and then comparing the tear layer 
thickness, between the cornea and the lens, to the standard lens thickness across the fitting set 
of 350µm (van der Worp, 2015).  
The control of limbal clearance could be achieved separately from central corneal clearance by 
modifying the lens SAG at the limbal area, without affecting the central clearance by the 
utilisation of the smart curve, a design feature unique to the Zenlens, which enables the fitter 
to achieve the desired central lens clearance from the cornea, with minimum effect from other 
lens modifications (Alden Optical, 2016). The mean OZR of the 56 lenses fitted was 7.48mm, 
mean SAG = 4627.7µm, mean lens power = -3.25DS and -1.61 cylinder with a mean axis of 
120°.  
The modification of the Alignment Peripheral Curve System facilitated appropriate scleral 
alignment via symmetrical 360° modification or the utilisation of toric haptic curves. The toric 
Alignment Peripheral Curve System fitting set facilitated the fitting of SRGPcl with toric haptic 
or bi-toric lenses (toric haptic with front toric optics). Standard APS was used in 16 (29%) 
lenses, in the non-standard APS in the 40 (71%) lenses, 36 (64%) were with a toric haptic 
portion, 10 (18%) were bi-toric (toric haptic and toric front optics). Other custom features such 
as front surface toric optics [n=1 (2%) with a standard APS] and pinguecula / pterygium 
channels called MicroVaults [n=6 (11%)] were employed when required to optimise visual 
acuity and lens sclera fitting relationship respectively.  
Appropriate clinical guidelines and best practice were followed for the fitting and use of both 
types of contact lenses (Appendix ID and IE). The chief investigator who is a hospital eye 
service contact lens practitioner with over 20 years’ experience, personally fitted all the 
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experimental lenses. During the research, contact lens supply and after-care was carried out to 
the usual standard adopted at CMH. 
Once the fitting had been completed the lenses were checked by the chief investigator at 
collection and rechecked one to three weeks after collection. All participants were 
appropriately instructed regarding contact lens wear, care and safety and written information 
was provided to them (Appendix ID and IE). The final check was performed 8-12 weeks post 
initial lens collection. During the final check appointment, the visual performance was 
measured and recorded by the research coordinator Mr Anthony Stanton or Mr Daniel Gorjian 
in the hospital clinic and by Mr Daniel Gorjian in community practice, during this time both 
were naive to the type of lenses worn by the participants (Appendix IIB). The visual quality of 
life questionnaire completed by the participants during that appointment or a few days prior 
was collected by the chief investigator. 
After this check-up the other lens type was fitted by the chief investigator and ordered from the 
manufacturer. The collection appointment was scheduled to a date in accordance with the 
mandatory washout period at least one month later. During the washout period, participants 
wore their original CRGPcl until the scheduled appointment to collect the crossover 
intervention to start the second period. During the crossover phase, check-ups were performed 
in an identical manner to the first phase. At the end of the crossover phase the participants were 
informed that their participation in this research was completed and they asked to choose one 
of the two experimental lenses as their lens of choice for continued habitual wear.  
 
 
Research outcome-measures 
 
The primary outcome measures of the RCT is ETDRS logMAR, monocular VA measurement 
(see below). The secondary outcome measures were the CSF visual performance measured by 
the CSV 1000E console (VectorVision, 2013), the validated NEI-VFQ (Mangione, 2000; 
Mangione et al., 2001) and the SPV and SPC developed by the chief investigator, the Levit 
subjective vision score (LSVS) and the Levit subjective comfort scores (LSCS).  
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The ETDRS logMAR VA is the most commonly used measure of high contrast visual 
resolution in research and clinical practice (British Standards Institution., BS 4274-1:2003; 
Arditi and Cagenello, 1993; Ferris et al., 1982). The ETDRS logMAR and the CSF scores were 
measured by repeated, forced choice, letter by letter scoring for logMAR (Vanden Bosch and 
Wall, 1997), and each of the eight pairs of gratings in each of the 4 CPD rows for CSF. 
These outcome measures were assessed at the beginning of the study with the participants’ 
habitual CRGPcl for baseline and familiarisation purposes and at the end of the two 
interventions. Both BCVA and CSF were measured using the commercially available 
instruments: the CSV 1000E manufactured by Vector Vision (VectorVision, 2013) for the CSF 
and the chart manufactured by Precision Vision http://www.precision-vision.com/  for the 
logMAR BCVA at the CMH. The 1000E console was used for both CSV and logMAR BCVA 
in the three participants recruited in the community practice. Both instruments are used 
extensively in research and clinical trials worldwide, and are approved and recommended by 
both the FDA and NEI (VectorVision, 2013). Chart illumination in this research was a 
standardized uniform retro illumination of 85 cd/m², which is the ideal standard for research 
(Ricci et al., 1998), generally in clinical practice there is insignificant change in performances 
above 80 cd/m2 (Sheedy et al., 1984). 
The other secondary outcome measure was the NEI-VFQ validated by Mangione (2000). This 
is a vision related Qol instrument designed to assess subjective perception of visual function 
and quality of life. This instrument, which has been used by other researchers investigating 
keratoconus (Kymes et al., 2008c; Kymes et al., 2004; Tatematsu-Ogawa et al., 2008) was 
applied to give baseline values at the beginning of the study and repeated the completion of the 
period of use of each intervention.  
Further secondary outcome measures were the SPV and SPC assessed with LSVS and LSCS 
respectively, which are Likert-like scales from 1-10 (worse- best) grading of the participants’ 
perception of their own vision and comfort in each experimental lens. 
The final outcome measure of this research was the participants’ choice of one of the two 
experimental lenses for future habitual wear. This choice was correlated to other outcome 
measures to establish if there are possible clinical reasons for that choice. 
The tertiary outcome measure, which was not expected to differ with the two lens types but 
was measured as a precaution, was the ocular integrity post contact lens wear. The integrity of 
96 
 
the cornea and the conjunctiva was examined on lens removal and was accurately recorded 
utilising the validated scales of contact lens induced corneal fluorescein staining scales (Efron, 
1996; Efron, 1998; Efron et al., 2001). For the conjunctiva the validated scale of conjunctival 
hyperaemia was used (Efron, 1997a). These measurements of contact lens wear induced 
complications are a mandatory part of standard clinical practice and as such their accurate 
assessment and recording in this research enabled an objective comparison of the effects of the 
two lens types on the ocular status of the participants.  
 
 
Data 
 
Visual outcome measures 
 
It was considered that in this clinical trial the measurement of both BCVA and CS, whilst 
wearing contact lenses may provide a more complete understanding of the effects of treatment 
on the quality of vision than either measure alone (Rubin, 2013). ETDRS logMAR BCVA and 
CSF numeric and logCS values were measured at baseline and at the completion of each period. 
Detailed discussion of these outcome measures is presented in the chapter 1. 
 
 
Visual acuity (VA) 
 
VA is the most widely used measure of visual function both in optometric clinical practice and 
in vision research and is routinely used for evaluating the effectiveness of refractive, medical 
and surgical treatments (British Standards Institution., BS 4274-1:2003). The preferable 
forced-choice testing, with letter counting scoring procedure were used in this research (Ricci 
et al., 1998). A difference of 1 line (5 letters or 0.10 logMAR) was considered significant, with 
95% confidence that a real change has occurred (Bailey et al., 1991).  
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Contrast sensitivity 
 
The CSV-1000E provides a full contrast sensitivity curve, which is very useful for the 
evaluation of ocular disease, particularly cataracts (Shandiz et al., 2011), glaucoma (Gandolfi 
et al., 2005), optic neuritis in multiple sclerosis (Sisto et al., 2005), diabetes (Sadeghpour et 
al., 2015), macular degeneration (Richer et al., 2004), visual performance in contact lenses 
(Porisch, 2007; Wachler et al., 1999) and after refractive surgery (Tuan and Liang, 2006). Two 
different charts versions were used in this research to provide apparently randomised locations 
for the grating targets (Ginsburg, 1984; VectorVision, 2013). The forced choice testing 
procedure was implemented for CSF testing as well. 
 
 
 
The NEI-VFQ 
 
The validated NEI-VFQ (Mangione, 2000; Mangione et al., 2001) was used in this research as 
a subjective measure of the participant’s perceptions of their visual wellbeing during the 
periods of use of both the experimental and control contact lenses. The first time this 
questionnaire was completed by the participants as a baseline was in the beginning of the study, 
describing the visual Qol in their habitual CRGPcl. The following two times this questionnaire 
was completed were at the end of each treatment period. 
NEI-VFQ was developed as a survey which measures various aspects of self-reported vision-
targeted health status in individuals with chronic eye diseases. The survey measures the 
influence of visual symptoms and disability on health issues such as emotional well-being and 
social functioning, as well as task-oriented visual functions. The survey contents were based 
on issues which were identified during a series of condition-specific focus groups, using 
patients who had variety of ocular pathologies (Mangione et al., 1998). The NEI-VFQ 
represents a shortened version of the 51-item version, it consists of 25 questions representing 
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12 domains, 11 vision-related and a single general health rating question [Table 4.5 Appendix 
V.F. Mangione (2000)].  
The NEI-VFQ generates the following vision-targeted subscales: 1 global vision rating 
question, 3 questions regarding difficulty with near vision activities, 3 questions regarding 
difficulty with distance vision activities, 2 questions regarding limitations in social functioning 
due to vision, 2 questions regarding role limitations due to vision, 3 questions regarding 
dependency on others due to vision, 4 questions regarding mental health symptoms due to 
vision, 3 questions regarding driving difficulties, 1 questions regarding limitations with 
peripheral vision and colour vision, 2 questions regarding ocular pain and 1 general health 
rating question.  
 
 
NEI-VFQ data entry, coding and analysis 
 
Detailed description of data entry, data extraction, recoding individual answers, accounting for 
missing answers and generating average scores are in Appendix IV. A. B and C. Table 4.6 
exhibits the items which are averaged to generate VFQ-25 + optional in the NEI-VFQ 
(Mangione, 2000). 
Table 4.6 Averaging of items to generate (VFQ-25+optional Items) (Mangione, 2000) 
Scale No of Items Items to be averaged 
General Health  2 1, A1 
General Vision 2 2, A2 
Ocular Pain 2 4, 19 
Near Activities 6 5, 6, 7, A3, A4, A5 
Distance Activities 6 8, 9, 14, A6, A7, A8 
Vision specific 
Social Functioning 3 11, 13, A9 
Mental Health 5 3, 21, 22, 25, A12 
Role Difficulties 4 17, 18, A11a, A11b 
Dependency 4 20, 23, 24, A13 
Driving 3 15c, 16, 16a 
Colour Vision 1 12 
Peripheral Vision 1 10 
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Subjective perception of comfort (SPC) and subjective perception of vision (SPV) 
 
The assessment of the SPC and SPV in contact lenses is an integral part of symptoms and 
history examination in optometric practice. Typically, these variables are assessed in an 
informal, binary way: “Are your contact lenses comfortable?” and “Is your vision with the 
contact lenses clear?”. For this research, a numerical rating scale was used as described below. 
Numerical rating scales and visual analogue scales are considered equally useful tools in the 
assessment of subjective quality of vision in contact lenses (Gullon and Schock, 1991; Papas 
and Schultz, 1997) and comfort during contact lens wear (La Hood, 1988). Grading scales are 
commonly used in clinical research, particularly in relation to the grading of pain. Williamson 
and Hoggart (2005) reviewed the literature regarding the visual analogue, verbal, and 
numerical pain rating scales and concluded that, “all three pain-rating scales were valid, 
reliable and appropriate for use in clinical practice”, further, they reported that “the 
Numerical Rating Scale has good sensitivity and generates data that can be statistically 
analysed for audit purposes” (Williamson and Hoggart, 2005).  
In this research the subjective measures of comfort and vision with the two experimental 
lenses were elicited after each period of lens wear and graded on a specially designed Likert-
like scales from 1-10, with 1 constituting the worst and 10 the best vision and comfort scores 
(Appendix IIA and IIB).  These grading scales were designed by the chief investigator and 
are routinely used by the chief investigator in his contact lens practice and have been found to 
be useful for decision making in contact lens management. These instruments however, were 
never validated. It was nevertheless considered appropriate to use these instruments alongside 
the other validated outcomes and apply statistical analyses to establish their significance in 
this research. 
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Final lens choice 
 
The final outcome was the participants’ lens choice to use as their habitual lens. The plan was 
to find out whether a correlation could be established between the final lens choice and any 
statistically significant differences between the primary and secondary outcomes in the two 
experimental lenses.  
Recommendation for validation of significant findings and their implementation in specialist 
and general optometric practice to aid in the decision-making processes would be made 
regarding the appropriateness of CRGPcl and SRGPcl and the likelihood of success when 
refitting from one type to another. 
 
 
Ocular integrity 
 
The integrity of the cornea and the conjunctiva were examined on lens removal at each stage 
of the research, at baseline, after wear of the randomised lens and after wear of the crossover 
lens, as required in standard clinical practice. Although not an outcome measure in this 
research, it was decided that should any unusual or adverse effects have occurred, these would 
be reported. 
Wolffsohn et al., (2015) performed an international survey of eye care practitioners regarding 
their anterior eye health recording practices to formulate guidelines for best practice. They 
recommended specifying the grading scales used and record scores to 1 decimal place. They 
advised that the following conditions are graded in every contact lens examination; bulbar and 
limbal conjunctiva hyperaemia, limbal neovascularisation, conjunctival papillary redness and 
roughness, both in white light and with sodium fluorescein (NaFl). They recommended 
recording the grades of blepharitis, meibomian gland dysfunction and NaFl staining of both the 
cornea and conjunctiva (Wolffsohn et al., 2015). These recommendations were followed in this 
research, using the validated grading scale for contact lens complications developed and 
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validated by Efron et al., (1996), (1997), (1998) and (2001) (Efron et al., 2001; Efron, 1998; 
Efron, 1997b; Efron, 1996).  
There are 16 sets of grading images; these represent the key anterior ocular complications of 
contact lens wear. The conditions are illustrated in five stages of increasing severity from 0-4, 
with ‘traffic light’ colour coding from green (normal) to red (severe) (Table 4.7. Appendix 
IV.D). 
 
 
Sample size calculation 
 
For the purpose of sample size calculation in this research the primary outcome measure of 
ETDRS logMAR BCVA was selected. The calculation was carried out considering the worst-
case scenario. This is that a differential carryover effect and / or significant period effect were 
found, in which case the data would have to be analysed as a parallel group trial instead of a 
crossover trial. Therefore, the sample size calculation was based on the most conservative 
approach, calculating the number of participants required if it were just a parallel group trial 
without crossover. For the calculation, data from previous work by Marsack et al., (2007), 
Nejabat et al., (2012), Davis et al., (2006), Sabesan et al., (2013), Gumus et al., (2011) were 
used to provide the information of BCVA in CRGPcl and SRGPcl (Table 4.8, Figure 4.4).  
Table 4.8 Research used to establish mean and standard deviation for sample size 
calculation (Marsack et al., 2007; Nejabat et al., 2012; Davis et al., 2006; Sabesan et al., 
2013; Gumus et al., 2011) 
Authors CRGPcl logMAR mean (StdDev) SRGPcl logMAR mean (StdDev) 
Gumus et al., (2011)   0.09 (±0.10) 
Marsack et al., (2007) 0.15 (±0.11)   
Nejabat et al., (2012) 0.04 (±0.04)   
Sabesan et al., (2013)   0.40 (±0.18) 
Davis et al., (2006) 0.12 (±0.16)   
Total mean and StdDev 0.10 (±0.10) 0.25 (±0.14) 
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The required number of subjects (n) can be calculated from the following formula: (Armitage 
and Berry, 1987); N > 2 {(Z2α + Z2β) Ϭ /δ0}2 
The value Z2α represents the level of result that will be taken as being statistically significant. 
This will be a two-tailed (p=0.05), giving Z2α=1.96. Z2β represents the desired statistical power, 
set at 0.80, giving Z2β=0.842. δ0 represents the clinically significant difference and Ϭ is the 
standard deviation of the population.  
The key variable in the sample size calculation is high contrast logMAR BCVA, the most 
widely used and quantitatively rigorous measure of visual performance. The figures were taken 
from the aforementioned studies in which BCVA with CRGPcl was measured. The studies 
with CRGPcl only were used for the sample size calculation as these were performed on large 
numbers of participants with keratoconus who wear CRGPcl as required by the eligibility 
criteria in the current RCT. Furthermore, the SRGPcl study: Sabesan et al., (2013) was a pilot 
study with only 11 eyes of 6 participants, and the larger SRGPcl study by Gumus et al., (2011), 
exhibited similar logMAR BCVA scores to those found in the CRGPcl studies. A single line 
change (0.10 logMAR) was taken as representing a clinically significant change in logMAR 
BCVA (Bailey et al., 1991; Brown and Yap, 1995).  
Davis et al., (2006) showed a mean logMAR visual acuity with CRGPcl in participants with 
keratoconus of 0.12 (±0.16), Marscack et al., (2007); 0.15 (±0.11), Nejabat et al., (2012); 0.036 
(±0.04). From these studies the average standard deviation obtained was 0.10. The variance of 
both values was calculated and averaged and the square root of the mean variance calculated 
to give the common standard deviation. This was used in the above formula with an alpha of 
0.05 and for power of 80% to give a required sample size of 15 in each group (Table 4.9). This 
was checked with an online calculator www.stat.ubc.ca/~rollin/stats/ssize/n2.html, which also 
gave a sample size of 15 in each group. The plan was therefore to continue the study until at 
least 30 participants have completed the study, 15 starting with CRGPcl and 15 with SRGPcl. 
Recruitment continued until 30 participants had finished both periods.  
Table 4.9 Sample size calculation 
For power of 80% Mean SD Variance Mean variance Common SD N 
CRGPcl  0.10 0.10 0.01 
0.01 0.10 15.70 
SRGPcl  0.20 0.10 0.01 
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The fact that the ratio of participants in the 2 experimental groups changed from the planned 
15 in each group to 13 in group 1 and 17 in group 2, should have a minimal effect on the 
significance and power of the study, see discussion in strengths and limitations.  
 
 
 
Minimising measurement bias 
 
Blinding is more difficult to achieve in non-pharmacologic trials (Boutron et al., 2004), and 
participants knew what type of contact lens they inserted every morning. To minimise possible 
investigator-bias the outcome measures of VA and CS were performed by the research 
coordinator and the chief investigator’s clinical optometrist assistant Mr Daniel Gorjian, both 
naive to the type of contact lenses worn by the participant at the time of measurement. This 
was achieved by the chief investigator performing the initial examination of symptoms and 
history, grading of comfort and vision, visual acuity, over-refraction and contact lens condition 
and fit evaluation. The visual acuity and contrast sensitivity were measured and recorded by a 
naïve examiner in a different room. After the completion of these procedures the chief 
investigator copied the recorded results into the computer-based research database program.  
 
 
Statistical analysis 
 
The chief investigator ensured that all relevant data were collected and recorded, data from 
participants who did not participate in both arms of this research were not included in the 
statistical analysis.   
The IBM-SPSS version 21 was used for all statistical calculations, Microsoft Excel 2010 was 
used for data storage as well as the generation of some graphs and tables, the data was recorded 
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in a specially designed database in LibreOffice version 5.0.4, prior to being transferred to the 
Excel files (see below and Appendix IVA, B and C).  
The chief investigator carried out all statistical analyses under the guidance and supervision of 
the research supervisors Prof. Bruce Evans and Dr Martin Benwell. A preliminary statistical 
analysis was carried out after 12 participants had fully completed their participation; this was 
done to assess the significance of the carryover effect in this research. The complete statistical 
analysis was carried out after the data were collected for all participants who completed the 
research. 
 
Pooling of data 
 
Following the recommendation of Armstrong (2013) and personal communications with 
Armstrong, experimental data were collected from both eyes in most (Armstrong, 2013). 
Keratoconus is a bilateral disease (Gomes et al., 2015), with significant asymmetry between 
the two eyes (Zadnik et al., 2002), it was therefore hypothesised that it may be appropriate to 
use the visual scores of each eye as an independent sample to increase sample size and 
maximally utilise the available data.  
The counter argument for pooling the data are that measurements obtained from right and left 
eyes are usually correlated (Katz et al., 1994), and therefore may not be treated as if they are 
independent samples, an assumption made in statistical procedures, such as t-tests, analysis of 
variance, confidence intervals and linear regression. When testing hypotheses, the use of 
inappropriately pooled data from both eyes increases the possibility of a type 1 error because 
the variance between the eyes of the same subject is usually less than that between subjects, 
the overall variance of a sample of measurements combined from both eyes is therefore likely 
to be an underestimate of the true variance. Hence, data collected from both eyes from a sample 
of subjects cannot be combined without taking the correlation into account (Armstrong, 2013).  
In order to avoid this problem, data from one eye only may be analysed, which would lead to 
rejection of the valid data from the fellow eye, reduction of the potential power of the study, 
and may raise ethical questions of subjecting patients to measurements that were not used in a 
subsequent analysis (Armstrong, 2013). 
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The decision was taken in this experiment to perform a correlation analysis of the baseline 
logMAR scores of the right and left eyes of each participant, and a separate analysis of 
correlation between the scores of the right eye and randomised scores of the left eye. The 
significantly higher correlation found between the right and left scores taken from the same 
subject compared with the random correlation, indicated that treating the right and left eyes as 
independent samples and pooling the data from both eyes would be inappropriate. The 
statistical analyses for the carryover, period and treatment effects were therefore performed on 
the mean of the right and left eye’s scores of each participant. 
 
 
Inferential Statistics 
 
In normally distributed data the skewness and kurtosis z values, which are the ratio of skewness 
and kurtosis values and their respective standard error value, should be between -1.96 to +1.96 
and the visual analysis of the data histogram, quantile-quantile plots and box plots should 
indicate that the data are approximately normally distributed (Cramer, 1998; Doane and 
Seward, 2011). Analysis for normality was performed on all data and appropriate statistical 
tests for parametric and non-parametric data were employed in the descriptive and inferential 
statistics, results sections 
Crossover trials have sometimes been analysed using repeated-measures statistical tests, 
although this approach has been criticised by Wellek and Blettner (2012). A similar point is 
made in the respected text book on the analysis of crossover trials by Jones and Kenward 
(2015). Therefore, the inferential statistical analyses of the outcome measures were performed 
as recommended by the above authors.  
Preliminary checks were carried out to ensure that there was no carryover effect from the first 
to the second treatment periods, as recommended in the literature (Jones and Kenward, 2015; 
Wellek and Blettner, 2012; Haynes et al., 2006). It was considered unlikely that a significant 
differential carryover effect would be found because contact lenses do not cure but only 
manage the optical distortions caused by corneal ectasiae. Furthermore, measurements of visual 
performance are not affected by previous visual experiences in adult visual systems (Bailey, 
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2006; Borish and Benjamin, 2006). Additionally, participants who were randomised to SRGPcl 
all had a one-month washout period of returning to wearing their habitual CRGPcl. Despite the 
relatively long duration required for corneal stability post CRGPcl prior to measurements for 
refractive surgery in normal individuals (Tsai et al., 2004), a one-month washout to mitigate 
against the unlikely significant differential carryover effect was considered adequate, as no 
corneal recovery is required in RGPcl wear, since RGPcl neutralise corneal irregularities. It 
was decided that in the unlikely event of a significant differential carryover effect or if a large 
proportion of participants drop out before the second treatment period then the study would be 
treated as a parallel group RCT and the data from the first period will be analysed in the usual 
way as recommended by Haynes et al., (2006). Our conservative sample size calculation 
allowed for this possibility. 
As a precaution, we carried out an unpaired t-test to compare any potential confounding 
variables, e.g., visual acuity and age, in the two randomised groups. It was planned that if these 
analyses identified any statistically significant differences between the two groups in a 
confounding variable then further statistical analysis of covariance (ANCOVA) would be 
carried out to evaluate the treatment effects whilst controlling for these confounding variables. 
 
 
Compliance and withdrawal 
 
Participants’ compliance with wearing of the appropriate contact lenses at each stage was 
established by interviewing participants during each review appointment. No issues with 
compliance were anticipated and none were found as expected, since all subjects were 
experienced contact lens wearers. The chief investigator ensured that compliance with the 
washout period prior to crossover was complied with by supplying the lenses for the crossover 
period only after the completion of the one-month washout period. 
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Data handling and record keeping 
 
Data were collected manually on pre-prepared research clinical records files (CRF) (Appendix 
IIIA, IIIB, IIIc). These were kept in the CMH in a locked cabinet, with no access except for the 
chief investigator. The results were later entered into a password protected digital database 
computer program (see below) which was stored on a password protected computer.  
The relevant clinical information contained in these research records was added to the 
participants’ hospital records during the various consultations.  
The anonymised data were used for the writing of the doctoral thesis and may be used in 
professional publications. The only details used in publications may include the participants' 
gender, age and allocated research serial number, but no personal data. The ethics committee 
had approved that the anonymised data may be kept for five years after the completion of the 
research and may be used for further analysis and publications. 
The chief investigator is responsible for data collection, recording and data analysis. All 
research data were collected by the chief investigator the research coordinator and clinical 
assistant during the scheduled consultations at the hospital eye department’s contact lens clinic 
and community practice. The chief investigator ensured that all data recorded was legible and 
stored in the correct CRF.  
The chief investigator personally double-checked all entries and ensured that correct entries 
were made into the appropriate sections of the database program. 
 
 
The database software for research data recording 
 
A customised database was created using the Base component of LibreOffice version 5.0.4 
configured by a software specialist commissioned by the chief investigator for data collection 
in this research (Appendix IVA, B and C). 
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When a query is run the output is in the form of a table of data.  This is copied and pasted into 
Excel, for example, and it can then be saved to disk and/or used for basic analysis in Excel.  
Although Excel is not the right tool for complex data analysis, some basic data manipulation 
is possible. 
An Excel spreadsheet was used for processing NEI-VFQ data.  An Excel template spreadsheet 
has been created, and raw data from a database query is pasted into this template. Cell 
calculations then flow from these data and the last worksheet of the spreadsheet shows the 
average scores for each participant, with the raw answers recoded according to Version 2000 
of the NEI-VFQ.  
 
 
Monitoring, quality control and assurance 
 
This research adhered to the tenets of the Declaration of Helsinki and was approved by the 
NRES Committee London-Camden & Kings Cross NHS Health Research Authority, via the 
Integrated Research Application System (IRAS) (Appendix IIIB) as well as LSBU REC and 
Institute of Optometry REC. This research was also reviewed and approved by the North 
London Hospitals research and development department and has been registered and updated 
throughout with clinicaltrials.gov. The chief investigator and the research coordinator have 
received Good Clinical Practice accreditation by examination prior to starting this clinical trial 
(Appendix IIIA). This accreditation course and examination cover all ethical aspects of clinical 
research so that researchers possess the knowledge to comply with the requirements for 
conducting research ethically.   
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Adverse Events  
 
Although it was considered that adverse events would be unlikely to occur, the potential 
adverse events which infrequently can occur in individuals with keratoconus when fitted with 
contact lenses were carefully looked for during the review appointments. These adverse events 
can be summarised as related to contact lens wear or related to the conditions treated / managed 
which in this research is mostly keratoconus.  
It was considered unnecessary to report the non-serious, commonly encountered contact lens 
related complications, which include allergic / toxic reactions to contact lens materials and care 
products and normal resident bacteria as well as minor physical corneal insult during contact 
lens handling and wear. 
Infrequently condition related complications may be the more serious and may result in disease 
progression or rarely in corneal infection. Corneal abrasion is another possible event which is 
usually minor but could be extensive and potentiality serious and may lead to complications 
such as corneal infection and / or scarring. In the unlikely event of the occurrence of a serious 
adverse event like corneal infection, which requires hospitalisation, immediate clinical action 
would take place and the event was to be reported to the sponsor within 7 days. This was to be 
followed to resolution and reported in the annual safety report of the sponsor as well as in 
publications describing the research. In the unlikely event of serious unexpected suspected 
adverse reactions reports to the NHS ethics committee, NHS trust and MHRA were to be 
generated within 15 days. These were to be followed until total resolution and reported in the 
annual safety report as well as in publications describing the research. 
To minimise the risk of adverse events best practice protocols of lens fitting, participant 
education and instructions in aspects of hygiene, contact lens handling and care as well as 
appropriate follow up schedules were followed. The participants were carefully instructed 
regarding the signs and symptoms of these adverse events as well as the actions to take in the 
event of these occurring. Protocols from Moorfields eye hospital and association of optometrist 
were used (Appendix ID and IE).  
Serious adverse events like corneal infection and the non-serious events were to be treated at 
the ophthalmology department, CMH and if occurred, were to be reported by the chief 
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investigator in the participants’ clinical record as well as the research records. The consultant 
ophthalmic surgeon, Mr Simon Levy was the onsite research supervisor and was consulted 
regarding all aspects of safety issues in this research prior to and during the research process. 
The natural progression of keratoconus and related conditions were monitored during this 
research more vigilantly than during the normal contact lens practice as during this research 
the participants were reviewed more frequently than during their standard care. 
 
 
Safety monitoring committee 
 
The persons responsible for the trial safety monitoring, were the chief investigator, the 
optometrist Anthony Stanton, the onsite supervisor; consultant ophthalmic surgeon Mr Simon 
Levy and the academic supervisors. 
 
 
Communication of urgent matters 
 
The protocol was that should any urgent issues arise, which might influence participants’ 
continued participation, it would be conveyed to all participants by e-mail, telephone or by a 
written letter with appropriate urgency. The participants’ contact details are kept on the 
password protected computers at the hospital clinic. Routine information was to be conveyed 
to the participants during their routine check-ups. 
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Summary 
 
This chapter outlined the research design and its rationale in the context of the current 
research. Important aspects of participants recruitment, informed consent and the ethical 
accreditation of this research were discussed. The experimental lenses used and the outcome 
measures to evaluate their performance were outlined and discussed. The sample size 
calculation and the important statistical considerations pertinent to this research were 
outlined. Important aspects relating to confidentiality, data handling, record keeping and 
participants’ safety were outlined and discussed. 
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Chapter 5: Results 
 
 
Overall 124 patients were approached for consideration of participating in this research. Forty-
seven patients did not meet the inclusion criteria, the majority of whom (n=36), did not satisfy 
the criterion of adequate satisfaction with or performance of CRGPcl: and 43 declined to 
participate. Thirty-four patients completed the consent procedure, underwent baseline 
measurements, and randomised to the first arm of the study. Four participants were lost to after-
care and were not included in the data analysis. Overall 56 eyes of 30 participants were 
analysed, 4 participants who required management to one eye only were included in this 
research because it was considered an appropriate representation of the keratoconus population 
presenting for contact lens management (Gomes et al., 2015; Zadnik et al., 2002).  
During the randomisation 17 participants were randomised to each study arm / group. Group 
1, sequence AB, started with CRGPcl and crossed over to SRGPcl and group 2, sequence 
BA, started with SRGPcl and crossed over to CRGPcl. In group 2 all 17 participants crossed 
over to CRGPcl, completed their participation and were analysed for primary outcome 
measures. In group 1, 13 out of the 17 recruited participants crossed over to SRGPcl, 
completed their participation and were analysed for primary outcome measures (Figure 5.1). 
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Research flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Research flow diagram according to Consolidated Standards of 
Reporting Trials (CONSORT) (Schulz et al., 2010) 
 
 
Assessed for eligibility (n=124) 
- Not meeting inclusion criteria 
       1. Poor CRGP tolerance (n=36) 
       2. Other (n=11) 
 - Declined (n=43) 
- Lost to aftercare (n=4) 
Declined to participate (n= 41) 
   Other reasons (n=50) 
Analysed (n=17) 
Excluded from analysis (n=0) 
 
Allocated first to SRGPcl (n=17) Allocated first to CRGPcl (n=17) 
Analysed (n=13) 
Excluded from analysis (n=4)  
 
Allocation 
Analysis 
Randomized (n=34) 
Enrolment 
    Crossover 
Crossed over to CRGPcl (n=17)  
Did not crossover (n=0) 
Crossed over to SRGPcl (n=13)  
Did not crossover (n=4) 
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Baseline Demographics 
 
 
Gender 
 
Out of the total population of 30 participants entering the study, 77% (n=23) were males and 
23% (n=7) were females. The male participants outnumbered the female participants by 3:1. 
 
 
Age  
 
The population age was not normally distributed; Shapiro-Wilk (p=0.039), with a range of 46 
years (22-68). The median age was 36.0, (IQR=16.0) years, skewness of 0.8 (SE 0.434, z=1.91) 
and kurtosis of -0.01 (SE 0.845, z=-0.02) (Table 5.1 and Figure 5.2). 
 
Table 5.1 Population age demographics. 
 
Age Shapiro-Wilk (p=0.039) Statistic Std. Error 
Median 36.0  
Interquartile Range 16.0  
Mean 39.1 2.1 
95% CI for Mean 34.8 - 43.3  
Std. Deviation 11.5  
Minimum 22.0  
Maximum 68.0  
Range 46.0  
Skewness 0.8 0.4 (z = 1.91) 
Kurtosis 0.0       0.8 (z = -0.02) 
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Figure 5.2 Population age frequency. 
 
 
Gender ages 
 
The gender ages were normally (p=0.697) and not normally (p=0.005) distributed for the 
female and male genders respectively, with high positive skewness in males of 1.4 (SE=0.5, 
z=2.9) (Table 5.2). The difference between the male (Median=34, IQR=13) and female 
(Mean=47.0, ±8.45, Median=45, IQR=14) ages respectively was statistically significant, 
Mann-Whitney U (p=0.010) (Figure 5.3). 
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Figure 5.3 Box plots of age by gender demographics. 
 
Table 5.2 Demographic of age by gender. 
Male (n=23) [Shapiro-Wilk (p=0.005)] Statistic Std. Error 
Median 34.0  
Interquartile Range 13.0  
Mean 36.7 2.4 
95% CI for Mean 31.8 - 41.5  
Std. Deviation 11.3  
Minimum 22.0  
Maximum 68.0  
Skewness 1.4 0.5 (z = 2.9) 
Kurtosis 1.6 0.9 (z = 1.8) 
Female (n=7) [Shapiro-Wilk (p=0.697)]   
Mean (Median) 47.0 (45.0) 3.2 
95% CI for Mean 39.2 - 54.8  
Std. Deviation (IQR) 8.4 (14)  
Minimum 36.0  
Maximum 59.0  
Skewness 0.2 0.8 (z = 0.20) 
Kurtosis -1.5 1.6 (z = -1.0) 
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Age at diagnosis (AAD)  
 
The AAD was not normally distributed; Shapiro-Wilk (p=0.010), with significant positive 
skewness of 1.1 (SE 0.4, z=2.6) and a kurtosis of 1.1 (SE 0.8, z=1.3). The median AAD for the 
population was 22 (IQR=8.0) years [Mean=22.7 (± 6.6)] (Table 5.3, Figure 5.4). 
 
Table 5.3 AAD population demographics. 
 AAD [Shapiro-Wilk (p=0.010)] Statistic Std. Error 
Median 22.0  
Interquartile Range 8.0  
Mean 22.7 1.2 
95% CI for Mean 20.2 - 25.1  
Std. Deviation 6.6  
Minimum 13.0  
Maximum 40.0  
Range 27.0  
Skewness 1.1 0.4 (z=2.6) 
Kurtosis 1.1 0.8 (z=1.3) 
 
 
Figure 5.4 AAD population distribution histogram. 
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AAD by gender 
 
The AAD was also not normally (p=0.016) and normally (p=0.541) distributed in the male and 
female populations respectively. The male participants exhibited significant positive skewness 
of 1.3 (SE 0.5, z=2.7) and kurtosis of 1.9 (SE 0.9, z=2.1) (Table 5.4). The gender AAD were 
not statistically significantly different Mann-Whitney U (p=0.190) (Figures 5.5 and 5.6).  
 
Table 5.4. AAD by Gender Demographics. 
AAD by Gender Mann-Whitney U (p=0.190)   
Male AAD [Shapiro-Wilk (p=0.016)] Statistic Std. Error 
Median 20.0  
Interquartile Range 7.0  
Mean 21.8 1.3 
95% CI for Mean 19.1 - 24.5  
Std. Deviation 6.2  
Minimum 13.0  
Maximum 40.0  
Skewness 1.3 0.481 (z=2.7) 
Kurtosis 1.9 0.935 (z=2.1) 
Female AAD [Shapiro-Wilk (p=0.541)]   
Mean 25.6 2.8 
95% CI for Mean 18.8 - 32.3  
Std. Deviation 7.3  
Minimum 16.0  
Maximum 39.0  
Skewness 0.9 0.794 (z=1.2) 
Kurtosis 1.5 1.587 (z=1.0) 
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Figure 5.5 Box plot AAD by gender. 
 
 
 
Figure 5.6 Mean age and age at diagnosis (AAD) by gender, with standard deviations. 
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Participants’ reported duration of CRGPcl wear at enrolment  
 
The AAD was taken as the date when each participant presented for first hospital consultation 
and fitting of CRGPcl. The duration of the CRGPcl wear period from the original fitting to the 
time of enrolment to this study may therefore be estimated from the difference of the age at 
enrolment and AAD. The estimated length of CRGPcl wear was not normally distributed; 
Shapiro-Wilk (p=0.014), had a median length of 14.5 years with an IQR of 12 years, significant 
positive skewness of 1.2 (SE 0.4, z=2.8) and kurtosis of 1.6 (SE 0.8, z=1.9) (Table 5.5, Figure 
5.7).  
  
Table 5.5 Participant reported duration of CRGPcl wear at enrolment. 
 
Duration of CRGPcl Wear [Shapiro-Wilk (p=0.014)] 
  Statistic Std. Error 
Median 14.5  
Interquartile Range 12.0  
Mean 16.4 1.8 
95% CI for Mean 12.7 - 20.1  
Std. Deviation 10.0  
Minimum 4.0  
Maximum 47.0  
Range 43.0  
Skewness 1.2 0.4 (z=2.8) 
Kurtosis 1.6 0.8 (z=1.9) 
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Figure 5.7 Participant reported duration of CRGPcl wear at enrolment 
 
With respect to gender, no statistically significant difference in the length of CRGPcl wear 
was found between male and female participants, Mann-Whitney U (p=0.190) (Figure 5.8). 
The distributions of the length of wear of CRGPcl was not normally distributed in the male 
population; Shapiro-Wilk (p=0.004) and normally distributed in the female population; 
Shapiro-Wilk (p=0.790) (Table 5.6, Figure 5.8).  
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Table 5.6 Gender duration of estimated time of where of CRGPcl at enrolment. 
Duration of CRGPcl wear by Gender [Mann-Whitney U (p=0.190)]  
    Statistic Std. Error 
Male [Shapiro-Wilk (p=0.004)] Median 12.0  
 IQR 11.0  
 Mean 14.9 2.1 
  95% CI for Mean 10.5 - 19.2  
  Std. Deviation 10.1  
  Minimum 4.0  
  Maximum 47.0  
  Range 43.0  
  Skewness 1.6 0.5 (z=3.4) 
  Kurtosis 3.5 0.9 (z=3.8) 
Female [Shapiro-Wilk (p=0.790)] Mean 21.4 3.3 
  95% CI for Mean 13.5 - 29.4  
  Std. Deviation 8.6  
  Minimum 10.0  
  Maximum 34.0  
  Range 24.0  
  Skewness 0.4 0.8 (z=0.5) 
  Kurtosis -1.0 1.6 (z=-0.6) 
           
 
Figure 5.8 Box plot of duration of CRGPcl wear by gender 
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Participant’s occupations / education 
The number of participants with university education was 17, which constituted 56.7% of the 
total research population (Table 5.7). 
Table 5.7 The occupations of research participants. 
Participant No Gender Occupation University Education 
1 M Company director Yes 
2 F Office worker No 
3 M TV market research Yes 
4 M Finance Yes 
5 M Retired sales assistant No 
6 M Computer programmer Yes 
7 M Finance Yes 
8 M Graphic designer Yes 
9 F Office administrator No 
10 M Finance Yes 
11 M Finance, student Yes 
12 M Engineer Yes 
13 M Driving instructor No 
14 M Teacher Yes 
15 F Book keeper Yes 
16 M Teacher Yes 
17 M Administration No 
19 M Actor No 
20 F Medical secretary No 
21 M Business No 
23 M Customer service No 
24 M Train station manager No 
26 F Entertainment Consultant Yes 
27 F Mother No 
28 M Manager at MacDonald’s No 
30 F Investment management Yes 
31 M Accountant Yes 
32 M Student Yes 
33 M Truck driver No 
34 M Electrical engineer Yes 
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No of participants with university education 17 
Percentage of participants with university education 56.7% 
 
 
Race / ethnicity  
 
Although racial / ethnic differences were not the subject of this investigation, the role of 
ethnicity is significant in both the prevalence and incidence of keratoconus (Georgiou et al., 
2004; Pearson et al., 2000). Broad race classification was included in this research, in line with 
the recommendation of the Office of National Statistics, census 2011, which stipulates that: 
“Ethnic group classifies people according to their own perceived ethnic group and cultural 
background” (Office for National Statistics, ONS., 2013). To broadly classify participant’s 
race, the participants themselves chose, from the office of national statistics listing, their 
national/geographical origin combined with colour, in groups which were considered relevant 
for research in which epidemiology of ectatic corneal disorders was important (Senior and 
Bhopal, 1994). This resulted in 4 groups (Table 5.8, Figure 5.9). 
The multiracial profile of the participants is typical of the diverse ethnicity of a London based 
population. Tables 6 and Figures 9 and 10 exhibit details of race distribution and the 
relationship between participant’s race, age and age at diagnosis.  
 
 
Figure 5.9 Race frequencies: a number and percentage of participant’s ethnicities. 
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The mean ages and AAD of the four ethnic groups are specified in Table 5.8 and Figure 5.10. 
The Caucasian White participants featured the youngest mean age but oldest AAD. The Black 
African participants exhibited the youngest age at diagnosis.  
 
Table 5.8 Ethnicity demographics 
Race N % Mean Age Age StdDev AAD AAD StdDev 
Black African 5 16.7% 43.8 ±16.4 18.8 ±3.4 
Asian Indian 13 43.3% 36.8 ±12.1 22.5 ±4.5 
Black Afro Caribbean 3 10.0% 32.3 ±3.2 22.3 ±4.7 
Caucasian white 9 30.0% 31.9 ±7.0 25.2 ±9.9 
 
           
 
 
Figure 5.10 Mean age and mean AAD with respective standard deviations for each ethnicity. 
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Corneal characteristics 
 
Keratoconus was the most prevalent corneal ectatic disorder in the study population, featuring 
in 54 (93.1%) out of the 58 eyes. Two eyes (3.4%) exhibited pellucid marginal degeneration 
(PMD) and 2 (3.4%) eyes had Deep Lamellar Keratoplasty (DLK) treatments [corneal 
transplant due to advanced keratoconus]. Of the 54 eyes with keratoconus, 33 eyes (56.9%) 
featured a nipple type cone, 21 (36.2%) eyes featured the oval type (Perry et al., 1980). 
Collagen cross-linking (CXL) treatment has been applied to 6 eyes (10.3%), 4 (6.9%) of which 
featured a nipple shaped keratoconus and 2 eyes (3.4%) an oval type. Two eyes (3.4%) with 
the oval type cone had been treated with intra-stromal rings (INTACS), eyes with DLK were 
present in one eye of 2 participants and were not included in this research (Figure 5.11). 
 
           
 
Figure 5.11 Corneal pathology frequencies, including CXL and INTACS treatments 
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Corneal metrics 
 
Ectatic corneal disorders feature corneal metrics which are outside the expected range of 
normal corneae. Three corneal parameters, which reflect the degree of corneal normality were 
measured,  
1. Corneal curvature, specifically maximal radius of curvature: Kmax.  
2. Corneal thickness: pachymetry.  
3 Corneal Surface Regularity Index (SRI). 
 
Maximum corneal curvature (Kmax) 
 
The Kmax, represents the steepest corneal curvature/radius of the area measured by corneal 
topography, Kmax values (in millimetres) of the research population (Table 5.9) were normally 
distributed, Shapiro-Wilk (p=0.882) (Figure 5.12).  
 
Table 5.9 Research participant’s Kmax metrics in mm. 
Kmax (Shapiro-Wilk p=0.882) N=56  
  Statistic Std. Error 
Mean 6.2 0.1 
95% CI for Mean 6.0 - 6.3  
Std. Deviation 0.6  
Minimum 5.0  
Maximum 7.0  
Range 2.0  
Skewness 0.0 0.3 (z=-0.1) 
Kurtosis -0.6 0.6 (z=-0.9) 
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Figure 5.12 Research participant’s Kmax corneal curvature distribution. 
 
Corneal thickness (pachymetry) 
 
Corneal pachymetry, measured in micrometres (µm), exhibited normal distribution, Shapiro-
Wilk (p=0.569) [1000µm=1mm] (Table 5.10, Figure 5.13). 
 
Table 5.10 corneal thickness (pachymetry in µm) metrics of the research population. 
Pachymetry (Shapiro-Wilk p=0.569) N=56  
  Statistic Std. Error 
Mean 445.11 6.51 
95% Confidence Interval for Mean 432 - 458   
Std. Deviation 48.72   
Minimum 309   
Maximum 556   
Range 247   
Skewness 0.02 0.32 (z=0.6) 
Kurtosis 0.43 0.63 (z=0.7) 
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          Figure 5.13 Research population corneal thickness (pachymetry in µm) histogram.  
 
Corneal surface regularity index  
 
Corneal surface regularity index (SRI) describes corneal optical regularity in the central 4.5 
mm area of the cornea. SRI measures the dioptric (DS) optical power differences between 
adjacent corneal areas in 256 equidistant locations in the central 4.5mm (Cavas-Martinez et al., 
2016). SRI correlates well with the measure of BCVA (r = 0.80, p <0.001), with normal values 
below 0.56DS (Wilson et al., 1991; Cavas-Martinez et al., 2016; Liu and Pflugfelder, 1999). 
The SRI of the research population was not normally distributed: Shapiro-Wilk’s (p=0.001) 
(Table 5.11 and Figure 5.14). 
Table 5.11 Research population corneal surface regularity index (in dioptres) metrics. 
Surface Regularity Index (n=56) (Shapiro-Wilk p=0.001) 
  Statistic Std. Error 
Median 1.53  
Interquartile Range 0.40  
Mean 1.55 0.05 
95% CI for Mean 1.45 - 1.65   
Std. Deviation 0.36   
Minimum/Maximum 1.00/3.00   
Skewness 1.00 0.32 (z=3.14) 
Kurtosis 4.07 0.63 (z=6.48) 
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          Figure 5.14 Corneal surface regularity index (in dioptres) of the research population. 
 
The corneal metrics were normally distributed in the right and left eyes of the study participants 
with the exception of the right eye SRI index which was not normally distributed; Shapiro-
Wilk (p=0.001).  Despite the difference in the mode of distribution, the SRI means of the right 
(Median =1.450) and left (Median =1.590) eyes were not statistically significantly different; 
Mann-Whitney U (p=0.168). Independent samples t-test demonstrated no statistically 
significant differences between means of the right and left eyes pachymetry and Kmax, 
(p=0.481) and (p=0.119) respectively. 
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Randomisation demographics 
 
The participants in this research were randomised to the two treatment groups (Table 5.13). 
The following section presents the analysis and comparison of participant demographics in 
the two randomised groups (summary Table 5.43a, Appendix V.J). 
 
Table 5.13 Participant randomisation into the two treatment groups and crossover. 
 
Crossover study design              Treatment periods AB/BA 
Randomisation to treatment groups 1&2 Period 1 Period 2 (Crossover) 
Participant 
Allocation 
Group 1 / Sequence AB A = CRGPcl B = SRGPcl 
Group 2 / Sequence BA B = SRGPcl A= CRGPcl 
 
 
 
 
Gender, age and age at diagnosis 
 
The gender frequencies after randomisation were as follows: 2 females and 11 males versus 5 
females and 12 males in Groups 1 and 2 respectively (Figure 5.15). The Chi-square goodness 
of fit analysis revealed no significant difference in gender allocation between the 2 groups: χ2 
(1, n=17) = 2.570, (p=0.109).   
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Figure 5.15 Gender numbers in group 1 (AB) and group 2 (BA). 
 
 
The ages of participants randomised to group 1 [Mean=39.5 (±14.2)] and group 2 
[Mean=38.8 (±9.3)] were normally distributed, Shapiro-Wilk (p=0.188) and (p=0.147) 
respectively (Table 5.14, Figures 5.16 and 5.17). A two tailed independent samples t-test 
showed no statistically significant difference in the means of the ages between the two 
randomised groups [p=0.872, 95% CI -8.093 – 9.487]. 
 
 
Table 5.14 Descriptive statistics of the ages of the randomised groups. 
 
Age (t-test p=0.872)       
Randomised to   Statistic Std. Error 
CRGPcl (Shapiro-Wilk p=0.188)       
 Mean 39.5 3.9 
  95% CI for Mean 30.8 - 48.1   
  Std. Deviation 14.2   
  Minimum 22.0   
  Maximum 68.0   
  Range 46.0   
 Variance 201.9  
  Skewness 0.8 0.6 (z=1.3) 
  Kurtosis -0.4 1.2 (z=-0.3) 
SRGPcl (Shapiro-Wilk p=0.147)       
 Mean 38.8 2.2 
2
5
11
12
Group 1 (AB) Group 2 (BA)
F M
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  95% CI for Mean 34.0 - 43.5   
  Std. Deviation 9.3   
  Minimum 26.0   
  Maximum 57.0   
  Range 31.0   
 Variance 85.9  
  Skewness 0.7 0.6 (z=1.3) 
  Kurtosis -0.2 1.1 (z=-0.2) 
 
 
The AAD of participants randomised to Group 1 [Mean=23.2 (±5.0)] was normally 
distributed, Shapiro-Wilk (p=0.439), the AAD in group 2 (Median =20.0) was not normally 
distributed, Shapiro-Wilk (p=0.008) (Table 5.15 and Figures 5.16 and 5.17). There was no 
statistically significant difference in the AAD between group 1 (Median =22), and group 2 
(Median =20.0), Mann-Whitney U test: (p=0.363), U=88.50 (z=-0.924). 
 
 
Table 5.15 Descriptive statistics of AAD of the randomised groups 
 
AAD (Mann-Whitney U test p=0.363)    Statistic  Std. Error 
Group 1(Shapiro-Wilk p=0.43) Mean 23.2 1.4 
  95% CI for mean 20.1 - 26.2   
  Variance 25.0   
  Std. Deviation 5.0   
 Median 22.0  
  Minimum/maximum 16.0/31.0   
  Skewness 0.3 0.6 (z=0.5) 
  Kurtosis -1.0 1.2 (z=-0.9) 
Group 2 (Shapiro-Wilk p=0.008) Median 20.0  
 Interquartile range 8.0  
  Mean 22.3 1.9 
  95% CI for mean 18.3 - 26.3   
  Variance 59.2   
  Std. Deviation 7.7   
  Minimum/maximum 13/40   
  Skewness 1.4 0.6 (z=2.5) 
  Kurtosis 1.4 1.1 (z=1.3) 
     
 
 
134 
 
             
 
Figure 5.16 Mean age and AAD and StdDev of the 2 randomised groups. The vertical axis is 
age in years. 
 
 
Figure 5.17 Boxplots of age and AAD in group 1(AB) and group 2 (BA). 
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Participant reported duration of CRGPcl wear at enrolment 
 
The estimated duration of CRGPcl wear at enrolment was normally distributed in group 2 
Shapiro-Wilk (p=0.214) [Mean=16.47, (±6.33)] and not normally distributed for group 1, 
Shapiro-Wilk (p=0.022) [Median =10.0 IQR=22.0, Mean=16.47 (±13.76)]. This parameter 
was not significantly different in the two randomised groups Mann-Whitney U (p=0.363) [z=-
0.923], U=88.50. 
 
 
Race / ethnicity in the randomised groups 
 
The distribution of the different races/ethnicities in the randomised groups is presented in 
Figure 5.18, the Chi-square goodness of fit analysis in the two randomised groups showed no 
statistically significant difference between the groups: χ2 (3, n=13) =0.810 (p=0.613).   
 
Figure 5.18 Race frequencies in the randomised groups 
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Corneal metrics in the randomised groups 
 
The corneal metrics in this research were measured, analysed and compared to the expected 
parameters in normal disease free corneae and between the two randomised groups. 
 
 
 
Kmax 
 
The Kmax values of the corneae in the research population as a whole and in the 2 randomised 
groups were normally distributed (Table 5.16, Figure 5.19).  
Of the Kmax means analysis of the randomised groups by an independent samples t-test 
showed that the two groups exhibited no statistically significant difference:  t (30) =1.898, 
(p=0.068), d =-0.699, 95% CI [-0.0617–0.0235]. 
 
 
Table 5.16 Kmax descriptive statistics. 
 
Corneal Kmax (t-test p=0.068)     
Randomised to   Statistic Std. Error 
Group 1 (Shapiro-Wilk p=0.301) Mean 6.04 0.09 
 95% CI for Mean 5.84-6.23   
  Variance 0.22   
  Std. Deviation 0.47   
  Min/Max 5.13/6.72   
  Range 1.59   
  Skewness -0.12 0.46 (z=0.26) 
  Kurtosis -0.98 0.90 (z=1.09) 
Group 2 (Shapiro-Wilk p=0.773) Mean 6.31 0.11 
 95% CI for Mean 6.10-6.53   
  Variance 0.35   
  Std. Deviation 0.59   
  Min/Max 5.0/7.28   
  Range 2.28   
  Skewness -0.26 0.42 (z=0.62) 
  Kurtosis -0.43 0.82 (z=0.52) 
          
137 
 
 
Figure 5.19 a. Box plot of the Kmax in the randomised groups. 
 
 
Surface regularity index (SRI) 
 
The surface regularity index values of the corneae in group 1 were normally distributed, 
Shapiro-Wilk (p=0.991), but not normally distributed in group 2, Shapiro-Wilk (p=0.009), 
these variables are summarised in Table 5.17 and Figure 5.19b.  
 
Mann-Whitney U test for independent samples, revealed that the corneal SRI index was not 
statistically significantly different in the 2 randomised groups, (p=0.252) (z=-1.146), 
U=318.00. 
 
Table 5.17 Surface Regularity Index descriptive statistics in the two randomised groups. 
 
Corneal SRI (Mann-Whitney U p=0.252)   
Randomised to Statistic Std. Error 
CRGPcl (Shapiro-Wilk p=0.991) Mean 1.59 0.05 
 95% CI for Mean 1.49-1.69   
  Variance 0.06   
  Std. Deviation 0.24   
  Min/Max 1.11/2.12   
  Range 1.01   
  Skewness 0.2 0.46 (z=0.44) 
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  Kurtosis -0.15 0.90 (z=-0.17) 
SRGPcl (Shapiro-Wilk p=0.009) Median 1.47  
  Interquartile Range  0.48    
 Mean 1.52 0.08 
 95% CI for Mean 1.36-1.68   
  Variance 0.19   
  Std. Deviation 0.44   
  Min/Max 0.69/2.96   
  Range 2.27   
  Skewness 1.19 0.42 (z=2.83) 
  Kurtosis 3.46 0.82 (z=4.22) 
            
 
 
 
 
 
 
Figure 5.19 b. SRI Box plot of the randomised groups 1 and 2 
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Corneal pachymetry 
 
The analysis of pachymetry values in the corneae of the two randomised groups revealed 
normal distribution, Shapiro-Wilk (p=0.560) and (p=0.227) in group1 and group 2 
respectively, the variables are summarised in Table 5.18 and Figure 5.20. 
 
An independent samples t-test, pachymetry means comparison, indicated that the two 
randomised groups did differ significantly:  t (54) = -3.279, (p = 0.002), d = -0.881, 95% CI 
[-63.77 – -15.38], with group 1 [Mean= 423.20 (±45.10)] exhibiting a mean pachymetry 
thinner than the mean in group 2 [Mean=462.77 (±44.73)]. 
 
 
 
Table 5.18 Corneal pachymetry descriptive statistics. 
 
Corneal Pachymetry (t test p=0.002) 
Randomised to   Statistic Std. Error 
CRGPcl (Shapiro-Wilk p=0.560) Mean 423.2 9.02 
 95% CI for Mean 404.6-441.8   
  Variance 2034.5   
  Std. Deviation 45.1   
  Minimum 309   
  Maximum 498   
  Range 189   
  Skewness -0.44 0.46 (z=-0.96) 
  Kurtosis 0.05 0.9 (z=0.06) 
SRGPcl (Shapiro-Wilk p=0.227) Mean 462.8 8.03 
  95% CI for Mean 446.4-479.2   
  Variance 2001.1   
  Std. Deviation 44.7   
  Minimum 389   
  Maximum 556   
  Range 167   
  Skewness 0.46 0.42 (z=1.10) 
  Kurtosis -0.17 0.82 (z=-0.21) 
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Figure 5.20 Randomised pachymetry Box and whiskers plot, groups 1 and 2 
 
 
 
 
The main outcome measures 
 
Thirty participants completed the study. The data collected were analysed for hypothesis 
testing with respect to the primary and secondary outcome measures (summary Table 5.43b 
Appendix V.K). 
 
 
Visual performance, ETDRS logMAR 
 
The logMAR scores of all the measurements [baseline, period 1 and period 2] of the 
individual eyes of the research population, (n=504) were not normally distributed Shapiro-
Wilk (p<0.0001), positively skewed and leptokurtic, with a median logMAR score of 0.02 
and IQR=0.14. These repeated measures data are presented as a demographic of interest and 
were not used in any other statistical analyses (Figure 5.21, Table 5.19). 
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Figure 5.21 ETDRS logMAR scores all eyes and measurements of the research population 
 
Table 5.19 ETDRS logMAR scores of all eyes and measurements of the research population 
 
ETDRS logMAR BCVA (Shapiro-Wilk p<0.0001) 
  Statistic Std. Error 
Mean 0.04 0.01 
95% CI for mean 0.03-0.05   
Median 0.02   
Variance 0.01   
Interquartile Range 0.14   
Minimum -0.2   
Maximum 0.48   
Range 0.68   
Skewness 1.08 0.11 (z=9.92) 
Kurtosis 1.49 0.22 (z=6.88) 
 
           
The distributions of the average OD/OS logMAR scores of groups 1(AB) and 2 (BA) were 
not normally distributed in group 2, Shapiro-Wilk (p<0.0001), and normally distributed in 
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group 1, Shapiro-Wilk (p=0.833).  The medians and IQRs (in brackets) of the logMAR scores 
in group 1 and 2 respectively were, 0.05 (0.13) and 0.01 (0.08) (Tables 5.20, Figure 5.22).  
 
 
 
Figure 5.22 Box Plots ETDRS logMAR BCVA groups 1and 2 
Table 5.20 ETDRS logMAR BCVA group 1, sequence AB: and group 2 sequence BA 
 
Log MAR mean OD/OS Scores by Group 
   Statistic Std. Error 
Group 1 (AB) Mean 0.05 0.02 
Shapiro-Wilk p=0.833 95% CI for Mean 0.01-0.09   
  Median 0.05   
  Std. Deviation 0.09   
  Minimum -0.11   
  Maximum 0.24   
  Range 0.35   
  Interquartile Range 0.13   
  Skewness 0.24 0.46 
  Kurtosis -0.56 0.89 
 Group 2 (BA) Mean 0.02 0.02 
Shapiro-Wilk p<0.0001 95% CI for Mean -0.01-0.06   
  Median 0.01   
  Std. Deviation 0.10   
  Minimum -0.11   
  Maximum 0.35   
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  Range 0.46   
  Interquartile Range 0.08   
  Skewness 1.80 0.40 
  Kurtosis 4.52 0.79 
 
 
 
Analysis of the 2x2 crossover trial 
 
Pooling data obtained from the right and left eyes is considered inappropriate in ophthalmic 
research as discussed in the statistical analysis section in the methods chapter. To determine 
whether pooling the data obtained from the right and left eyes was appropriate in this research, 
a correlation analysis of the baseline logMAR scores between OD and OS of all participants 
who had both eyes fitted, was performed and compared to that between the scores of OD and 
randomised OS (ROS) (Table 5.21). It was postulated that if the correlation coefficients from 
both analyses are fairly equal, each eye may be treated as an independent sample, as the 
differences between the two eyes in the same individual are sufficiently similar to random eyes. 
The OD logMAR scores from the same individual had normal distribution (Shapiro-Wilk 
p=0.25), the scores of OS and ROS had not normal distribution (Shapiro-Wilk p=0.006). The 
Kendall’s tau correlations of the baseline logMAR scores of OD and OS were significantly 
different to the correlations of OD and ROS: 0.663 (p=0.01) and -0.102 (p=0.478) respectively. 
This difference indicates that the logMAR scores may not be pooled data analysis. The 
statistical analyses for the carryover, period and treatment effects were therefore performed 
utilising the mean of the right and left eye’s scores of each participant. 
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Table 5.21 Baseline logMAR scores of OD OS and ROS 
ETDRS logMAR Baseline Scores 
SN OD OS R OS 
1 -0.10 -0.10 0.09 
2 -0.05 -0.04 -0.02 
3 0.03 0.03 0.07 
6 -0.02 -0.02 0.10 
7 0.03 0.10 0.09 
9 0.11 0.11 -0.12 
10 0.10 0.07 0.15 
11 0.29 0.15 -0.07 
12 -0.02 -0.02 -0.04 
13 -0.05 -0.04 0.09 
14 0.10 0.09 -0.03 
15 -0.11 -0.15 -0.04 
16 -0.17 -0.12 0.11 
17 -0.06 0.09 -0.02 
19 0.05 -0.03 -0.10 
20 -0.05 -0.04 0.07 
21 0.05 0.09 -0.15 
23 0.14 -0.01 0.25 
24 -0.03 -0.02 0.35 
27 -0.03 -0.07 -0.03 
28 0.02 0.02 -0.04 
30 0.03 0.07 -0.01 
31 0.01 -0.03 0.03 
32 0.27 0.35 0.45 
33 0.16 0.25 -0.02 
34 0.05 0.45 0.02 
 
A linear model for the data may be used to derive two-sample t-tests or a non-parametric 
equivalent for testing hypotheses about the direct treatment and carry-over effects (Jones and 
Kenward, 2015; Wellek and Blettner, 2012). 
The general notation to be used in this section is as follows. The participants were randomised 
into two groups of sizes n1=13 and n2=17. The n1 subjects in group 1 received the lenses in 
the order CRGPcl-SRGPcl: sequence AB and the n2 subjects in group 2 received the lenses in 
the order SRGPcl-CRGPcl: sequence BA. The outcome of subject k in period j of group i is 
denoted by yijk. The group-by-period means for the ETDRS logMAR BCVA data are given in 
Table 5.22 and Figure 5.23. 
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Table 5.22 Group by period means for the mean ETDRS logMAR BCVA 
Group  Mean logMAR Period 1 Mean logMAR Period 2 Mean logMAR 
1 (AB) n1=13 ȳ11. =0.06 ȳ12 =0.04 ȳ.1 total = 0.05 
2 (BA) n2=17 ȳ21. =0.01 ȳ22 =0.01 ȳ.2 total. = 0.01 
Mean logMAR ȳ.1. = 0.04 ȳ.2. =0.03 ȳ.. total = 0.03 
    
 
       
 
Figure 5.23 Boxplots of group by period for the mean OD/OS ETDRS logMAR BCVA 
 
The boxplot in Figure 5.24 exhibits the OD/OS means of the logMAR scores of the 2 
experimental lenses of the whole research population. The logMAR scores for CRGPcl 
[Mean=0.04, (±0.11)] were normally distributed; Shapiro-Wilk (p=0.0654), the SRGPcl 
logMAR scores [Mean=0.03, (±0.09), Median=0.02, IQR=0.09] were not normally 
distributed; Shapiro-Wilk (p=0.016). 
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Figure 5.24 Mean OD/OS logMAR scores of CRGPcl vs SRGPcl 
 
 
 
Group by Period analysis 
 
The plots of the means of OD/OS, ETDRS logMAR scores for each participant in period 1 vs 
period 2 for group 1(AB) and group 2(BA) are illustrated below (Figures 5.25 and 5.26). The 
Kendall’s tau correlations between the periods were 0.517 and 0.331 for groups 1 and 2 
respectively.  
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Figure 5.25 and 5.26 Mean OD/OS ETDRS logMAR BCVA period 1 versus period 2 in both 
groups 
 
 
To determine evidence for a direct treatment effect, Figure 5.27 exhibits the mean OD/OS 
logMAR scores from both groups on a single graph and indicates the centroid of each group 
with a solid enlarged character [centroid is the mean position of all the points/objects in a 
cluster]. Kendall’s tau correlation between ETDRS logMAR BCVA of period 1 and period 2 
of both groups is 0.464 (p<0.01). 
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Figure 5.27 Mean OD/OS logMAR scores period 1 vs period 2 for both groups with 
centroids (solid black) 
 
The subject-profile plots illustrate the differences between period 1 and 2, in the mean OD/OS 
logMAR scores of all participants (inter-subject differences) and in each individual participant 
(intra-subject difference) in each group (Figure 5.28). 
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             Group 1(AB)                   Group 2(BA) 
    
 
Figure 5.28 Profiles Plots for ETDRS logMAR by Group intra-participant period difference 
 
Having looked at the logMAR scores from individual participants, a group-by-period plot, 
which compares the average logMAR scores of each group in each period, was generated.  The 
four group by period means ȳ11, ȳ12, ȳ21 and ȳ22 were plotted against their corresponding 
period labels and joined the means of period 1 of group 1 and period 2 of group 2 [1A and 2A] 
and period 2 of group 1 with period 1 of group 2 [1B and 2B] (Figure 5.29). The blue and red 
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circles represent the mean logMAR scores of participants in groups 1 and 2 wearing CRGPcl 
in periods 1 and 2 respectively and the red and blue triangles represent mean logMAR scores 
of participants in groups 2 and 1 wearing SRGPcl in periods 1 and 2 respectively.  
 
 
Figure 5.29 Group-by-period plot for mean ETDRS logMAR data. 
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Crossover and treatment effect analysis 
 
A general technique for analysing 2x2 crossover designs [two treatments with two sequence 
groups], involves reducing the two responses / scores of each subject to a single value and 
comparing the mean of this derived variate between the two groups (Jones and Kenward, 2015). 
For normally distributed data, an independent two-sample t-test is used to compare the group 
means, for data that are not normally distributed; the Mann-Whitney U test for independent 
samples can be used. The logMAR scores, sums and differences by period in each group are 
exhibited in Tables 5.23a and 5.23b. 
 
Table 5.23a. Group 1 ETDRS logMAR scores, sums and differences periods 1 & 2 
Group 1 (Sequence AB) 
SN Period 1 Period 2 Sum of Periods P1+P2 Δ of Periods (P2-P1) Crossover Δ (A-B) 
1 -0.02 0.02 0.00 0.04 -0.04 
2 0.00 0.02 0.02 0.02 -0.02 
5 0.13 0.10 0.23 -0.03 0.03 
7 0.06 0.12 0.18 0.06 -0.06 
10 0.24 0.10 0.34 -0.14 0.14 
11 0.17 0.18 0.35 0.01 -0.01 
13 -0.08 0.03 -0.05 0.11 -0.11 
14 0.10 0.08 0.18 -0.02 0.02 
20 -0.07 -0.08 -0.15 -0.01 0.01 
23 0.08 0.06 0.14 -0.02 0.02 
28 -0.02 -0.01 -0.03 0.01 -0.01 
31 -0.04 -0.11 -0.15 -0.07 0.07 
33 0.21 0.02 0.23 -0.19 0.19 
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 Table 5.23b. Group 2 ETDRS logMAR scores, sums and differences periods 1 & 2 
Group 2 
SN Period 1 Period 2 Sum of Periods P1+P2 Δ of Periods (P2-P1) Crossover Δ (A-B) 
3 0.04 0.03 0.07 -0.01 -0.01 
4 -0.01 0.05 0.04 0.06 0.06 
6 -0.01 -0.02 -0.03 -0.01 -0.01 
8 -0.06 0.09 0.03 0.15 0.15 
9 0.02 0.00 0.02 -0.02 -0.02 
12 0.03 0.07 0.10 0.04 0.04 
15 0.01 -0.10 -0.09 -0.11 -0.11 
16 -0.02 -0.11 -0.13 -0.09 -0.09 
17 -0.10 -0.10 -0.20 0.00 0.00 
19 0.06 -0.01 0.05 -0.07 -0.07 
21 0.05 0.08 0.13 0.03 0.03 
24 0.12 0.00 0.12 -0.12 -0.12 
26 -0.05 -0.07 -0.12 -0.02 -0.02 
27 -0.04 0.02 -0.02 0.06 0.06 
30 -0.02 -0.01 -0.03 0.01 0.01 
32 0.33 0.35 0.68 0.02 0.02 
34 0.03 0.12 0.15 0.09 0.09 
 
 
 
Carryover and period effects analysis  
 
A preliminary analysis, after the first 12 participants completed their participation, for 
carryover effect was performed as recommended by Wellek and Blettner (2012) and Jones and 
Kenward (2015), by an independent sample t-test. The results exhibited no significant 
difference: t (12) = 2.228, df = 10, (p=0.056), 95% CI [-0.29087, 0.0042] NS, Cohen’s d = -
1.250. The mean sum of BCVA, of the better eye for participants randomised to SRGPcl [Mean 
=0.10, ±0.112] was not significantly different to that of participants randomised to CRGPcl 
[Mean =0.04, ±0.048]. This finding does not support the presence of a significant carry over 
effect in that group of participants, indicating that it is appropriate to progress with analysing 
for treatment effects based on the crossover data.  
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A similar analysis was carried out once the study was completed for the full study population. 
The comparison of the sums of the mean OD/OS logMAR scores of the 2 periods between 
groups 1 and 2 of the whole population, by the Mann-Whitney U test indicated that there was 
no statistically significant difference between the period sums of group 1 (Median=0.14, IQR= 
0.27) and group 2 (Median=0.03, IQR=0.17), U=84.5 (p=0.281) [z=-1.089], which confirmed 
the absence of a carryover effect (Table 5.24a. and b). 
 
Table 5.24 Carryover effect statistics Mann-Whitney U test 
   
Sum P1+P2       
Group N Mean Rank Sum of Ranks 
Group 1 (AB) 13 17.5 227.5 
Group 2 (BA) 17 13.97 237.5 
Total 30   
a. 
Test Statistics Sum of Means 
Mann-Whitney U 84.5 
Wilcoxon W 237.5 
Z -1.089 
Exact. Sig. [2-(1-tailed Sig.)] 0.281 
b. 
 
To calculate the period effect as recommended by Wellek and Blettner (2012) and Jones and 
Kenward (2015), the crossover period differences [Crossover Δ (A-B), Tables 5.23 a and b] 
were compared between the two randomised groups. The crossover period differences were 
normally distributed, Shapiro-Wilk (p=0.417) and (p=0.853) group 1 and 2 respectively. An 
independent samples t-test means comparison of the period crossover differences between 
group 1 [Mean=0.0177, (±0.08)] and 2 [Mean=0.0006, (±0.07)] revealed no significant 
difference between the two groups, t (0.62), df 28, (p=0.541), 95% CI (-0.04 -0.07), d=0.23. 
This finding indicated that there was no significant period effect in the logMAR scores in this 
research. 
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ETDRS logMAR BCVA treatment effect analysis 
 
To establish whether a statistically significant difference exists between the ETDRS logMAR 
BCVA of the eyes wearing CRGPcl compared with SRGPcl, the nonparametric independent 
samples Mann-Whitney U test was applied, to the period differences; (period 2 - period 1) 
between group 1; sequence AB and group 2; sequence BA. Mann-Whitney U test indicated that 
despite the slightly better (numerically lower) logMAR score of SRGPcl in group 1, there was 
no statistically significant difference between the period differences of group 1 (Median=-0.01, 
IQR=0.08) and group 2 (Median=0.00, IQR=0.10), U=96.5, (p=0.563) [z=-0.588] (Table 
5.25a and b, Figure 5.30 and 5.31). In other words, as stipulated by the H0, the ETDRS logMAR 
BCVA with CRGPcl was not statistically significantly different to that with SRGPcl. 
 
 
Table 5.25 Mann-Whitney U test logMAR scores period differences between groups 1 and 2. 
Ranks         
Group  N Mean Rank Sum of Ranks 
logMAR Difference (P2-P1) Group 1 (AB) 13 14.42 187.50 
  Group 2 (BA) 17 16.32 277.50 
  Total 30   
a. 
Test Statistics Difference P2-P1 
Mann-Whitney U 96.500 
Wilcoxon W 187.500 
Z -0.588 
Exact. Sig. [2 (1-tailed Sig.)] 0.563 
b. 
 
Figures 5.30 and 5.31 show the mean OD/OS logMAR values of all participants in CRGPcl 
and SRGPcl and the frequency distribution of the logMAR scores with CRGPcl and SRGPcl 
in the research population respectively. 
155 
 
 
Figure 5.30a. Individual logMAR scores in CRGPcl and SRGPcl of the research population 
 
 
Figure 5.30b. Frequency distribution logMAR BCVA with CRGPcl and SRGPcl 
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Contrast sensitivity function (CSF) visual performance outcomes 
 
The OD/OS mean numerical CS scores of the four CPD tests of the research population were 
not normally distributed and are exhibited in Table 5.26 (Appendix V.H) and Figure 5.31b. 
The CSF per CPD data for all eyes is exhibited in Figure 5.31a.  
 
Figure 5.31a. Numeric values of experimental CS scores distribution by CPD of OD and OS 
of the research population 
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The OD/OS averages of the CS numerical scores for CRGPcl and SRGPcl are shown in table 
5.27.a (Appendix V.A), total means per CPD in Table 5.27.b. and Figure 5.31b and 5.33.  
 
 
Table 5.27.b CS numerical means and StdDev. for averages of OD/OS scores in CRGPcl and 
SRGPcl for the research population 
 
 
  Mean 3 CPD Mean 6 CPD Mean 12 CPD Mean 18 CPD Total Mean 
CRGPcl 5.39 (±1.46) 4.79 (±1.58) 5.00 (±1.96) 4.61 (±1.98) 4.95 (±1.75) 
SRGPcl 5.57 (±1.01) 5.18 (±1.47) 4.79 (±1.92) 4.96 (±1.73) 5.13 (±1.53) 
Mean Population 5.48 (±1.25) 4.98 (±1.53) 4.89 (±1.93) 4.79 (±1.86) 5.03 (±1.64) 
 
 
 
 
Figure 5.31b. OD/OS means of numeric CSF scores and standard deviations; CRGPcl vs 
SRGPcl of the research population 
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The normative means of the general population (Table 5.28) for photopic light conditions are 
exhibited below; these data were collected as base-line in an FDA clinical trial for refractive 
surgery [unpublished data quoted in (VectorVision, 2013)]. These results are based on the 
evaluation of 79 patients with an age range of 21–55 years, mean 36.6 (±9.02) years. Mean 
pre-operative acuity for these patients was logMAR -0.10 (±0.06). Another population-based 
study, evaluated 370 subjects with normal 20/20 [logMAR 0.00] visual acuity (Hashemi et al., 
2012). A comparison of CSF values of the research population to participants with keratoconus 
from a study by Wei et al., (2011) is exhibited in Figure 5.32c. 
 
Table 5.28 Normative data ages 21-51 FDA study and Hashemi et al., (2012) italicised. 
Spatial Frequency Log Average (Contrast Level Numeric) Standard Deviation 
Row A (3 CPD) 1.84 (6.38) / 1.63 (5.0) 0.14 (0.93) / 0.18 (1.2) 
Row B (6 CPD) 2.09 (6.67) / 1.90 (5.4) 0.16 (1.08) / 0.20 (1.3) 
Row C (12 CPD) 1.76 (6.46) / 1.58 (5.3) 0.17 (1.15) / 0.23 (1.5) 
Row D (18 CPD) 1.33 (6.50) / 1.14 (5.3) 0.19 (1.31) / 0.24 (1.6) 
 
 
Plotting the CSF of the whole research population together with normative data from the 
sources described above is presented in Table 5.29 and Figure 5.32a-c. 
 
Table 5.29 CS normative vs research population data 
  3 CPD  6 CPD  12 CPD  18 CPD 
Normative data (FDA) 6.38 (±0.93) 6.67 (±1.08) 6.46 (±1.15) 6.50 (±1.31) 
Hashemi et al., (2012) 5.00 (±1.20) 5.40 (±1.30) 5.30 (±1.30) 5.30 (±1.60) 
Research population data 5.48 (±1.25) 4.98 (±1.53) 4.89 (±1.93) 4.79 (±1.86) 
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c. 
Figure 5.32 CSF mean and std. deviation of the research population data versus: a. FDA 
normative data, b. Hashemi et al., (2012) normative data, c. Wei et al., (2011). 
 
 
Figure 5.33 Boxplots mean logCS experimental lenses current research 
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The average OD/OS mean of 3,6,12,18 CPD, logCS scores in the experimental lenses were 
normally distributed, Shapiro-Wilk (p=0.731) and (p=0.144) in CRGPcl and SRGPcl 
respectively. The logCS scores for CRGPcl were [Mean 1.53, (±0.14)] and SRGPcl 
[Mean=1.50, (±0.20)] (Figure 5.33). 
 
 
Crossover data analysis 
 
The summary of the average OD/OS mean of the 4 CPD scores logCS, by group and period 
are exhibited in Table 5.30. The sums and differences of the mean OD/OS logCS scores for the 
2 groups are exhibited in Table 5.31. The descriptive statistics of the periods in the two groups 
are exhibited in Table 5.32. The logCS period data are normally distributed, Shapiro-Wilk 
p>0.30 in periods 1 and 2 of groups 1(AB) and 2(BA) respectively.  
 
Table 5.30 Summary of CS scores by group and period 
Group  Mean logCS Period 1 Mean logCS Period 2 Mean logCS 
1 (AB) n1=13 ȳ11. =1.46 ȳ12 =1.42 ȳ.1 total = 1.44 
2 (BA) n2=17 ȳ21. =1.56 ȳ22 =1.59 ȳ.2 total. = 1.58 
Mean logCS ȳ.1. = 1.51 ȳ.2. =1.51 ȳ.. total = 1.51 
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Table 5.31 logCS all CPD period scores, sums and differences of OD/OS means, group 
1(AB) and 2 (BA) 
Group 1 (AB) Mean OD/OS logCS   Group 2(BA) Mean OS/OS logCS 
SN P1(A) P2(B)  P1+P2 ΔP2/P1 ΔA/B   SN P1(B) P2(A) P1+P2 ΔP2/P1 ΔA/B 
1 1.53 1.47 3.00 -0.06 0.06   3 1.42 1.40 2.81 -0.02 -0.02 
2 1.62 1.63 3.25 0.01 -0.01   4 1.63 1.49 3.12 -0.14 -0.14 
5 1.40 1.28 2.67 -0.12 0.12   6 1.50 1.53 3.03 0.02 0.02 
7 1.43 1.68 3.12 0.25 -0.25   8 1.58 1.52 3.10 -0.06 -0.06 
10 1.27 1.27 2.54 -0.01 0.01   9 1.44 1.55 2.99 0.11 0.11 
11 1.51 1.21 2.73 -0.30 0.30   12 1.47 1.40 2.87 -0.07 -0.07 
13 1.54 1.49 3.03 -0.05 0.05   15 1.77 1.78 3.55 0.01 0.01 
14 1.38 1.30 2.68 -0.08 0.08   16 1.57 1.58 3.14 0.01 0.01 
20 1.63 1.52 3.15 -0.11 0.11   17 1.80 1.80 3.61 0.00 0.00 
23 1.42 0.90 2.32 -0.52 0.52   19 1.52 1.57 3.09 0.05 0.05 
28 1.41 1.57 2.97 0.16 -0.16   21 1.59 1.53 3.12 -0.06 -0.06 
31 1.64 1.72 3.36 0.08 -0.08   24 1.72 1.69 3.40 -0.03 -0.03 
33 1.21 1.48 2.69 0.27 -0.27   26 1.75 1.70 3.46 -0.05 -0.05 
  
27 1.41 1.65 3.06 0.24 0.24 
30 1.68 1.68 3.37 0.00 0.00 
32 1.33 1.41 2.74 0.08 0.08 
34 1.32 1.76 3.08 0.44 0.44 
 
 
 
Table 5.32 Descriptive statistics of Mean OD/OS logCS in the 2 periods in both groups 
  Group 1(AB) Group 2(BA) 
  Period 1 Period 2 Period 1 Period 2 
  Statistic StdEr Statistic StdEr Statistic StdEr Statistic StdEr 
Shapiro-Wilk p 0.522  0.35  0.632  0.348  
Mean 1.46 0.04 1.42 0.06 1.56 0.04 1.59 0.03 
95% CI 1.38-1.54  1.29-0.56  1.48-1.64  1.52-1.66  
Std. Deviation 0.13  0.23  0.15  0.13  
Minimum 1.21  0.90  1.32  1.4  
Maximum 1.64  1.72  1.80  1.8  
Range 0.43  0.82  0.48  0.4  
Skewness -0.33 0.62 -0.91 0.62 0.05 0.55 0.1 0.6 
Kurtosis -0.51 1.19 0.96 1.19 -1.07 1.06 -1.1 1.1 
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Average OD/OS, mean of CPDs: 3,6,12 and 18, logCS scores of period 1 versus period 2 in 
groups 1 and 2 separately and together with centroids are exhibited in Figures 5.34 and 5.35 
respectively. Individual participant scores in both periods are exhibited in Figure 5.36 
[noticeable outlier in group 1, with poor logCS scores in period 2, results confirmed in 
participant 23]. 
 
 
Figure 5.34 Mean OD/OS logCS period 1 versus period 2 in both groups 
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Figure 5.35 Average OD/OS logCS mean of CPD 3,6,12,18 scores period 1 vs period 2 for 
both groups with centroids (solid black) 
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Figure 5.36 Individual participant’s logCS scores in group 1 and 2, periods 1 and 2 
 
Having looked at the logCS scores from individual participants, a groups-by-period plot, which 
compares the average logCS scores of each group in each period, was generated. The four 
group by period means ȳ11, ȳ12, ȳ21 and ȳ22 were plotted against their corresponding period 
labels and joined the means of period 1 of group 1 and period 2 of group 2 [1A and 2A] and 
period 2 of group 1 with period 1 of group 2 [1B and 2B] (Figure 5.37). The blue and red circles 
represent the mean logCS scores of participants in groups 1 and 2 wearing CRGPcl in periods 
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1 and 2 respectively and the blue and red triangles represent mean logCS scores of participants 
in groups 1 and 2 wearing SRGPcl in periods 2 and 1 respectively. 
 
 
 
Figure 5.37 Group-by-periods plot for mean logCS data. 
 
 
 
Carryover and period effect analysis 
 
Independent samples t-test comparing the means of the period sums of the two groups found 
a statistically significant difference between the period sums in group 1 [Mean=2.89, 
(±0.31)] and the period sums in group 2 [Mean=3.15, (±0.25)], (p=0.019), 95% CI [-0.45 -    
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-0.47]. This result indicates that because the mean of period sums in group 2 is significantly 
higher than that in group 1, there is a possibility of the presence of a differential carryover 
effect. Owing to this finding, the analysis of the data with respect to the treatment effect was 
performed in two ways: as a crossover trial, using data from both periods and as a parallel 
group trial, using data from the first period only. 
To calculate the period effect as recommended by Wellek and Blettner (2012) and Jones and 
Kenward (2015), the crossover period differences [Crossover Δ (A-B), Tables 5.31] of the 
logCS scores were compared between the two randomised groups. The crossover period 
differences were normally distributed in group 1 and not normally in group 2, Shapiro-Wilk 
(p=0.464) and (p=0.002) respectively. A Man-Whitney U test comparison of the period 
crossover differences between group 1 [Mean=0.369, (±0.214), Median=0.050, IQR=0.24] 
and group 2 [Median=0.00, IQR=0.12)] revealed no significant difference between the two 
groups, U=101.50, (p=0.711). This finding indicated that despite the significant carryover 
effect, there was no significant period effect in the logCS scores in this research. 
 
 
Crossover analysis of the treatment effect 
 
The determination whether there was a difference between the two experimental lenses in the 
visual performance with respect to logCS scores, analysis was performed as recommended by 
Wellek and Blettner (2012) and Jones and Kenward (2015), by comparing the period score 
differences of the two randomised groups with an independent samples t-test.  
The mean OD/OS logCS mean of the four CPD period difference of groups 1 and 2 [Mean=-
0.0354, SD=0.21469] and [Mean=0.0300, SD=0.13500] respectively, showed that the higher 
scores of logCS achieved with CRGPcl in both groups did not reach statistical significance: 
(p=0.316), t(30)=-1.022, df=28, d=-0.258, 95% CI [-0.1965-0.0657] (Figure 5.38). This result 
indicates that there was no statistically significant difference between the two experimental 
lenses with respect to the logCS scores achieved with each contact lens as stipulated by the H0. 
Due to the indication of a differential carryover effect in the analysis of the period sums of both 
groups, the study protocol required a treatment effect analysis by an independent samples t-test 
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comparing the logCS mean of the four CPDs scores of the two contact lens types in the two 
groups in period 1only (without the crossover scores), as performed in a parallel group RCT. 
This means comparison also supported the H0, as it showed no statistically significant 
difference between the logCS mean scores of the two lens types (p=0.070), t(30)=-1.881, 
df=28, 95% CI [-0.20739 - 0.00884]. The SRGPcl exhibited a higher mean logCS score 
[Mean=1.5624, SD ±0.5127] than the CRGPcl [Mean=1.4631, SD ±0.13181], a difference of 
0.10 logCS, which is less than the smallest; 0.15 logCS score increment.  
 
 
Figure 5.38 Average OD/OS logCS mean of all CPDs distribution CRGPcl ~vs~ SRGPcl 
 
 
The logCS scores at 6 CPD are of interest because normative data suggests that the highest 
scores are achieved at 6 CPD compared with the other three, because it represents visual 
detail of a relatively large size: x2 and x3 larger than 12 and 18 CPD respectively and 
169 
 
because the score difference between the two experimental lenses of the research population 
was largest at 6 CPD (Figure 5.31b). It was therefore decided to compare by an independent 
samples t-test, the means of the period differences of the average OD/OS logCS scores at 6 
CPD in the two randomised groups (Table 5.33, Appendix V. G). Group 1 [Mean=-0.0285, 
SD ±0.1579] and group 2 [Mean=0.0641, SD ± 0.1431], showed that the higher levels of 
logCS at 6 CPD achieved with CRGPcl in both groups did not reach statistical significance: t 
(30) = -1.68, df =28, d = -0.435, (p = 0.104), 95% CI [-0.2055 – 0.0203]. This therefore 
indicates that there was no statistically significant difference in the performance of the two 
experimental lenses, supporting the H0. 
Due to the indication of a differential carryover effect in the analysis of the period sums of both 
groups, the study protocol required a treatment effect analysis by an independent samples t-test 
comparing the logCS mean of 6 CPD scores of the two contact lens types in the two groups in 
period 1only, as performed in a parallel group RCT. This means comparison also showed no 
statistically significant difference between the two lens types with respect to the logCS mean 
scores at 6 CPD, supporting the H0. The higher scores of SRGPcl [Mean=1.84, SD ±0.16] 
compared with CRGPcl [Mean=1.75, SD ±0.17] in period 1 did not reach statistical 
significance: t (30) =-1.651, df=28, d=-0.435, (p=0.110), 95% CI [-0.2069–0.0222].  
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The National Eye Institute-Visual Function Questionnaire (NEI-VFQ)  
 
The summary of the descriptive statistics of the twelve domains measured by the NEI-VFQ are 
exhibited in Table 5.34 (Appendix V.I.) and Figure 5.40a. All domains were not normally 
distributed, but means and SD are included for comparison with the literature (previous 
workers seem to have assumed that NEI-VFQ data are normally distributed). 
 
 
Research population vs CLEK study population 
 
Figure 5.40 exhibits the the NEI-VFQ means and StdDev of the current study in both the 
experimental lenses and the CLEK study (Kymes et al., 2004) 
  
 
Figure 5.40a NEI-VFQ means and StdDev; current study vs CLEK 
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Figure 5.40b NEI-VFQ current study vsNormative CRGPcl wearers Walline et al., (2000)  
(Kymes et al., 2004) 
 
CRGPcl vs SRGPcl 
The means and standard deviations of the mean scores of the NEI-VFQ 12 domains for CRGPcl 
vs SRGPcl for the whole research population are shown in Figure 5.41a. The NEI-VFQ scores 
were not normally distributed, Shapiro-Wilk (p=<0.0001) and (p=0.014) for CRGPcl and 
SRGPcl respectively, the medians and IQRs of all 12 domains in CRGPcl and SRGPcl were 
[Median=89.53, IQR=17.38], [Median=88.35, IQR=14.04] respectively (Figure 5.41b). 
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a. 
 
b. 
Figure 5.41. a NEI-VFQ 12 domains means and StdDev, CRGPcl vs SRGPcl. b. Boxplots 
CRGPcl vs SRGPcl. 
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NEI-VFQ group 1 vs group 2 
 
The means and standard deviations of the scores of the NEI-VFQ 12 domains of group 1 vs 
group 2 are exhibited in Figure 5.42. 
 
 
 
Figure 5.42. NEI-VFQ 12 domains group 1 vs group 2 with means and standard deviations 
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Carryover and treatment effects 
 
The mean scores of the 12 domains of NEI-VFQ of groups 1 and 2 in periods 1 and 2, as well 
as the period sums and differences for the purpose of calculation of period and treatment effects 
are exhibited in Table 5.35 (Appendix V B). 
The comparison of the period sums between group 1 (Median=182.0, IQR=20.23) and group 
2 (Median= 178.1, IQR=32.97) by Mann-Witney U test, indicated that there was no statistically 
significant difference between the two groups; U=82.0, (p=0.245) [z=-1.193] (Table 5.36a, b). 
 
Table 5.36 Statistics of Sum of periods, carryover effect. 
Sum P1P2       
Group N Mean Rank Sum of Ranks 
Group 1 (AB) 13 17.69 230 
Group 2 (BA) 17 13.82 235 
Total 30   
a. 
Test Statistics Sum P1P2 
Mann-Whitney U 82 
Wilcoxon W 235 
Z -1.193 
Exact Sig. [2(1-tailed Sig.) 0.245 
b. 
 
This indicates that there was no evidence for a carryover effect with respect to visual quality 
of life levels measured by the NEI-VFQ. 
To calculate the period effect as recommended by Wellek and Blettner (2012) and Jones and 
Kenward (2015), the crossover period differences [Crossover Δ (A-B), Tables 5.35] of the NEI-
VFQ scores were compared between the two randomised groups. The crossover period 
differences were normally distributed, Shapiro-Wilk (p=0.442) and (p=0.082) group 1 and 2 
respectively. An independent samples t-test means comparison of the period crossover 
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differences between group 1 [Mean=-0.9231, (±1.37)] and 2 [Mean=-1.2353, (±1.98)] 
revealed no significant difference between the two groups, t (0.965), df 28, (p=0.343), 95% CI 
(-3.965 - 11.025), d=0.35. This finding indicated that there was no significant period effect in 
the NEI-VFQ scores in this research 
The treatment effect was calculated by analysing the period differences in the means of all 
NEI-VFQ domains in the randomised groups by the Mann-Whitney U test, as recommended by 
(Wellek and Blettner, 2012; Jones and Kenward, 2015). This analysis showed that there was 
no significant difference in the period differences between group 1 (Median=1.67, IQR=10.53) 
and group 2 (Median=-1.74, IQR=9.23), U=93.0, (p=0.483) [z=-0.732] (Table 5.37 a and b). 
This result therefore supports the H0, despite slightly higher Qol scores in SRGPcl, there was 
no statistically significant difference between the experimental contact lenses with respect to 
their effect on the total (across all domains) visual Qol, measured by the NEI-VFQ instrument.  
 
Table 5.37 Statistics of period differences; treatment effect. 
Difference P2P1     
Group N Mean Rank Sum of Ranks 
Group 1 (AB) 13 16.85 219 
Group 2 (BA) 17 14.47 246 
Total 30   
a. 
Test Statistics Difference P2P1 
Mann-Whitney U 93 
Wilcoxon W 246 
Z -0.732 
Exact Sig. [2 (1-tailed Sig.)] 0.483 
b. 
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Subjective measures of comfort and vision 
 
The subjective measures of comfort and vision with the two experimental lenses were elicited 
after each period of lens wear and graded on LSCS and the LSVS. These are Likert-like scales 
from 1-10, with 1 constituting the worst and 10 the best SPC and SPV scores. 
The LSVS in the experimental lenses were not normally distributed, both CRGPcl, Shapiro-
Wilk (p=0.024), [Median=8.0, IQR=2.0)] and in SRGPcl, (p=0.007), [Median=8.0, 
IQR=2.0]. The LSCS were normally distributed in CRGPcl, Shapiro-Wilk (p=0.091), 
[Mean=7.78, (±1.45)] and not normally distributed in SRGPcl, (p=0.001), [Median=9.0, 
IQR=2.0, Mean=8.88, (±1.10)].  
The total LSCS and LSVS were not normally distributed in both periods. The LSCS in periods 
1 and 2 respectively were [Median=9.0, IQR=1.13] (p=0.016) and [Median=8.5, IQR=3.00] 
(p=0.009).  LSVS in periods 1 and 2 respectively were [Median=8.0, IQR=2.00] (p=0.007) 
and [Median=8.0, IQR=2.00] (p<0.0001).  
The LSCS for each participant in periods 1 and 2 are exhibited in Figures 5.43 and 5.44 for 
groups 1 and 2 respectively and the LSVS in each participant are exhibited in Figures 5.45 and 
5.46 for groups 1 and 2 respectively (Appendix V C). 
The scatter plots below exhibit the individual scores for SPC and SPV in periods 1 and 2 in 
each group (Figure 5.47a and 5.48). The LSCS period by group comparisons in Figures 5.47a 
exhibit higher scores in group 1, period 2 (SRGPcl) and group 2, period 1 (SRGPcl). Figure 
5.47b exhibits the LSCS of both groups on a single graph, with group1 concentration above 
the diagonal and group 2 below, indicating better results for SRGPcl, with centroids on 
opposite side of the diagonal, indicating the possibility of treatment effect. Figure 5.47c 
exhibits the individual participants LSCS profiles in both groups, with larger inter-subject 
variation in group 2 and noticeable difference in the slope directions in both groups, indicating 
higher LSCS in SRGPcl, more noticeable in group 2.  
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Figure 5.47a Individual LSCS in periods 1 and 2 in groups 1 and 2 
 
Figure 5.48 Individual LSVS in periods 1 and 2 in groups 1 and 2 
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Figure 5.47b. LSCS both groups with centroids 
 
Figure 5.47c. LSCS individual profiles groups 1 and 2 
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To calculate the likelihood of a period carryover effect and the treatment effect, the scores for 
the SPC and SPV as well as the sums of periods and period differences of these scores for each 
participant were calculated and are exhibited in Tables 5.38 and 5.39. 
 
Table 5.38 LSCS by period and sums and differences of periods in both groups 
Comfort Quality 
Group 1   Group 2 
SN P1 P2 P1+P2 P2-P1 A-B   SN P1 P2 P1+P2 P2-P1 A-B 
1.0 8.0 9.0 17.0 1.0 -1.0   3.0 9.0 7.0 16.0 -2.0 -2.0 
2.0 8.0 8.0 16.0 0.0 0.0   4.0 6.0 8.0 14.0 2.0 2.0 
5.0 9.0 8.0 17.0 -1.0 1.0   6.0 10.0 4.0 14.0 -6.0 -6.0 
7.0 7.0 7.0 14.0 0.0 0.0   8.0 10.0 9.0 19.0 -1.0 -1.0 
10.0 7.5 10.0 17.5 2.5 -2.5   9.0 9.0 5.0 14.0 -4.0 -4.0 
11.0 8.0 10.0 18.0 2.0 -2.0   12.0 8.0 7.0 15.0 -1.0 -1.0 
13.0 9.0 9.0 18.0 0.0 0.0   15.0 9.0 9.0 18.0 0.0 0.0 
14.0 9.0 8.0 17.0 -1.0 1.0   16.0 9.0 6.5 15.5 -2.5 -2.5 
20.0 7.0 10.0 17.0 3.0 -3.0   17.0 9.0 10.0 19.0 1.0 1.0 
23.0 7.5 10.0 17.5 2.5 -2.5   19.0 9.0 10.0 19.0 1.0 1.0 
28.0 7.0 9.0 16.0 2.0 -2.0   21.0 9.0 6.0 15.0 -3.0 -3.0 
31.0 9.0 10.0 19.0 1.0 -1.0   24.0 8.0 8.0 16.0 0.0 0.0 
33.0 10.0 10.0 20.0 0.0 0.0   26.0 7.0 6.0 13.0 -1.0 -1.0 
        27.0 8.0 7.0 15.0 -1.0 -1.0 
        30.0 10.0 9.0 19.0 -1.0 -1.0 
        32.0 9.5 7.0 16.5 -2.5 -2.5 
        34.0 9.0 9.0 18.0 0.0 0.0 
 
Table 5.39 LSVS by period and sums and differences of periods in both groups. 
Vision Quality 
Group 1   Group 2 
SN P1 P2 P1+P2 P2-P1 A-B   SN P1 P2 P1+P2 P2-P1 A-B 
1.0 10.0 7.0 17.0 -3.0 3.0   3.0 8.0 -8.0 0.0 -16.0 -16.0 
2.0 8.0 8.0 16.0 0.0 0.0   4.0 7.0 7.0 14.0 0.0 0.0 
5.0 8.0 7.0 15.0 -1.0 1.0   6.0 7.0 9.0 16.0 2.0 2.0 
7.0 7.0 7.5 14.5 0.5 -0.5   8.0 9.0 9.0 18.0 0.0 0.0 
10.0 9.0 9.0 18.0 0.0 0.0   9.0 8.5 6.0 14.5 -2.5 -2.5 
11.0 6.5 8.0 14.5 1.5 -1.5   12.0 8.0 7.0 15.0 -1.0 -1.0 
13.0 10.0 10.0 20.0 0.0 0.0   15.0 9.0 4.0 13.0 -5.0 -5.0 
14.0 7.0 7.0 14.0 0.0 0.0   16.0 9.0 6.5 15.5 -2.5 -2.5 
20.0 10.0 10.0 20.0 0.0 0.0   17.0 9.0 9.0 18.0 0.0 0.0 
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23.0 7.0 7.0 14.0 0.0 0.0   19.0 8.0 9.0 17.0 1.0 1.0 
28.0 10.0 10.0 20.0 0.0 0.0   21.0 10.0 9.0 19.0 -1.0 -1.0 
31.0 9.0 8.5 17.5 -0.5 0.5   24.0 7.0 9.0 16.0 2.0 2.0 
33.0 6.5 7.5 14.0 1.0 -1.0   26.0 8.0 8.0 16.0 0.0 0.0 
        27.0 8.0 8.0 16.0 0.0 0.0 
        30.0 10.0 9.0 19.0 -1.0 -1.0 
        32.0 9.0 8.0 17.0 -1.0 -1.0 
        34.0 7.0 6.5 13.5 -0.5 -0.5 
 
 
 
Subjective perception of comfort and vision carryover and period effects 
 
The analyses to establish the presence of period and differential carryover effects were 
performed as recommended by Wellek and Blettner (2012) and Jones and Kenward (2015), by 
the comparison of the LSCS period sums between group 1 (Median=17.0, IQR=1.50) and 
group 2 (Median=16.0, IQR=4). A Mann-Witney U test indicated that with respect to SPC 
there was no statistically significant difference between the two groups; U=78.5, (p=0.183) 
[z=-1.349].  
With respect to LSVS the comparison of the period sums between group 1 (Median=16.0, 
IQR=4.75) and group 2 (Median=16.0, IQR=3.25) by Mann-Witney U test, indicated that with 
respect to SPV there was no statistically significant difference between the two groups; 
U=97.0, (p=0.592) [z=-0.568]. 
This indicates that there is no evidence for the presence of a differential carryover effect with 
respect to the scores of these outcomes. 
To calculate the period effect as recommended by Wellek and Blettner (2012) and Jones and 
Kenward (2015), the crossover period differences [Crossover Δ (A-B), Tables 5.38, 5.39] of 
the subjective comfort and vision scores were compared between the two randomised groups. 
The crossover period differences of the LSCS were normally distributed, Shapiro-Wilk 
(p=0.204) and (p=0.526) group 1 and 2 respectively. An independent samples t-test means 
comparison of the period crossover differences between group 1 [Mean=-0.9231, (±1.37)] and 
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2 [Mean=-1.2353, (±1.98)] revealed no significant difference between the two groups, t 
(0.486), df 28, (p=0.630), 95% CI (-1.003 - 1.627), d=0.18. This finding indicated that there 
was no significant period effect in the LSCS in this research. 
The crossover period differences of the vision scores were not-normally distributed, Shapiro-
Wilk (p=0.009) and (p=0.000) group 1 and 2 respectively. A Man-Whitney U test comparison 
of the period crossover differences in subjective vision scores between group 1 [Median=0.00, 
IQR=0.50] and 2 [Median=-0.50, IQR=1.75)] revealed no significant difference between the 
two groups, U=76.500, (p=0.157). This finding indicated that there was no significant period 
effect in the SPV scores in this research. 
 
 
Subjective comfort and vision treatment effect 
 
The comparison of the two groups with respect to the treatment effect was performed as 
recommended by (Wellek and Blettner, 2012; Jones and Kenward, 2015) by the analysis of the 
difference in the period scores of the two randomised groups. This was performed by the Mann-
Whitney U test, which revealed that with respect to subjective comfort, the period difference in 
group 1 (Median=1.0, IQR=2.25) and the period difference in group 2 (Median=-1.0, 
IQR=2.50), were significantly different, (p=0.002) [z=-2.993], U=40.0. This result rejects the 
H0 and indicates that the higher subjective comfort score achieved with SRGPcl was 
statistically significant (Figure 5.49a).  
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Figure 5.49a. Boxplots of subjective comfort scores in CRGPcl and SRGPcl 
With respect to the subjective vision score, the comparison of the score differences in the two 
periods in group 1 (Median=0.0, IQR=0.50) and group 2 (Median=-0.5, IQR=1.75), by Mann-
Whitney U test indicates that there was no significant difference, (p=0.213) [z=-1.301], 
U=80.50. This result therefore supports the H0 with respect to the subjective perception of the 
participant’s quality of vision (Figure 5.49b).  
 
 
Figure 5.49b. Boxplots of subjective vision scores in CRGPcl and SRGPcl 
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NEI-VFQ ocular pain domain 
 
Due to the statistically significant difference between the two experimental lenses in the SPC, 
an analysis of the period and treatment effects of the NEI-VFQ ocular pain domain was 
performed. The only normally distributed scores in this domain were of group 1 period 1; 
Shapiro-Wilk (p=0.095), the rest of the scores were not normally distributed; (p=0.019, 0.005 
and 0.034) in Group 1 period 2, group 2 period 1 and period 2 respectively. 
The analyses of the two groups with respect to period carryover and treatment effects were 
performed as recommended by (Wellek and Blettner, 2012; Jones and Kenward, 2015). The 
Mann-Whitney U analysis of the period sums of group 1 (Median=175.0, IQR=56.25) and 
group 2 (Median=150.0, IQR=75.0) indicated that here was no differential carryover effect 
(p=0.263), [z=-1.141] U=83.50. The crossover differences were normally distributed in group 
2 (p=0.015) and not normally in group 1 (p=0.467). The Mann-Whitney U analysis of the 
crossover differences of group 1 (Median=0.02, IQR=0.21) and group 2 (Median=0.04, 
IQR=0.16) indicated that there was no significant period effect (p=0.563). 
The treatment effect analysis by Mann-Whitney U test of the period differences of group 1 
(Median=12.5, IQR=37.5) and group 2 (Median=0.00, IQR=25.0), indicated that the better 
ocular pain scores with SRGPcl in group 1, did not reach statistical significance (p=0.170) 
[z=-1.423], U=77.00, which supports the H0. 
 
 
Final lens choice 
 
At the end of the second experimental sequence participants were asked to choose either 
CRGPcl or SRGPcl as their habitual contact lens. Fourteen (46.7%) participants chose SRGPcl 
and 16 (53.3%) chose CRGPcl as their preferred habitual lens. 
The only statistically significant outcome in this experiment was the better SPC in SRGPcl 
compared to CRGPcl, which was supported by the better scores in the ocular pain domain of 
the NEI-VFQ (statistical significance not reached). Therefore, it was decided to determine 
184 
 
whether there is a significant correlation between the scores of SPC in the experimental lenses 
and final lens choice.  
 
The participants’ SPC and SPV in the experimental CRGPcl and the final lens choice are 
presented in table 5.40 (Appendix V D). 
 
The LSCS approximated a normal distribution Shapiro-Wilk (p=0.091), with a mean of 7.78 
(±1.45), range of 6.0 [4.0 – 10], 95 CI for mean 7.24–8.33 (Figure 5.51). 
 
 
Figure 5.51. Distribution of the scores of SPC in experimental CRGPcl 
 
The LSCS in CRGPcl means / medians and SD / IQR for the participants who selected CRGPcl 
and SRGPcl were 8.44 (±1.03) / 9.00 (1.75) and 7.04 (±1.54) / 7.00 (1.54) respectively, with 
non-normal distribution of the scores of CRGPcl selectors and normal distribution of scores of 
SRGPcl selectors, Shapiro-Wilk (p=0.019) and (p=0.980) respectively. A means comparison 
between the subjective comfort scores (Table 5.41) of those participants who selected CRGPcl 
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and SRGPcl as their habitual lenses, was performed by the independent samples t-test, due to 
the non-significant variance between the scores [Levene’s test for equality (p=0.426)]. 
Due to the not-normal distribution of the SPC scores of the 16 participants who selected 
CRGPcl an additional analysis was performed by the non-parametric Mann-Whitney U test, to 
confirm agreement between the parametric and non-parametric analyses regarding this 
important outcome (Figure 5.52).   
 
Table 5.41 Mean, median, StdDev and IQR scores of subjective comfort for final lens choice 
Final Lens choice CRGPcl SRGPcl 
Comfort in CRGPcl mean and (StdDev) 8.44 (±1.03) 7.04 (±1.54) 
Comfort in CRGPcl median and (IQR) 9.00 (1.75) 7.00 (2.00) 
 
 
Figure 5.52 Subjective comfort scores in CRGPcl in participants who chose CRGPcl and 
SRGPcl 
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Both these analyses showed a significant difference in the CRGPcl SPC scores between the 
participants who chose CRGPcl and those who chose SRGPcl; t=2.967, (df=28), (p=0.006), 
d=1.086, 95% CI [0.434-2.37]. Mann-Whitney U test: (p=0.009), (z=-2.605), U=50.5, 
Wilcoxon W=155.5.  
The expected better LSCS in SRGPcl in participants who chose SRGPcl [Median=9.750, 
IQR=1.3] compared to participants who chose CRGPcl [Median=9.00, IQR=1.0], did not 
reach statistical significance regarding the LSCS difference (p=0.052).  
These results indicate that the subjective score of perceived comfort in the experimental 
CRGPcl was significantly lower in the participants who selected SRGPcl [Mean=7.04, 
(±1.54)] than those who selected CRGPcl [Mean=8.44, (±1.03)], (p=0.006) and (p=0.009) by 
independent samples t-test and Mann-Whitney U test respectively, thus rejecting the H0. It is 
of note that no participant who selected to remain in CRGPcl scored their SPC lower than 7.0. 
Despite the absence of statistically significant carryover effect in the subjective comfort, it was 
decided to explore whether the sequence of contact lens wear had an effect on the subjective 
comfort in CRGPcl. Such an effect could for example occur in group 2, after wearing the first 
sequence SRGPcl. It is possible that some loss of tolerance to CRGPcl could occur, which may 
have contributed to the lower score in the washout period and sequence 2, when the habitual 
and experimental CRGPcl were worn. 
Group 1 [Mean=8.15, (±0.97)] and group 2 [Mean=7.5, (±1.71)] were normally distributed 
with respect to subjective comfort scores in the experimental CRGPcl, Shapiro-Wilk (p=0.139) 
and (p=0.481) respectively. An independent samples t-test comparison of means exhibited no 
statistically significant difference in the subjective score of comfort of the two groups: t=1.322, 
(df= 26), (p=0.198), d= 0.454, 95% CI [-0.363 – 1.670]. This result indicates that the sequence 
of wear did not have a significant effect on the subjective score of comfort reported by the 
participants in two randomised groups. 
A χ2 analysis was performed to also establish whether the sequence of lens wear had any effect 
on the final lens choice for the same reason as stipulated regarding the subjective comfort 
scores. The results of this analysis (Table 5.42) indicate that there was no significant difference 
between the participants in the 2 groups in their choice of preferred habitual lens χ2=0.475, 
(n=30), (p=0.713).  
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Table 5.42 χ2 analysis of final lens choice by randomised groups 
Final lens choice 
Group   CRGPcl SRGPcl   Total 
Group 1 (AB) Count of participants 6 7   13 
  % within group 46.20% 53.80%  100.00% 
  % within final lens choice 37.50% 50.00%  43.30% 
Group 2 (BA) Count of participants 10 7   17 
  % within group 58.80% 41.20%  100.00% 
  % within final lens choice 62.50% 50.00%  56.70% 
            
Total Count 16 14   30 
  % within group 53.30% 46.70%  100.00% 
  % within final lens choice 100.00% 100.00%  100.00% 
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Chapter 6: Discussion 
 
 
In this RCT with a 2x2 crossover, 34 participants entered the study and 17 participants were 
randomised to each of the 2 experimental groups. The participants randomised to group 1 
(sequence AB), started with CRGPcl (lens A) in period 1 and after completing period 1 and a 
1-month washout period, crossed over to wear SRGPcl (lens B) in period 2 (Figure 4.1). 
Participants in group 2 (sequence BA), started with SRGPcl (lens B) in period 1 and after 
completing period 1 and a 1-month washout period, crossed over to wear CRGPcl in period 2 
(lens A). All 17 participants in group 2 completed their participation, whereas in group 1, 
thirteen participants completed the study (see limitations) (Figure 5.1). Data collected from 56 
eyes of the 30 participants who completed this research were analysed, with right and left eye 
data averaged for participants who wore lenses in both eyes. The inclusion of 4 participants 
who were fitted in one eye only, was considered appropriate representation of the population 
in the clinic, as keratoconus is a bilateral disease (Gomes et al., 2015) and patients may present 
for contact lens management with significant asymmetry between the two eyes (Zadnik et al., 
2002).  
 
 
Descriptive statistics of the study population 
 
Gender 
 
Epidemiological studies regarding keratoconus gender preponderance are inconclusive, with 
reported female dominance of 53% (Jonas et al., 2009), 65% (Amsler, 1961) and 66% 
(Hammerstein, 1972) and reported male dominance of 62% (Ertan and Muftuoglu, 2008), 
53% (Fatima et al., 2010), 57% (Pouliquen et al., 1981) and 59% (Owens and Gamble, 
2003). Others have demonstrated no significant gender differences (Kennedy et al., 1986). 
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The overall consensus appears to be that keratoconus has similar prevalence in both genders 
(Ramez et al., 2017).   
The progression of keratoconus in the CLEK study was found to be equivalent in both genders; 
however, gender differences were found in patient history, vision and ocular symptoms (Fink 
et al., 2010). Women were older, more likely to report symptoms of dryness, reported less 
hours per day of contact lens wear and more hours of near work and scored significantly lower 
with respect to driving (p<0.0001), distance activities (p=0.0001) and general health (p=0.003) 
domains of the NEI-VFQ (Fink et al., 2010).  
The male population in this research, n=23 (77%) outnumbered the female population n=7 
(23%), 3:1. This ratio is different to the expected 1:1 gender ratio of individuals affected by 
keratoconus (Feder and Gan, 2011; Ramez et al., 2017). The reason for this discrepancy is 
unclear. 
 
Gender ages 
 
The 10-year age difference between the genders, male (Median=34.0) and female 
(Median=45) (Table 5.2, Figure 5.3) was significant: Mann-Whitney U (p=0.010), with older 
females, as found by (Fink et al., 2010).    
The gender numbers and age imbalance in this research may be important, because female 
gender, estrogen therapy in postmenopausal women, androgen deficiency and older age are all 
risk factors in dry eye disease (DED) (Stapleton et al., 2015). Dry eye symptoms, especially in 
DED have a detrimental effect on contact lens tolerance, and SRGPcl may be indicated to 
alleviate these symptoms and increase contact lens tolerance in patients with keratoconus 
(Visser et al., 2016). This could bias the female participants to choose SRGPcl over CRGPcl 
due to improved comfort, which may increase the scores of the SPC and the scores of the NEI-
VFQ. This potential bias however, may have been minimised in this study by the relatively 
small number of female participants and by the fact that at the time of enrolment all participants 
were successful CRGPcl wearers and were therefore unlikely to suffer significantly from DED. 
The crossover study design is another important aspect which minimises bias due to inter-
subject variability, as each participant acts as his or her own control. 
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Age and age at diagnosis (AAD) 
 
Keratoconus is a disease with a typical onset at adolescence and young adulthood (Feder and 
Gan, 2011), with some delay between onset and time of diagnosis and management with 
RGPcl. Keratoconus is typically diagnosed between the ages of 20 and 30 years (Galvis et al., 
2015) and rarely after age 35 (Krachmer et al., 1984). The age of the research population 
[Median=36.0, IQR=16.0, Mean=39.1 (±11.5)] was not normally distributed (p=0.039), due 
to skewness towards younger age [0.8 (SE 0.4)] normally found in individuals with keratoconus 
(Feder and Gan, 2011; Ramez et al., 2017).  
It has been hypothesised that the surprisingly low numbers of patients diagnosed with 
keratoconus over the age of 50 years, given the chronic nature of this disorder (Gordon-Shaag 
et al., 2015), may be due to association of keratoconus with such conditions as mitral valve 
prolapse (Beardsley and Foulks, 1982), obesity, obstructive sleep apnoea (Pihlblad and 
Schaefer, 2013) and Down syndrome, although the mortality rate in individuals with 
keratoconus is similar to that of the general population (Moodaley et al., 1994). The reason for 
this is therefore unclear, but could in my opinion be because significant keratoconus is 
diagnosed early in life and if keratoconus remains insignificant, it is unlikely to progress and 
therefore unlikely to be diagnosed later in life. 
The non-normal distribution of the AAD of the research population (Figure 5.4), is most likely 
due to the significant positive skewness (1.1, SE 0.4), with 80% of participants diagnosed 
before age 30, as expected in a population affected by keratoconus (Krachmer et al., 1984). 
The female AAD was normally distributed, the male AAD featured positive skewness and 
kurtosis and had a non-normal distribution (Table 5.4). The research population did not exhibit 
a statistically significant difference between the genders in the AAD (Figure 5.5), Mann-
Whitney U (p=0.190), which is consistent with the impression that keratoconus exhibits no 
clear gender preponderance (Alio, 2017; Fink et al., 2010). 
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Participants’ reported duration of CRGPcl wear at enrolment  
 
An essential selection criterion in this study required that all participants were experienced and 
successful CRGPcl wearers. The length of CRGPcl wear prior to enrolment was not normally 
distributed, with a total range of 43 years, a minimum of 4 and a maximum of 47 years 
[Median=14.5, IQR=12, (mean=16.4, ±10)].  There was no statistically significant difference 
between the genders in the duration of CRGPcl wear at enrolment (Figure 5.8); Mann-Whitney 
U test: (p=0.190).  
The duration of contact lens wear may have implications on the visual acuity scores because in 
the longitudinal assessment of visual acuity in 925 CLEK subjects over a seven-year period, 
high-contrast and low-contrast visual acuity decreased by 10 or more letters (logMAR ≥0.2) in 
19.0% and 30.8% of subjects, respectively (Davis et al., 2006). The NEI-VFQ scores also 
reduced over a 7 year follow up in all domains except ocular pain and mental health (Kymes 
et al., 2008). 
 
 
Occupation / education 
 
All participants were either employed or in an education programme, with 56% of the 
participants having university education (Table 5.7). 
 
 
Ethnicity 
 
Ethnicity may be an important factor in this research since aspects of keratoconus such as 
disease incidence, may vary from 25 cases per 100,000, per year for Asians compared with 3.3 
cases per 100,000, per year for Caucasians (p < 0.001) (Georgiou et al., 2004). In the UK 
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keratoconus incidence in Asians Indians vs white Caucasians is respectively: 19.6 vs 4.5 cases 
per 100,000 population, per year (Pearson et al., 2000).  
Ethnicity also plays a role in the progression and severity of keratoconus; with the Asian Indian 
ethnicity presenting at a significantly younger age and progressing to more severe levels than 
the Caucasian white population (Georgiou et al., 2004). The 13 Asian Indian participants 
constituted 43.3% of all participants and exhibited an earlier mean AAD of 22.5 (±4.5), 
compared with the 30% (n=9) of white Caucasian participants, whose mean AAD was 25.2 
(±9.9), consistent with Georgiou et al., 2004. The 10% (n=3) black Afro Caribbean 
participants, whose AAD was 22.3 (±4.7), were second only to the black African participants 
14.7% (n=5) of the sample, who exhibited the earliest mean AAD of 18.8 (±3.4) and who also 
featured the oldest mean age of 43.8 (±16.4) years (Tale 5.8, Figures 5.9, 5.10). 
The confounding aspects of age, gender and ethnicity were also minimised in this research by 
participant randomisation and the crossover research design (Wellek and Blettner, 2012; Jones 
and Kenward, 2015). 
 
 
Corneal characteristics  
 
As noted in the methods section of this thesis, this research was designed to study corneal 
ectatic disorders in general, as would typically be encountered in a hospital “keratoconus 
clinic”. It was anticipated that the vast majority of participants would have keratoconus because 
this is the preeminent ectatic disorder. Other ectatic disorders such as keratoglobus and pellucid 
marginal degeneration (PMD) are considered variations of keratoconus. In a pilot for the global 
consensus on ectasias, there was a 94% agreement among experts that these are ectatic corneal 
disorders and 100% agreed that the only aspects that distinguish between keratoconus, PMD 
and keratoglobus were the thinning location and pattern (Ambrósio et al., 2014).  
The purpose of the present research was to study a population which is managed with CRGPcl 
as a consequence of being affected by corneal ectatic disorders. Analysis revealed that 
keratoconus was indeed the main corneal ectatic disorder in the study population affecting 93% 
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(n=54) of the eyes, 2 eyes (1 participant) exhibited PMD. Two eyes had previously undergone 
deep lamellar keratoplasty (DLK) [corneal transplant surgery] due to severe keratoconus. 
Minor treatments such as collagen crosslinking (CXL) and intra-stromal corneal ring segments 
(INTACS) were previously applied to 6 eyes and 2 eyes respectively, more than 1 year prior to 
participation in this research (Figure 5.11). Individuals with keratoconus commonly undergo 
the various treatments such as CXL to slow down / arrest the disease progression, INTACS to 
improve the optical integrity and DLK to replace severely distorted corneae (Bao et al., 2017; 
Kılıç et al., 2017; O’Brart, 2017; del Barrio et al., 2017). These treatments were not expected 
to materially affect contact lens management of the participants, all of whom were successful 
CRGPcl wearers. Although INTACS may be indicated to contact lens intolerant individuals, 
they are not contraindicative to contact lens wear, and have even been reported in previous 
studies to facilitate contact lens fitting and comfortable wear (Ertan and Colin, 2007; Hladun 
and Harris, 2004). Contact lens wear post CXL is indicated for the management of the visual 
disability caused by keratoconus (Michaud and Breton, 2018) and significant regular and 
irregular astigmatism post keratoplasty may often be best managed with RGPcl (van Dijk et 
al., 2014).  
 
 
Research Population Corneal Metrics 
 
Pathological corneal irregularity was an inclusion criterion in this research. Objective measures 
of corneal topography indices confirmed that the research population exhibited pathological 
levels of corneal irregularity. The three indices measured are now discussed in turn.  
 
 
Kmax 
 
Kmax represents the maximum (steepest) corneal radius of curvature, which in keratoconus 
would normally exhibit values below 7.03mm (above 48D), significantly steeper [shorter 
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radius of curvature in mm and larger magnitude in dioptres] than the value of 7.85mm (±0.31) 
expected in a normal cornea (Sorbara et al., 2010).  
Sorbara et al., (2010) analysed the corneae of 40 normal eyes and found corneal curvature to 
be normally distributed with a mean radius of 7.85mm (±0.31), 95% CI: 8.70-7.24 mm (Sorbara 
et al., 2010). Corneal radius values between 7.03mm (48D) and 6.75mm (50D) are considered 
suspect for keratoconus, and values below 6.75mm denote abnormally steep corneal curvature 
(Cavas-Martinez et al., 2016; Pinero et al., 2010). The analysis of Kmax in the research 
population exhibited a normal distribution (p=0.882), [Mean=6.20mm (±0.6)] (Table 5.9, 
Figure 5.12), which is more than 3 standard deviations steeper than the steepest value of the 
95% CI of normal corneae found in Sorbara et al., (2010). Means comparison by an 
independent sample t-test with the normative data presented in Sorbara et al., (2010) confirmed 
that the research population exhibited a statistically significantly steeper radius of curvature 
than normal corneae (p<0.0001), with a mean difference of 1.62mm, 95% CI 1.43–1.80mm. 
 
 
Pachymetry 
 
Corneal ectasiae, such as keratoconus are by definition associated with corneal thinning. Pinero 
et al., (2010) evaluated 51 eyes with various degrees of keratoconus and 20 normal eyes, of 29 
male and 22 female patients, aged 16-54. Pachymetry readings were progressively lower in 
eyes with subclinical, early, or moderate keratoconus compared with the normal mean value of 
549.90µm (±28.48) (p<0.01) (Pinero et al., 2010). In the moderate to advanced keratoconus 
they found a mean pachymetry value of 457.61µm (±38.77).  
The central corneal thickness in the research population (Table 5.10, Figure 5.13) was normally 
distributed, (p=0.569) and an independent samples t-test comparison with the mean 
pachymetric values reported in Pinero et al., (2010), confirmed that this research population 
exhibited significantly thinner values than both the normal; Mean=544.74, ±42.42), 
(p<0.0001) and the moderate and advanced keratoconus groups; Mean=475.19, ±48.4 
(p=0.020).  
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Surface regularity index (SRI) 
 
SRI describes central corneal optical regularity; it is a measure of the dioptric optical power 
differences in 256 equidistant locations in the 4.5mm central corneal area. SRI correlates well 
with the measure of BCVA (r=0.80, p<0.001), with normal values below 0.56DS (Wilson et 
al., 1991; Cavas-Martinez et al., 2016; Liu and Pflugfelder, 1999). The SRI index in a normal 
cornea is expected to be below 0.56DS (Wilson et al., 1991; Cavas-Martinez et al., 2016). Liu 
and Pflugfelder (1999) confirmed this assertion in their comparison of the SRI index in 64 eyes 
of 33 normal and 42 dry eye subjects (Liu and Pflugfelder, 1999). Burns et al., (2004) analysed 
a total of 13 different corneal topographic indices in 73 patients with keratoconus and found 
mean SRI indices in the right and left eyes of 1.24 (±0.83) [range 0.10-4.59] and 1.24 (±0.82) 
[range 0.02-4.02] respectively (Burns et al., 2004).  
The SRI of the research population (Table 5.11 , Figure 5.14) is almost 3 times higher than the 
SRI value of 0.56DS expected in normal corneae (Wilson et al., 1991; Cavas-Martinez et al., 
2016; Liu and Pflugfelder, 1999).  
 
 
Right eye vs left eye corneal metrics 
 
Keratoconus is a bilateral disease (Gomes et al., 2015), with significant asymmetry between 
the two eyes (Zadnik et al., 2002), the SRI index difference between the right and left eyes in 
the population of this study exhibited no significant difference, Mann-Whitney U (p=0.168). 
Independent samples t-test analysis of the means of the right and left eye’s pachymetry and 
Kmax values also showed no statistically significant difference between the two eyes, (p=0.481) 
and (p=0.119) respectively.  
In summary all three corneal indices were consistent with the abnormal indices found in 
populations with pathological, ectatic corneal disorders such as keratoconus and were 
statistically significantly different to the indices found in populations with normal corneae. 
These objective measures of corneal topography parameters confirm the presence of corneal 
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pathology consistent with keratoconus in the research participants and the appropriateness of 
the optical management with rigid contact lenses, of the visual disability caused by this 
pathology.  
 
 
Randomisation demographics 
 
Gender 
 
The gender allocation to the two groups did not exhibit gender bias with 2 versus 5 females 
and 11 versus 12 males randomised to group 1and 2 respectively (Figure 5.15). The Chi-square 
(χ2) goodness of fit analysis confirmed that there was no statistically significant difference 
between the two randomised groups with respect to gender allocation (p=0.109). 
 
Age 
 
The age distributions in the two randomised groups (Table 5.14, Figures 5.16 and 5.17) were 
normal and the mean ages of 39.82 and 28.12 years in Group 1 and 2 respectively, were not 
statistically significantly different when compared by an independent samples t-test, 
(p=0.872).  
 
AAD 
 
The research participants’ 95% CI for mean age spanned a substantially larger time period: 
30.8-48.1 than that of the 95% CI for mean AAD: 18.3-26.3 (Figures 5.16 and 5.17). This is 
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consistent with the nature of keratoconus, which is normally diagnosed in early life and persists 
throughout life (Ramez et al., 2017; Galvis et al., 2015). 
 
 
Estimated duration of CRGPcl wear at the time of enrolment 
 
The estimated duration of CRGPcl wear at enrolment was not statistically significantly 
different between the randomised groups (Mann-Whitney U test p=0.363). This aspect of the 
population demographics is important because both visual acuity and quality of life scores may 
significantly reduce in a substantial proportion of keratoconic contact lens wearers over a 
period of 7 years (Davis et al., 2006; Kymes et al., 2008a). The equivalence of the estimated 
duration of CRGPcl wear was therefore unlikely to reduce the validity of the visual and NEI-
VFQ outcomes in this study. 
 
 
Ethnicity 
 
The race/ethnicity frequency in the two randomised groups exhibited a balanced distribution 
(Figure 5.18) and the χ2 goodness of fit test indicated that there was no significant difference 
between the two randomised groups with respect to the distribution of ethnicities (p=0.613). 
The validity of this analysis however, is sub-optimal because of the small number of 
participants: less than 5, in 3 of 4 ethnic groups. The possibility of some bias in the 
randomisation groups with respect to ethnicity was considered insignificant due to the 
crossover research design, as discussed above. 
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Corneal metrics in the randomised groups  
 
Kmax and SRI did not differ significantly in group 1 and 2 (Figures 5.19a and 5.19b). An 
independent samples t-test revealed a significantly thinner mean corneal thickness in group 1 
than in group 2 (p=0.019), (Figure 5.20). The actual difference between the means was 37µm, 
which is unlikely to be clinically significant, because both groups mean values are higher than 
400µm. Estrada et al., (2017) described grading systems of keratoconus, which include more 
than one corneal feature for characterizing the disease (Estrada et al., 2017). They reviewed 
the anatomical grading system of Amsler-Krumeich and the optical grading of Alio-Shabayek, 
both systems stipulate that corneal thickness >400µm is considered as grade II; early to 
moderate keratoconus. This indicates that the means of both randomised groups fall into the 
same grade category of keratoconus. The more recent visual function-based grading system 
developed by Estrada et al., (2017) uses narrower pachymetry bands of 20µm from grade I to 
IV and 80µm for the most severe keratoconus grade IV plus, which based on pachymetry alone 
may allocate a different grade to group 1 and 2. However, with respect to the other 6 parameters 
of this grading system, one of which is corneal radius, the 2 groups are not statistically 
significantly different.  
The difference in the pachymetry values may suggest that the level of the ectatic disease in 
group 1 was somewhat more advanced despite statistical equivalence with respect to the other 
2 indices; Kmax and SRI. This possible difference in the severity of keratoconus between the 
two groups may be a confounding element in the data analysis of a parallel groups RCT. 
However, the crossover RCT design of this research should minimise the effect of this 
difference, as each participant performs as his own control with respect to confounding 
parameters including disease severity. Furthermore, the selection criterion of good tolerance of 
CRGPcl of all participants supports the premise that there was no clinical indication for 
refitting with SRGPcl due to disease severity in any of the participants.  
The four participants who had one eye fitted were 3 males and 1 female, three fitted eyes were 
right and one eye left. Two participants SN 4 and 8 had a corneal transplant in the other eye, 
due to severe keratoconus and wore daily SRGPcl and glasses, with intermittent SRGPcl 
respectively. The other two, SN 5 and 26 wore CRGPcl and soft disposable lenses respectively. 
Randomisation was 1 to group 1 and 3 to group 2, resulting in 25 eyes fitted in group 1 and 31 
eyes in group 2. 
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Summary of demographics in the randomised groups 
 
In summary with respect to the effectiveness of randomisation it could be concluded that 
overall there were no marked differences in the demographics of the 2 randomised groups and 
the randomisation achieved its purpose.  
 
 
Main outcome measures 
 
 
Visual acuity, ETDRS logMAR BCVA 
 
It is well established that visual quality may be significantly improved in individuals with 
irregular corneal disorders such as keratoconus, with both CRGPcl and SRGPcl compared to 
unaided vision, spectacle and regular soft contact lenses corrections. These improvements may 
be demonstrated by subjective logMAR scores of improved visual resolution at 100% contrast 
and improved contrast sensitivity scores at progressively reduced levels of contrast (Zhou et 
al., 2003; Wei et al., 2011; Chaudhary et al., 2017; Visser et al., 2013b; Sabesan et al., 2013; 
Picot et al., 2015; Ozek et al., 2018). 
 
 
LogMAR demographics 
 
The mean and standard deviation of the logMAR scores in CRGPcl and SRGPcl in this study 
were similar to the published research used for the sample size calculations. This equivalence 
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confirms the appropriateness of the sample size calculation and the reliability of the logMAR 
data collection in this research.   
The ETDRS logMAR demographics of the 2 groups are exhibited in Figure 5.21 and Table 
5.19. ETDRS logMAR BCVA scores in individuals with keratoconus are expected to show 
good repeatability of measurements. Gordon et al., (1998) examined the repeatability of 
ETDRS logMAR scores of 134 participants (74.6% CRGPcl wearers) from the CLEK study, 
who exhibited a wide range of keratoconus. Good test retest repeatability, especially for same 
examiners, was demonstrated in both low and high contrast visual acuities, measured 
monocularly and binocularly, with inter-class correlation coefficient range of 0.757-0.853 
(Gordon et al., 1998). 
Pooling the data obtained from the right and left eyes could, in theory not only increase the 
power and significance of a study, but also optimally use the data obtained from the study 
population. However, in this research population, the significantly higher correlation of the 
logMAR scores of the two eyes from same individuals compared to randomised eyes means 
that pooling the data from both eyes as independent samples was inappropriate (table 5.21). 
The statistical analyses for the carryover and treatment effects of the visual outcome measures 
was therefore performed using the mean scores of the right and left eyes of each participant. 
 
 
Differential carryover and period effects analyses 
 
In a 2x2 crossover RCT the efficacy of treatments A and B is assessed on the basis of the 
comparisons of the within-subject difference between the two treatments with regard to the 
outcome variable. The recommended approach (Wellek and Blettner, 2012; Jones and 
Kenward, 2015) is to use a standard independent samples t-test for normally distributed data 
or a non-parametric equivalent such as the Mann-Whitney U test, using the within-subject 
differences between the outcomes in both periods as the raw data (Wellek and Blettner, 2012; 
Jones and Kenward, 2015). 
Prior to the analysis of the treatment effect, the possibility of a differential carryover and period 
effect must be tested for (discussion in the methods chapter). In the current research a carryover 
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effect was considered unlikely because visual acuity, which is the spatial resolving capacity of 
the visual system, is limited mainly by optical and neural factors or their combination (Bailey, 
2006). The neural factors are subject (eye) specific and are expected to be well controlled by 
randomisation, especially with a crossover, which controls for individual idiosyncrasy. The 
only significant variables to visual performance in this research are therefore the integrity and 
quality of the optical correction at the time of the examination. In a fully developed, adult visual 
system, when the quality of the visual correction is sub-optimal visual performance will be 
impaired irrespectively of the quality and timescale of previous visual experiences as may be 
demonstrated by the blur confirmation test performed during normal refraction. When the 
quality of the visual correction at the time of examination is optimised, the visual performance 
will be optimised irrespectively of the previous visual experience (Borish and Benjamin, 2006). 
Despite this accepted clinical wisdom, to conform to the crossover design analysis, it was 
considered prudent to perform the appropriate statistical analysis for a differential carryover 
and period effects, prior to performing the analysis of the treatment effect, as recommended in 
the literature (Wellek and Blettner, 2012; Jones and Kenward, 2015).   
The analysis of a carryover effect should include a pre-test confirmatory analysis, which 
consists of comparing the sums of means of the 2 periods for each subject in the two groups / 
sequences by means of another appropriate test for independent samples (Wellek and Blettner, 
2012; Jones and Kenward, 2015). If this test yields a statistically significant result, the usual 
crossover analysis which compares the intra-subject differences of the effects of the two 
treatments between the randomised groups, should not be applied and the analysis should be 
performed as in a parallel study using the data from the first period only, in each randomised 
group (Wellek and Blettner, 2012). 
A preliminary assessment was performed on the logMAR data as soon as the first 12 
participants completed the study. An independent sample t-test comparing the sums of the 
logMAR period scores revealed no significant difference, (p=0.056), which indicated an 
absence of a significant carry over effect. At the end of the study, a similar analysis of the full 
dataset (Table 5.23a and 5.23b), also revealed no statistically significant difference between 
the period sums of the two randomised groups, (p=0.281) (Table 5.24). This result indicates 
that there was no evidence for a carryover effect and enables the utilisation of the full crossover 
data in the analysis for treatment effect on visual performance measured by the ETDRS 
logMAR. 
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The period effect was also considered unlikely due to the relatively short period of the research. 
Period effect was calculated by an independent samples t-test means comparison of the period 
crossover differences (A-B) between the randomised groups (Tables 5.23 a and b), this finding 
indicated that there was no significant period effect in the logMAR scores in this research 
(p=0.541). 
 
 
Treatment effect, ETDRS logMAR 
 
The objective of a crossover trial is to determine whether within-subject treatment effect 
differences exist. This may be achieved by the comparison of the within participant score 
differences in periods 1 and 2, between the two randomised groups (Wellek and Blettner, 2012; 
Jones and Kenward, 2015). 
The summary table of the period means of the mean OD/OS logMAR scores in the two groups 
(Table 5.22) and the box plots of group by period logMAR scores (Figure 5.23) illustrate the 
similarity in the means of the scores and the differences in the interquartile range and total 
range in the two periods of the two groups. The logMAR scores with CRGPcl [group 1 period 
1, group 2 period 2] exhibit a larger interquartile range then the SRGPcl [group 1 period 2, 
group 2 period 1]. The wider interquartile and total range of the logMAR scores with CRGPcl 
compared with SRGPcl is also apparent in Figure 5.24, which exhibits the box plots of the 
whole population mean OD/OS logMAR scores in CRGPcl versus SRGPcl. 
The group by period analysis exhibited in Figures 5.25 and 5.26 highlights the logMAR score 
differences between participants and the subtle differences between the two groups, by the 
spread of scores along the diagonal (Jones and Kenward, 2015). Group 1 exhibits a larger inter-
subject variability, group 2 exhibits a single low scoring outlier (top of the graph), which is 
responsible for the lower Kendall’s tau_b correlation of 0.331 in group 2 versus 0.517 in group 
1. The majority (7 versus 6) of the plotted scores in group 1 are below the diagonal, which 
indicates a tendency for better logMAR scores (lower values) in period 2 (SRGPcl). The 
periods in group 2 exhibits more equal scores, 8 under and above the diagonal. The fairly 
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symmetrical distribution of the plotted scores in relation to the diagonal in both groups 
indicates an absence of a significant period effect (Jones and Kenward, 2015). 
To illustrate treatment effect, both groups were plotted on the same graph with their respective 
centroids plotted in Figure 5.27. The fact that both centroids are on the diagonal, at essentially  
the same position, indicates an absence of a significant treatment effect, or period score 
equivalence in both groups (centroids on the diagonal) and equivalence in the logMAR scores 
between group 1 and 2 (same position of centroids) (Jones and Kenward, 2015). 
A good plot for displaying within-participant treatment / period differences is the subject-
profiles plot (Figure 5.28) (Jones and Kenward, 2015). These plots exhibit the logMAR scores 
in the two periods for each participant. Larger inter-subject variability is apparent in group 1, 
with an obvious outlier with poorer scores in group 2 (top of the graph). The majority of 
logMAR score changes (slopes) are relatively small, 3 participants in each group exhibited 
significant changes of five or more letters. There is no clear trend (direction of slopes) which 
also indicates an absence of a significant treatment effect. 
Plotting the four groups by period means ȳ11, ȳ12, ȳ21 and ȳ22 against their corresponding 
period labels and joining the mean logMAR scores achieved in CRGPcl [periods 1 group 1 
with period 2 group 2] and joining the scores achieved in SRGPcl [period 2 group 1 with period 
1 group 2] (Figure 5.29) exhibits the difference in the mean logMAR scores between 
participants in groups 1 and 2 wearing CRGPcl and the difference between participants in 
groups 2 and 1 wearing SRGPcl (Jones and Kenward, 2015). In period 1 the mean logMAR 
score difference (A vs B) is 0.03 (1.5 letters) in period 2 (B vs A) is 0.02 (one letter), the 
crossing of the graph lines indicates that the participants in group 2 (red triangle and dot) 
exhibited lower logMAR scores (better visual acuity) in both CRGPcl and SRGPcl than the 
participants in group 1.  
To establish whether a statistically significant difference existed between the ETDRS logMAR 
scores of participants wearing CRGPcl compared with participants wearing SRGPcl a 
comparison of the logMAR score period differences between the two experimental groups 
(Table 5.23a and 5.23b) was performed by the non-parametric Mann-Whitney U test. This 
analysis confirmed the null hypothesis (H0) that despite the slightly better logMAR score in 
SRGPcl in group 1, there was no significant difference between group 1 (Median=-0.01) and 
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group 2 (Median=0.00), period differences: U=96.5, (p=0.563) [z=-0.588] (Tables 5.25 a, b, 
Figures 5.30 and 5.31).  
 
 
Summary of the ETDRS logMAR outcome measure 
 
The ETDRS logMAR results indicate that in patients with irregular cornea disorders such as 
keratoconus, who are successful CRGPcl wearers, with no clinical indications for refitting with 
alternative contact lenses such as SRGPcl, the logMAR visual acuity is expected to be 
equivalent in both CRGPcl and SRGPcl. With respect to logMAR visual acuity, no advantage 
is expected in refitting a successful CRGPcl wearer with SRGPcl and no disadvantage in 
refitting with SRGPcl, if and when this is clinically indicated.  
 
 
Contrast sensitivity measure of visual performance  
 
The second aspect of visual performance measured and compared in CRGPcl versus SRGPcl 
was the contrast sensitivity function (CSF), which measures the visual system’s resolution of 
4 different grating spatial frequencies, expressed in cycles per degree (CPD), at 8 levels of 
gradual contrast reduction. These scores may be expressed by a numerical value of contrast on 
a scale from 0-8, for each grating size, which may be plotted on a contrast sensitivity chart and 
also expressed in log contrast sensitivity (logCS) for statistical analysis. 
The research population’s numerical scores of CS (Table 5.26, Figure 5.31a) were lower at all 
four spatial frequencies (poorer performance) than normative data collected by the FDA 
researchers [unpublished data quoted in (VectorVision, 2013)] (Table 5.28, Figure 5.32a) and 
also poorer performance in CPD 6, 12 and 18 compared with the published normative data by 
Hashemi et al., (2012) (Table 5.29, Figure 5.32b). The reduced CSF of keratoconic CRGPcl 
wearers was found in other research; (Wei et al., 2011) (Figure 5.32c). The mean numerical 
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CS scores in this research (Tables 5.27.a (Appendix IV.A) and 5.27b) were similar to the Wei 
et al., (2011) scores at 3 and 6 CPD. However, at 12 and 18 CPD, the mean scores in this 
research were higher (≥1.0 CS scores) than in Wei et al., (2011). The reason for this difference 
is not clear, it is possible that in the Wei et al., (2011) study there were more eyes with advanced 
keratoconus, which negatively affected the higher resolution demands (Zadnik et al., 2002; 
Wagner et al., 2007; Wei et al., 2011) at 12 and 18 CPD [logMAR 0.5 and 0.20 respectively 
(Sukha and Rubin, 2013)].  
Numerical average OD/OS CSF scores means at 3, 6, 12 and 18 CPD in CRGPcl and SRGPcl 
and whole population are presented in Tables 5.27a and b and Figure 5.32. The two 
experimental lenses exhibit similar mean and StdDev numeric CSF scores at all four CPD 
(Figure 5.31b). 
 
 
Crossover data analysis 
 
The analysis of the CS data was performed in a similar manner to that of the ETDRS logMAR 
scores, the logCS scores of the right and the left eyes were averaged and a mean CPD score 
was calculated for each participant in periods 1 and 2, in group 1 (AB) and group 2 (BA) 
(Tables 5.30, 5.31 and 5.32).  
Plotting the logCS scores in periods 1 and 2, in groups 1 and 2 (Figure 5.34), highlights the 
larger inter-subject logCS score variation (spread of the scores along the diagonal) in group 1 
and the overall slightly higher (better) logCS scores in group 2 (higher concentration of scores 
in the upper part of the graph). In group 1 the logCS scores were higher in period 1 (CRGPcl) 
(more points under the diagonal) and in group 2 the scores were higher above the diagonal, 
period 2 (CRGPcl). Group 1 exhibited a single outlier (participant 23), with a significantly 
better score in period 1 (CRGPcl). The fairly symmetrical distribution of the plotted points in 
relation to the diagonal in both groups is an indication for the absence of a period effect (Jones 
and Kenward, 2015). 
To illustrate evidence of treatment effect both groups were plotted on the same graph with their 
respective centroids (Figure 5.35). The centroids are close to and on the opposite sides of the 
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diagonal, which indicates that there was a slight (proximity to diagonal) difference between the 
two periods in both groups and that in both groups, participants had higher logCS scores with 
CRGPcl (group 1 period 1, group 2 period 2). The higher overall performance was in group 2, 
indicated by the higher location of the group 2 centroid, is not indicative of a period carryover 
effect since the lens in period 1 in that group was SRGPcl, which had lower scores than 
CRGPcl. The fact that the centroids are placed either side of the diagonal line with some 
vertical separation may be an evidence of a direct treatment effect. (Jones and Kenward, 2015). 
The subject-profiles plot displays within-participant treatment / period differences, by 
displaying and connecting the logCS scores in the two periods for each participant (Figure 
5.36). Larger inter-subject variability is apparent in group 1 compared with group 2, with an 
outlier with poorer scores in group 1 period 2 (participant 23). The majority of logCS score 
changes are relatively small (less than 0.1 log units), four participants in group 1 and two 
participants in group 2, exhibited significant logCS score changes of ≥0.10 log units.  The trend 
for higher logCS scores in period 1 of group 1 can be detected in the general direction of slopes, 
in group 2, no obvious trend is apparent.  
Plotting the four group by period means ȳ11, ȳ12, ȳ21 and ȳ22 against their corresponding period 
labels and joining the mean logCS scores achieved in CRGPcl [period 1 group 1 with period 2 
group 2] and joining the scores achieved in SRGPcl [period 2 group 1 with period 1 group 2] 
(Figure 5.37), illustrates the small difference in the mean logCS scores between participants in 
groups 1 and 2 wearing CRGPcl and the difference between participants in groups 1 and 2 
wearing SRGPcl. In period 1 the mean logCS score difference (A vs B) is 0.10 logCS; better 
scores for SRGPcl: [CRGPcl Mean=1.46, SRGPcl Mean=1.56]. In period 2 (B vs A) the 
difference is 0.17 logCS, better scores for CRGPcl [CRGPcl Mean=1.59, SRGPcl 
Mean=1.42]. The crossing of the graph lines highlights the higher logCS of participants in 
group 2 in both lenses (red triangle and a red circle). A significant difference between the scores 
of groups may be indicative of a treatment-by-period interaction (carryover effect) (Jones and 
Kenward, 2015).  
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Carryover and period effects analysis 
 
Analysis of period carryover effect by an independent samples t-test indicated that due to the 
significantly higher mean of period sums in group 2 there is a possibility of a period carryover 
effect (p=0.019). The most likely explanation for this finding may be related to the absolute 
differences in the logCS scores between the two groups and not due to period interaction. As 
discussed above regarding carryover effect in the logMAR scores these arguments are equally 
applicable to the logCS scores (Bailey, 2006; Borish and Benjamin, 2006). However, despite 
this accepted clinical wisdom and the absence of a statistically significant difference in the 
period sums of the logMAR visual scores, it was decided to analyse the treatment effect both 
according to a crossover study protocol (ignoring the statistically significant finding regarding 
the sum of periods) and more conservatively as a parallel group RCT protocol, in which the 
results of period 1 only in both groups will be compared (Wellek and Blettner, 2012). 
The period effect was calculated by a Mann-Whitney U test comparison of the period crossover 
differences between the randomised groups (Tables 5.31), this finding indicated that there was 
no significant period effect in the logCS scores in this research (p=0.711). 
 
 
LogCS treatment effect 
 
An independent samples t-test comparing the means of the period differences between group 1 
and group 2 confirmed the H0, that the higher logCS scores achieved in CRGPcl in both groups 
were not significantly different to the logCS scores achieved in SRGPcl (p=0.316), (Figure 
5.38).  
The parallel group analysis was performed by an independent samples t-test comparing the 
logCS means of the four CPD scores achieved with the two contact lens types in period 1 of 
group 1 and period 1 in group 2. The 0.10 logCS higher scores achieved in SRGPcl (<0.15, 
single logCS increment, Figure 6.1) did not reach statistical significance and therefore also 
supported the H0, (p=0.070).  
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Figure 6.1. CSF score chart, 1 level difference between numbers in each row is equivalent to 
approximately 0.15logCS. (reproduced with permission of VectorVision) 
 
The magnitude of 0.10 logCS difference did not constitute a statistically significant difference 
in visual performance between the two experimental lenses. To determine whether this 
difference is clinically significant, it would be instructive to refer to clinical research in which 
CS scores are used to evaluate visual improvement due to therapeutic treatment. 
Bland and Altman (1986) suggested that for normally distributed data, the coefficient of 
repeatability (COR) describes the 95% CI for the variability of these data [COR=SD of test 
retest difference x 1.96]  (Bland and Altman, 1986). Reeves et. al., (1993) suggested that COR 
may be a useful criterion to determine the minimum change in test performance necessary to 
indicate a significant change in vision on a particular test. If the ratio of the score difference 
and COR is higher than 1, it would indicate that the difference in scores is higher than the 
normal variation between measurements and therefore significant, if lower than 1 then 
insignificant, as may be due to a normal measurement variability (Reeves et al., 1993). 
Pomerance and Evans (1994) used the CSV-1000 to measure the effect of glaucoma therapy 
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on vision. They compared the normative COR for each spatial frequency to the change in vision 
before and after therapy in glaucoma patients (Pomerance and Evans, 1994). They found that 
the average COR of normal subjects was 0.191 and that vision differences / COR ratios, were 
significant for CPDs 3, 6 and 12: 1.98, 1.15, 1.30, respectively and not significant for 18 CPD: 
0.64. Using the same normative data to establish the clinical significance of the logCS 
difference in the current research, the ratio of the mean score difference between the two 
groups: 0.10 and normative COR: 0.191 from Pomerance and Evans (1994), was lower than 1: 
[0.1/0.191=0.52], which confirms that this difference is unlikely to be clinically significant. 
 
 
LogCS scores at 6 CPD 
 
It was decided to compare the logCS scores of CRGPcl and SRGPcl at 6 CPD specifically, 
because the score difference between the experimental lenses was largest at 6 CPD (Figure 
5.31b) and because the resolution required for 6 CPD target is 6/30 / logMAR 0.70 (Sukha and 
Rubin, 2013). This level of resolution is relatively low and has been achieved by all eyes in 
this research. Another reason for choosing 6 CPD was that normative data indicate that the 
highest CS scores are achieved at 6 CPD compared with the other three and therefore could 
provide useful insight into visual performance in addition to that provided by the mean logCS 
and ETDRS logMAR.   
Due to the possibility of a period carryover effect the treatment effect analysis was again 
performed for the whole data of the crossover and the data from period 1 of both groups, (p= 
0.104) and (p=0.110) respectively. Analyses by both these methods supports H0.  
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Summary of subjective visual outcomes 
 
Both methods of assessing visual performance in this research, the ETDRS logMAR and the 
logCS, indicated that there was no statistically significant difference between the two 
experimental lenses with respect to the research participants’ visual performance. Similar 
results may be found in published research, such as was used in the sample size calculation 
(Davis et al., 2006; Marsack et al., 2007; Nejabat et al., 2012; Gumus et al., 2011; Sabesan et 
al., 2013). Other research exploring CSF visual performance in both lens types, Wei et al., 
(2011) in CRGPcl and Ozek et al., (2018) in 28 keratoconic, 4 PMD and 8 corneal grafts 
SRGPcl wearers, reported an identical mean logCS to this study, in CRGPcl and SRGPcl 
respectively (Wei et al., 2011; Ozek et al., 2018).  
In summary, no statistically or clinically significant differences were found in the visual 
performance, measured by logMAR and LogCS, between CRGPcl and SRGPcl in the 
participants in this research. The visual outcomes in this research therefore do not support the 
findings in other studies such as Baran et al., (2012) and Bergmanson et al., (2016), who found 
superior visual performance in SRGPcl compared with CRGPcl.  
The most likely explanation for this difference is the study design and the population 
demographics. The present research is a crossover RCT, whereas Baran et al., (2012) and 
Bergmanson et al., (2016) are retrospective analyses of participants who were refitted with 
SRGPcl due to clinical needs and therefore may have had more advanced levels of keratoconus. 
The suggestion that:  
“Given the here reported comfort and vision advantage, it may be argued that the 
scleral contact lenses should be tried at an earlier stage and possibly be the first rigid 
lens prescribed for keratoconus cases” (Bergmanson et al., 2016). 
is not supported by this research at least with respect to achieving better visual performance, 
when no other clinical indication for refitting CRGPcl wearers with SRGPcl are present.   
The visual outcome results in this research also indicate that patients who may require a 
refitting from CRGPcl to SRGPcl due to nonvisual clinical indications, such as reduced lens 
tolerance, should not be disadvantaged with respect of their vision from being refitted with 
SRGPcl.  
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National Eye Institute Visual Function Questionnaire (NEI-VFQ) 
 
 
The third outcome analysed was the National Eye Institute Visual Function Questionnaire 
(NEI-VFQ). Assessment of visual quality of life has been widely used in the monitoring of 
treatment efficacy in ocular disorders. The NEI-VFQ developed and validated by Mangione et 
al., (1998) evaluates the vision-related health status, and the impact of ocular diseases on 
individuals’ social function, emotional well-being and daily routine activities (Mangione et al., 
1998; (Mangione, 2000).  
Keratoconus has a significant detrimental effect on quality of life (Qol), which is equivalent in 
its severity to categories 3 and 4 (advanced stages) macular degeneration (Kymes et al., 2004). 
Baran et al., (2012) re-fitted 49 selected participants (43 with keratoconus) with SRGPcl from 
their habitual CRGPcl and found 27.6/100 points improvement in NEI-VFQ scores, across the 
12 domains (p < 0.001).  
Changes in the NEI-VFQ scores of 925 keratoconus patients were evaluated by the CLEK 
study over a 7-year follow-up period. The researchers reported a decrease in scores of all NEI-
VFQ domains, except ocular pain and mental health. These decreases in vision related Qol 
were associated with exacerbation of keratoconus and reduction in visual quality (Kymes et 
al., 2008). Nevertheless, Aydin Kurna et al., (2014) suggested that the higher visual acuity 
afforded by RGPcl may improve vision related Qol, which was supported by the finding that 
patients with keratoconus expressed higher levels of satisfaction after being fitted with CRGPcl 
than patients with normal corneae, who were fitted with CRGPcl for myopia correction (Lee 
et al., 2017).  
 
 
NEI-VFQ demographics 
 
From the 12 domains of the NEI-VFQ in this research (Table 5.34) ocular pain featured the 
lowest (worst) mean score of 77.6 (±21.19) followed by the participant perception of their 
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general health 79.55 (±12.45). These results were similar to the CLEK study by Kymes at al., 
(2004), the 1166 participants with keratoconus reported mean scores of 74.8 (±18.0) and 75.5 
(±21.4) for ocular pain and general health respectively. Both these populations graded the 
ocular pain and general health status lower than the normative population of CRGPcl wearers 
reported in Kymes et al., (2004); 85.4 (± 13.7) and 84.4 (±18.5) respectively (Figures 5.40a. 
and 5.40b).  
The NEI-VFQ score differences between the keratoconic participants and the normative 
CRGPcl participants, reach statistical significance for all 12 domains, (p<0.05), in the Kymes 
et al., (2004) study. The current study exhibited slightly higher (better) NEI-VFQ scores 
compared with Kymes et al., (2004), except in the domain of ocular pain (Figure 5.40a). 
However, the results in the current study were also lower in all domains than the normative 
data published by Kymes et al., (2004) taken form Walline et al., (2000) (Kymes et al., 2004; 
Walline et al., 2000) (Figure 35b).  
Kymes et al., (2008) followed the 1166 participants for 7 years and found a modest decline in 
all NEI-VFQ domains except ocular pain and mental health. The drop in these scores was 
associated with a significant decline of 10 letters in logMAR scores and a 3.00D increase in 
corneal curvature (0.6mm steeper). This finding is significant for the current research because 
of the association of contact lens wear duration with decline in logMAR scores and 
exacerbation of keratoconus, both of which may be associated with reductions in NEI-VFQ 
scores. This aspect however, should have been well controlled in this research due to 
randomisation and the overall equivalence between the two randomised groups with respect to 
age at diagnosis and equivalence with respect to the estimated reported duration of CRGPcl 
wear at enrolment (Figure 5.16 and 5.17). 
 
 
Summary NEI-VFQ demographics 
 
The comparison of the mean scores of individual domains between the two experimental lenses 
(Figures 5.41a and 5.41b) shows that the participants reported slightly higher scores in CRGPcl 
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[Median=89.53, IQR=17.38], than in SRGPcl [Median=88.35, IQR=14.04], except in the 
driving domain, in which SRGPcl featured slightly higher scores. 
 
 
Carryover and period effects analysis of NEI-VFQ 
 
The mean of the scores of the 12 domains of NEI-VFQ for each participant, in each period was 
calculated as well as period sums and crossover differences in the two groups [Table 5.35, 
(Appendix IV B)]. The absence of carryover effect was confirmed by Mann-Whitney U test 
(p=0.245). An independent samples t-test means comparison of the period crossover 
differences between the randomised groups confirmed the absence of a period effect (p=0.343) 
in the NEI-VFQ scores in this research. 
 
 
Treatment effect analysis 
 
The two randomised groups exhibited similar scores in all 12 domains of the NEI-VFQ with 
slightly higher mean scores in group 1, in 9 of 12 domains (Figure 5.42). To establish the 
treatment effect of the experimental lenses on the VFQ scores, data analysis was conducted as 
in previous outcome measures according to recommendations of Wellek and Blettner (2012) 
and Jones and Kenward (2015). The mean of the scores of the 12 domains of NEI-VFQ for 
each participant, in each period was calculated as well as period sums and differences in the 
two groups [Table 5.35, (Appendix IV B)]. 
The absence of carryover effect was confirmed by Mann-Whitney U test (p=0.245). 
The treatment effect analysis revealed that the higher scores reported by the participants in 
SRGPcl did not reach statistical significance (p=0.483). These results indicated that with 
respect to the mean score of the 12 domains of the NEI-VFQ there was no statistically 
significant difference between the experimental lenses, confirming H0. 
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The NEI-VFQ results in this research did not support the findings of other research which 
found higher NEI-VFQ scores in participants wearing SRGPcl compared with CRGPcl, such 
as Baran et al., (2012). This difference in results is most likely due to the difference in the 
research design with Baran et al., (2012) being a retrospective analysis of participants who 
were refitted with SRGPcl for clinical reasons. The current research design is a crossover RCT, 
of participants who had no clinical indications for refitting with SRGPcl. 
 
 
Summary of NEI-VFQ outcome measure 
 
The conclusion which may be drawn from the NEI-VFQ results of the current research are, that 
there would most likely be no significant improvement in the vision related Qol if patients with 
keratoconus and other irregular cornea disorders, who are successful CRGPcl wearers, with no 
clinical indications for refitting, are refitted with SRGPcl. There would also be no likelihood 
of a disadvantage with respect to vision related Qol if patients who wear CRGPcl are refitted 
with SRGPcl and vice versa, when clinically indicated. 
 
 
Subjective measures of comfort and vision 
 
Optometrists use grading scales in their daily practice for a variety of purposes. A study by 
Efron et al., (2011) concluded that grading scales for contact lens complications may “be 
considered as an expected norm in contact lens practice”, they further advocated “the 
incorporation of such grading scales into professional guidelines and standards for good 
optometric clinical practice” (Efron et al., 2011). Grading scales are also used in optometric 
practice for the recording of symptoms such as comfort levels due to ocular dryness (Begley et 
al., 2001). Numerical rating scales were found to be useful, repeatable and accurate when the 
visual quality is generally high (Papas and Schultz, 1997), as in the current research.  
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The measurement of contact lens discomfort is complex; the sensation experienced is 
inherently variable, and existing measurement scales may not be optimal. Appropriately 
designed questionnaires undergo a rigorous process of item development and validation. 
Interval scales (e.g. numerical rating scale and visual analogue scale) are frequently used to 
measure temporal characteristics of contact lens discomfort and remain useful in assessing 
qualities such as duration, onset and chronicity. Jalbert et al., (2015) reviewed the instruments 
used to assess contact lens comfort and stipulated that the majority of studies have used 
questionnaires designed and validated for use in dry eye patients, most commonly the ocular 
surface disease index (Schiffman et al., 2000) was used in 13 studies, the contact lens dry eye 
questionnaire (Begley et al., 2001) was used in 7 studies. The authors pointed out the 
questionable nature of such practice as the characteristics; epidemiology and underlying 
mechanisms of contact lens wearers differ from those reported by dry eye patients. They 
recommended that improved instruments need to be developed, but until then, interval scales 
and the short version of the contact lens dry eye questionnaire are the best validated instruments 
available for measuring contact lens discomfort (Jalbert et al., 2015). 
Wirth et al., (2016) initiated the development of the Contact Lens User Experience system. 
They interviewed 86 healthy adult, soft disposable contact lens wearers and identified three 
key areas patients consider important when describing their experience with contact lenses. 
These were: comfort, vision and contact lens handling. The authors claim that these instruments 
exhibit excellent psychometric properties (Wirth et al., 2016). To my best knowledge these 
instruments have not to date been used in research and because they were developed for healthy 
soft lens wearers are unlikely to be suitable for the current research. 
It was therefore decided to follow the advice of Jalbert et al., (2015) and develop a Likert-like 
interval scale from 1-10, (1=worst comfort and vision, 10= perfect comfort and vision) to grade 
personal perception of vision and comfort in the experimental contact lenses. This instrument 
was designed for this study by the chief investigator, with a view that if appropriate, it may 
after further validation be used in both specialist and standard contact lens practice.  
The individual scores for SPC and vision of each participant in periods 1 and 2 in both groups 
are presented in Figures 5.43, 5.44, 5.45 and 5.46 (Appendix IVC). Significant differences are 
apparent in some individuals in their scores of the subjective comfort such as in group 1; 
participants 10, 11, 20, 23, 28; scoring their comfort in SRGPcl higher by 2.5, 2, 3, 2.5 and 2 
points respectively. In group 2 smaller differences in subjective comfort scores were apparent 
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with participants 6 and 34 reporting a 3 and 2-point better comfort in SRGPcl, with the rest 
reporting differences of less than 2-points. Subjective grading of vision showed less obvious 
differences between the two experimental lenses in group 1: participant 1 reporting a 3 points 
better vision in CRGPcl, with the rest of the participants in that group reporting equivalence or 
differences smaller than 2 points. Participants in group 2 also reported equivalent results except 
participant 15, who reported 5-point better vision in SRGPcl, and participants 9, 16 and 24 
reporting differences of 2.5, 2.5 and 2-points respectively, the first 2 reported better vision with 
SRGPcl and the latter with CRGPcl. 
 
 
Crossover analysis of subjective scores of vision and comfort 
 
The analyses of the subjective scores of vision and comfort were performed in the same manner 
as the other outcome measures, as recommended by Wellek and Blettner (2012) and Jones and 
Kenward (2015).  
The period by group comparisons in Figures 5.47 and 5.48 highlight an important finding 
which shows that subjective comfort was better in period 2 in group 1 and period 1 in group 2, 
this finding indicates that overall participants reported better comfort in SRGPcl.  
Subjective grading of vision was fairly equally symmetrical around the diagonal in group 1, 
with 3 participants reporting better vision in period 2 (SRGPcl) and 3 participants reporting 
better vision in period 1 (CRGPcl), 7 participants reported equal SPV. In group 2, five 
participants reported better vision in period 1 (SRGPcl) and 6 reported better vision in period 
2 (CRGPcl), the remaining 5 participants reported equal vision. 
The Mann-Whitney U tests indicated that there was no statistically significant carryover effect 
in SPC and vision scores reported by the participants (p=0.183) and (p=0.592) respectively. 
The period effect analysis by an independent samples t-test means comparison of the period 
crossover differences between the randomised groups (Tables 5.38, 5.39), indicated that there 
was no significant period effect in the SPC and SPV scores in this research (p=0.630), 
(p=0.157) respectively. 
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The comparison of the two groups with respect to the treatment effect of the two experimental 
lenses was performed as recommended by Wellek and Blettner (2012) and Jones and Kenward 
(2015). The Mann-Whitney U tests indicated that the slightly higher (better) SPV scores 
achieved with SRGPcl did not reach statistical significance, (p=0.213), which supports the H0, 
(Figure 5.49b). The participants’ subjective grading of their own vision is also in agreement 
with the experimental visual findings that there was no significant difference between the two 
experimental lenses with respect to the visual performance measured by logMAR and logCS. 
Participants’ perception of their subjective comfort in the two experimental lenses, was also 
evaluated for treatment effect by the Mann-Whitney U test comparing the period difference in 
group 1 (Median = 1.0) to the period difference in group 2 (Median = -1.0). The group by 
period and individual profile plots reveal higher scores with SRGPcl (Figures 5.47a, b and c) 
and were confirmed as statistically significant (p=0.002). This result rejects the H0 and 
indicates that in this research population significantly higher subjective comfort scores were 
achieved with SRGPcl (Figure 5.49a).  
After establishing the statistically significantly higher SPC scores in SRGPcl, it was decided 
to explore whether other factors, unrelated to the lens type could have influenced the 
participants’ scoring of subjective comfort. The sequence of contact lens wear was considered 
as a possibility, because the loss of adaptation to CRGPcl after wearing SRGPcl [group 2, 
sequence: BA] could have detrimental effects on the perception of comfort on resumption of 
CRGPcl wear in the washout and experimental periods. If this assumption is true, the comfort 
score of the experimental CRGPcl in group 2 would be lower (worse) than in group 1 [CRGPcl 
worn first, sequence: AB]. An independent samples t-test comparing the means of the 
subjective comfort in experimental CRGPcl between group 1 and group 2 revealed no 
statistically significant difference between two groups: (p=0.198). This excluded the sequence 
of wear as a factor with significant influence on the subjective comfort scores.  
The other outcome measure which assesses participants’ comfort in this experiment may be 
found in the ocular pain domain of the NEI-VFQ. It was decided to evaluate this domain in 
isolation to determine whether a statistically significant difference between the two 
experimental lenses might be found with respect to ocular pain as well. The analysis was 
performed as recommended by Wellek and Blettner (2012) and Jones and Kenward (2015), 
after establishing the absence of significant period and differential carryover effects, the higher 
(better) ocular pain scores achieved with SRGPcl, supported the finding of the subjectively 
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reported levels of comfort in the experimental lenses, but this difference did not reach statistical 
significance (p=0.170). Therefore, still supported the H0 in this regard. 
 
 
 
Final lens choice 
 
Lens choice for future habitual use was the final outcome measure. Fourteen (47%) of 
participants chose the SRGPcl and 16 participants chose the CRGPcl (53%) as their habitual 
lens. The chosen habitual lenses of the four participants who had one eye fitted were: 
participants 4, 5 and 8 chose to remain in CRGPcl and participant 26 chose SRGPcl. 
Interestingly, participants 4 and 8 chose to remain in CRGPcl despite successfully wearing a 
SRGPcl in the other, non-experimental eye. 
Based on the absence of statistically significant differences in the participants’ visual 
performance or in their scores across the 12 domains of the QoL, it was of interest that almost 
50% of participants chose to abandon their habitual CRGPcl and wear SRGPcl, despite 
exhibiting no statistically significant visual or Qol advantages in these lenses.  
The only statistically significant difference found in this experiment was in the participants’ 
perception of comfort in the two experimental lenses, with better comfort scores in SRGPcl. It 
may be postulated that the significantly better perception of comfort in SRGPcl was the main 
reason for 47% of the participants to switch to SRGPcl from their habitual lens design, CRGPcl. 
The participants’ SPC and SPV together with the final lens choice are presented in Table 5.40 
(Appendix IV D) and Figure 5.51. 
To try and understand why a high proportion (47%) of successful CRGPcl wearers chose to 
change to SRGPcl, it was decided to analyse and compare the scores of the perceived subjective 
comfort in the experimental CRGPcl between the participants who chose CRGPcl and those 
who chose SRGPcl.  
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A means comparison of the subjective comfort scores reported in the experimental CRGPcl of 
the participants who selected CRGPcl [Mean=8.44 (±1.03)] and SRGPcl [Mean=7.04 (±1.54)] 
was performed by two independent samples methods, the t-test and Mann-Whitney U test 
(Figure 5.52).  
Both analyses revealed significantly higher scores of reported subjective comfort by the 
participants who selected CRGPcl as their habitual lens compared with participants who 
selected SRGPcl, (p=0.006) and (p=0.009) by independent samples t-test and Mann-Whitney 
U test respectively, thus rejecting the H0.  
These results indicate that there is a significant difference in the subjective comfort perception 
in CRGPcl between the participants who chose CRGPcl and those who chose SRGPcl as the 
preferred habitual contact lenses. This significance indicates that the difference in the 
subjective comfort in CRGPcl may be an important measure of the performance of CRGPcl in 
the wider population of patients with keratoconus managed by these lenses. 
After establishing the statistically significantly higher score of SPC in participants who chose 
CRGPcl as their future habitual lenses, it was decided to explore whether other factors, such as 
the sequence of contact lens wear could influence the final lens choice. Sequence was 
considered important due to the possibility of loss of adaptation to CRGPcl after wearing 
SRGPcl in group 2 [sequence BA]. Alternatively, the possibility of preferring the latest lens 
worn; SRGPcl in group 1 [sequence: AB] and CRGPcl in group 2 [sequence BA]. This analysis 
compared the number of participants selecting CRGPcl and SRGPcl in the two randomised 
groups. The non-significant χ2 results, (p=0.713), indicate that neither lens wear sequence nor 
the final lens worn by the participants had a significant influence on the choice of the final 
habitual lens (Table 5.42).  
It is of note that 12 (75%) of the 16 participants who chose CRGPcl scored their subjective 
comfort in these lenses as ≥8 and none scored their comfort level in these lenses at < 7, which 
seems reasonable for successful contact lens wear. Nevertheless, 8 (57%) out of the 14 
previously successful CRGPcl wearers scored their comfort level in these lenses at ≤7, and 
given an alternative choice selected SRGPcl. The other 6 (43%) participants, who chose 
SRGPcl, scored their subjective comfort in CRGPcl at ≥7.5, switched to SRGPcl most likely 
due to a combination of other factors, such as improved vision and equal or better comfort.   
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Summary of statistically significant results 
 
This research revealed statistically significantly higher subjective comfort scores in SRGPcl 
than in CRGPcl and also found that participants who chose CRGPcl as their habitual lenses, 
had statistically significantly higher subjective comfort scores in CRGPcl. Furthermore, no 
participant chose to remain in CRGPcl with subjective comfort scores <7. These findings 
indicate that for some wearers SRGPcl afford superior comfort to CRGPcl and habitual wearers 
of CRGPcl are likely to prefer SRGPcl if their subjective comfort score with CRGPcl are lower 
than 7. 
These results indicate that the LSCS instrument may be appropriate for use in patients with 
keratoconus and other irregular cornea disorders managed by CRGPcl, to determine the degree 
of their perceived comfort. Based on the findings of this research a comfort score <7 may 
indicate that despite reported satisfaction, and no clinical indications for refitting with 
alternative lenses, the contact lens experience may be improved with alternative contact lenses, 
such as SRGPcl. If the findings of this research regarding preference of SRGPcl by CRGPcl 
wearers with subjective comfort scores <7 are replicated and validated, the LSCS instrument 
may be used routinely to establish whether an alternative lens management may be appropriate 
to further improve contact lens tolerance of successful CRGPcl wearers, by refitting with 
SRGPcl. 
 
 
Strengths and limitations 
 
The main strength of this research is the RCT with a crossover design, employed to answer the 
research questions regarding the performance of the two experimental lenses in the specific 
research population. The causal inferences afforded by an RCT provide the strongest empirical 
evidence of a treatment’s efficacy. The randomisation of participants and concealment of their 
allocation ensured that allocation bias and confounding of unknown variables were minimised. 
This was further enhanced by minimisation of the detection bias by performing visual data 
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collection by practitioners who were naive to the type of lenses worn at the time, this masking 
was possible for all participants assessed, with both experimental lens types. 
The chronicity of the corneal pathology and the non-curative nature of the experimental lenses 
evaluated were appropriate for the crossover aspect of this research (Armitage and Hills, 1982), 
which minimised the confounding of individual idiosyncrasies such as gender, age, race, 
disease severity et cetera (Wellek and Blettner, 2012; Jones and Kenward, 2015).  
It is inevitable with research of this type that participants cannot be masked to the lens type. 
However, the research team took care to use neutral language in describing the lens options 
and not to make any comment that could lead participants to expect that one of the lens types 
may be preferable to the other.  
The potential disadvantages of RCT were not significant in this research, dropout / attrition 
rate was low (4 participants; 12%), the ethical considerations were appropriately addressed 
prior to the study commencement and there was sufficient prior knowledge about the clinically 
meaningful levels of improvement and expected variation of improvement in the sample size 
calculation (Levin, 2007). The sample size was calculated conservatively to allow for the 
possibility of analysing the results from period 1 only (50% of data) as in a parallel RCT, in 
the unlikely event of discovering a significant differential carryover effect.  
The imbalance between the two randomised groups in the number of participants who 
completed the study (13 and 17 participants, in group 1 and 2, respectively) occurred by chance 
and not due to any inherent differences between the two lens types. Two participants SN 18 
and 25 have emigrated. Participant 29 underwent a corneal cross-linking intervention after 
enrolling to this research and therefore could not continue participation. Participant 22, did not 
return to the CMH clinic and could not be reached by the clinic staff, therefore presumed to 
have moved away.   
The fact that the ratio of participants in the 2 experimental groups changed from the planned 
15 in each group to 13 in group 1 and 17 in group 2, should have no effect on the significance 
and power of the study because the sample size was calculated conservatively to enable 
analysis of results from period 1 only as in a parallel RCT design, if a significant differential 
carryover effect was established. The statistical power in this scenario, assigning group 2 as 
experimental (n=17) and group 1as control (n=13), the power of the study would change from 
0.80 to 0.75, α=0.05. However, in this research all outcomes except logCS, demonstrated no 
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significant differential carryover effect and were therefore analysed as a crossover RCT, which 
is considered more powerful than a parallel group analysis (Wellek and Blettner, 2012; Jones 
and Kenward, 2015). 
The specialist clinical setting of this research has both strengths and limitations. The strengths 
of such a setting are, the access to the specific population required for this research and 
minimisation of bias associated with non-specialist clinical settings with respect to disease 
severity range and experience of the treating professionals. The limitations of this setting are 
the challenges of allocating the extra time required for the additional examinations stipulated 
by the research protocol and the reliance on the contact lens fitting skills of a single practitioner, 
the chief investigator. 
Other limitations of this study are the inequality between the genders in the population, which 
may be significant due to poorer contact lens tolerance by older female participants (Stapleton 
et al., 2015; Fink et al., 2010) and alleviation of these symptoms by SRGPcl (Visser et al., 
2016). 
The variation / range of the scores of the reported subjective comfort in CRGPcl in the research 
population, although probably reflecting the different contact lens experience to that expected 
in normal myopic individuals (Kymes et al., 2004; Walline et al., 2000), may have contributed 
to the high proportion (47%) of participants who chose SRGPcl as their final habitual lens. 
Furthermore, the LSCS instrument has not been validated and the conclusions regarding 
participants’ comfort may be applied only to successful CRGPcl wearers and may not be 
applicable to neophytes. Other factors such as the relatively limited period of SRGPcl wear by 
the participants in this research and the relatively moderate severity of keratoconus, amenable 
to successful management with CRGPcl, may also have influenced the outcomes. 
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Conclusions 
 
The use of SRGPcl to manage patients with corneal disorders such as keratoconus who progress 
to advanced disease and /or fail to tolerate CRGPcl is well recognised and described in the 
literature (Tan et al., 1995; Pullum and Buckley, 1997; Segal et al., 2003; Pullum et al., 2005; 
Baran et al., 2012; Severinsky et al., 2014; Schornack, 2015; Bergmanson et al., 2016; 
Maharana et al., 2016).  
Due to significant advances in technology the use of SRGPcl has undergone a revival in 
specialist contact lens practice in recent years (van der Worp et al., 2014; Schornack, 2015). 
However, their use remains mainly in the realm of management of advanced keratoconus and 
as a problem-solving modality when CRGPcl and other lens options fail to appropriately 
manage the visual disability caused by the various irregular cornea disorders (Visser et al., 
2007b; Bergmanson et al., 2016). 
This research attempted to determine whether the role of SRGPcl may be expanded beyond the 
important but limited scope of current use to, as suggested by Bergmanson et al., (2016) a first-
choice lens for a neophyte keratoconic and/or a better option for a successful CRGPcl wearer.  
To address this question the participants in this research were successful CRGPcl wearers, 
which is considered the gold standard contact lens management of the visual disability caused 
by ectatic corneal disorders such as keratoconus (Robertson and Cavanagh, 2011). Refitting 
this population with SRGPcl in this experiment was not a problem-solving exercise but an 
exposure of experienced contact lens wearers to a significantly different, alternative contact 
lens type. The importance of successful CRGPcl wear experience was that it ensured a 
relatively straightforward transition and adaptation to the alternative contact lens wear and care 
and with the help of randomisation and crossover research design, facilitated a comparison of 
performance of these two lenses, in a non-problem-solving clinical scenario. 
The crossover RCT method was considered ideal due to the chronic nature of the disorder and 
the non-curative management of contact lenses. Additionally, it afforded the control of 
confounding variables such as gender, age, race, disease severity and other personal 
idiosyncrasies of contact lens wearers, because the comparisons in a crossover analysis are of 
the within-subject differences between the two randomised groups. 
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The analysis of the demographics of the research population confirmed that the population was 
consistent with that expected in a specialist contact lens clinic in a metropolitan city such as 
London. The demographics of the two randomised groups confirmed that the randomisation 
achieved its purpose with respect to age, gender, race and disease severity in the two 
randomised groups. 
The only statistically significant outcome in this research was a better subjective perception of 
comfort in SRGPcl compared to comfort in CRGPcl, measured by the LSCS. This finding was 
supported by the significantly lower LSCS in CRGPcl in participants who chose CRGPcl as 
their final habitual lens, compared with those who chose to remain in CRGPcl. 
The analysis of the main outcome measure, the ETDRS logMAR BCVA revealed no 
statistically significant difference between the two experimental lenses. 
The analysis of the CSF, revealed no statistically significant differences between the two 
experimental lenses in the logCS scores across the 4 CPD range and no significant difference 
in the logCS at specifically 6 CPD.  
The analysis of the NEI-VFQ revealed that the two experimental lenses did not differ in a 
statistically significant manner across the 12 domains investigated by this Qol tool, nor did the 
two experimental lenses exhibit a statistically significant difference in the specific domain of 
ocular pain. 
The score of SPV in the two experimental lenses, revealed no significant differences in the 
participants’ subjective score of their vision between the two experimental lenses.  
The score of the SPC revealed significantly higher (better) comfort scores in SRGPcl. This 
finding is of significance because although SRGPcl are better tolerated by patients who are 
unable to tolerate CRGPcl (Schornack, 2015; Bergmanson et al., 2016; Yan et al., 2017), this 
research indicates that 47% of successful CRGPcl wearers, who demonstrate equivalent visual 
and Qol outcomes in both experimental lenses, preferred SRGPcl for their future habitual use. 
The most likely explanation for this, is that even in individuals who are successful and well 
adapted CRGPcl wearers, the particular SRGPcl fitting features, corneal clearance and 
therefore absence of lens cornea interaction, minimal lens mobility and eyelid interaction and 
the continued lubrication of the ocular surface covered by the lens, may all contribute to the 
significantly better comfort and high participant proportion choice of SRGPcl as their habitual 
lens.  
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The final outcome measure in this research was the participants’ choice of one of the two 
experimental lenses as their habitual lens for future use. Sixteen participants chose to remain 
in CRGPcl and 14 chose to switch to SRGPcl. The finding that 47% preferred SRGPcl to their 
habitual well performing CRGPcl, may indicate that a significant proportion of keratoconic 
patients who are satisfied with CRGPcl, may prefer SRGPcl, most likely if they experience 
superior comfort levels in these lenses. 
The clinical conundrum of how to effectively identify those successful CRGPcl wearers who 
are most likely to benefit from being refitted with SRGPcl may to some degree have been 
answered by the findings in this research. The analysis of the subjective comfort scores in 
experimental CRGPcl indicated that participants who chose to remain in CRGPcl had 
significantly higher comfort scores of ≥7.0, than those participants who switched to SRGPcl. 
These findings indicate that a routine use of the LSCS tool designed for this research, may 
identify those patients who would benefit from a refit with SRGPcl even if no other clinical 
indications for refitting are apparent. If this research’s results can be replicated and the LSCS 
is validated, then this method may be considered appropriate for the selection of patients for 
refitting with SRGPcl if their LSCS score in CRGPcl is < 7, even if no other indication for 
refitting is apparent.   
The findings in this research that SRGPcl are significantly more comfortable than CRGPcl and 
that the two experimental lenses perform equally with respect to vision and visual quality of 
life, may support a practitioner’s decision to refit an existing CRGPcl wearer with SRGPcl or 
to fit a neophyte with either contact lens type, knowing that lens performance should be 
equivalent with respect to vision and quality of life and may be better with respect to comfort 
and therefore base their choice of lens on other clinical aspects. In a neophyte such clinical 
aspects may include an existing high ocular sensitivity, the presence or absence of allergies, 
ocular surface disorders, dry eye disease, environmental dryness or other idiosyncratic features 
of ocular sensitivity or factors which may adversely affect it.  
This research also demonstrates that there are unlikely to be visual or visual Qol advantages or 
disadvantages in refitting existing successful CRGPcl wearers with SRGPcl, or fitting a 
neophyte with SRGPcl even if CRGPcl are also appropriate.  
This research further supports a practitioners’ clinical decision to refit a CRGPcl wearer with 
SRGPcl and vice versa, by the indication that there should be no significant disadvantage in 
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either scenario with respect to their visual performance and visual Qol, provided that CRGPcl 
demonstrate equivalent comfort levels when patients are refitted from SRGPcl.  
The above conclusions and recommendations may extend the scope of SRGPcl fitting not only 
beyond the role of a problem solver but also in addition to the recommendations by Visser et 
al., (2016) who developed a flowchart for contact lens selection in a specialist contact lens 
practice. The authors recommended that SRGPcl may achieve better vision and longer wearing 
time / comfort when factors which cause reduced lens tolerance, such as advanced corneal 
irregularity, significant tear film deficiency or elevated corneal scar, are present (Visser et al., 
2016). This may be extended to include reduced subjective comfort in CRGPcl to a level <7 
on the LSCS. 
The equivalence of the two lens types with respect to visual performance and visual Qol is 
important considering the challenge of fitting CRGPcl in a way that does not risk 
compromising corneal integrity in corneal ectatic disorders (Chapter 3). Over a number of 
years, it may not be possible to avoid a flat CRGPcl fit, which may cause or exacerbate corneal 
scarring resulting in visual loss due to corneal morbidity. Alternatively, a steep, cone vaulting 
CRGPcl fit, attempted to prevent corneal damage associated with excessive cone bearing, can 
cause progression of keratoconus. Due to complete corneal vaulting it is reasonable to expect 
that SRGPcl will be more likely to avoid these problems. If there are long-term physiological 
advantages to SRGPcl, then the short-term equivalence in visual performance and visual Qol 
of SRGPcl and CRGPcl demonstrated in the present research may lead to the conclusion that 
SRGPcl may indeed be considered as the lens option of first choice in corneal ectatic disorders 
management. 
An additional recommendation which may be formulated from the results of this research is 
that existing well adapted and satisfied CRGPcl wearers, may benefit from routine, quick and 
straightforward assessment of their SPC with the LSCS instrument. If no clinical indications 
for a refitting exist, it would be an evidence-based conclusion that it is appropriate to continue 
wearing CRGPcl if comfort level on the LSCS are ≥7.0. However, if comfort level is <7, the 
evidence in this research suggests that refitting with SRGPcl may be of benefit, even when no 
other indications are present. 
Other considerations when fitting with or re-fitting to SRGPcl, with respect to patients, are the 
higher cost of lenses and additional care products and the considerable dexterity required for 
lens handling. From the perspective of the treating clinicians a consideration of the steep 
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learning curve required to achieve competence in this complex field of contact lens practice 
and the appreciation of the potential for complications associated with long term SRGPcl wear 
is also necessary. Recent research raised concerns regarding compromised corneal physiology 
due to reduced tear exchange in the sealed, post lens fluid reservoir and the considerable barrier 
to oxygen posed by the thickness of SRGPcl and the post lens tear layer (Michaud et al., 2012; 
Vincent et al., 2019). Concerns have also been raised regarding the physical pressure exerted 
by the haptic portion on the sclera causing increased intra-ocular pressure increasing the risk 
of glaucomatous optic neuropathy (Fadel and Kramer, 2019; Michaud et al., 2019). 
 
Further research is suggested to validate the LSCS in CRGPcl wearers, managed for corneal 
ectatic disorders. In addition, due to the significantly better comfort achieved in SRGPcl in the 
population of this research, a crossover RCT comparing CRGPcl to SRGPcl in neophytes 
requiring contact lens management for corneal ectatic disorders, would more specifically 
clarify the viability of using SRGPcl as a lens of first choice. 
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Appendix 
Appendix I 
A. Participant Information 
The Eye Department 
Central Middlesex Hospital 
Acton Lane 
London NW10 7NS 
 
                   Participant Information  
Investigation of the performance of Scleral and Corneal Rigid Gas Permeable (RGP) 
contact lenses in participants with keratoconus and other irregular cornea disorders 
 
You are being invited to take part in a research study comparing different types of contact lenses for a condition 
called keratoconus. Before you decide it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information and ask any questions before deciding 
whether or not you wish to take part.  
 
Introduction 
The cornea is the transparent layer at the front of the eye. The cornea's shape should be regular for good vision. 
Keratoconus is a condition in which the cornea gradually develops an irregular shape. This causes reduced 
vision which cannot be effectively corrected by spectacles and soft contact lenses. The usual management of 
keratoconus is Corneal RGP contact lenses (corneal lenses). Sometimes corneal lenses work well, but in other 
cases wearers can develop discomfort and scarring of the cornea.  
 
For many years people who experience problems with corneal lenses have been fitted with a different type of 
lens, called scleral lenses. These are larger than corneal lenses and sit on the sclera (the white part of the eye) so 
that they completely bridge over the cornea. Scleral lenses can be more comfortable and are thought to reduce 
the risk of scarring of the cornea. 
 
 
The Aim of the Research 
The aim of this research is to compare the performance of scleral and corneal lenses in adults with keratoconus 
who usually wear corneal lenses.  
We want to discover whether modern scleral lenses should be considered not only if problems occur with corneal 
lenses, but potentially as a lens of first choice in the management of keratoconus and related conditions.  
 
What would taking part involve? 
If you decide to take part in this research, you will be given additional information and be asked to sign a 
consent form. You are free to withdraw any time without giving a reason. A decision to take part, withdraw or 
not to take part, will not affect the level of care and treatment you receive. 
During the trial you will wear a pair of corneal lenses and a pair of scleral lenses, one after the other. We will 
decide (randomly) which pair you start with. We will ask you to attend for a fitting appointment so that both 
types can be fitted, ordered, and manufactured. 
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During the collection session these lenses would both be assessed in your eyes and detailed training and 
instructions in lens handling will be given.  
After 6-8 weeks you will return to wearing your own original lenses for a period of one month after which you 
will wear the other type of experimental lenses for 6-8 weeks.   
After each 6-8 weeks period of experimental lens wear we will check your eyes and vision and a quality of life 
questionnaire will be completed. 
 
Your involvement in the study is anticipated to last for approximately 6-7 months.  
Please note that compared with a new contact lens wearer, you will need 2-3 more appointments than would 
usually be expected. 
 
During the period of the study you will be able to contact the investigator Mr Levit directly (details below) if 
you have any questions or concerns. 
 
 
What are the possible advantages or disadvantages? 
 
An advantage is that you will be able to try different types of contact lenses and keep any that work well for 
you. 
 
It is not anticipated that you will be at any disadvantage or suffer any risk from this study, as these lenses are of 
high quality and are CE marked as well as approved for clinical use by the American Food and Drug Agency 
(FDA). These lenses are used in specialist contact lens practice and are routinely fitted to patients with 
keratoconus and other irregular corneal disorders.  
 
If for any reason you pull out of the research, for example due to health issues unrelated to your eyes, the 
research team would retain research data collected and continue to use it confidentially. 
 
Please note all information received from you will be held until the publication of the doctoral thesis in 2017 
and will be handled in a confidential manner and stored at the hospital premises and on a password protected 
computer in an environment locked when not occupied. 
 
At the completion of the study you may obtain a summary of the anonymous results from the Institute of 
Optometry website: www.ioo.org.uk. Any participants who do not have web access can contact the researchers 
for a paper version. 
 
This study is being completed as part of a Professional Doctorate in Optometry at London South Bank 
University and the Institute of Optometry. It has been reviewed and ethically approved by NHS Integrated 
Research Ethics Committee, the London South Bank University Research Ethics Committee and the Institute of 
Optometry Research Ethics Committee.  
  
 
If you have a concern about any aspect of this study, you should ask to speak with the researcher (details below) 
who will do his best to answer your questions. 
Alex Levit Bsc. (Hons)  FCOptom (CL CVP)  
The Eye Department, 
Central Middlesex Hospital. 
Acton Lane 
London NW10 7NS 
Mobile 07813160631   
e mail: Alexander.Levit@nwlh.nhs.uk 
 
If you wish for any further information regarding this study or have any complaints about the way you have 
been dealt with during the study or other concerns you can contact: Professor Bruce Evans who is an Academic 
Supervisor for this study, on 0207 7407 4183 or email bjwe@bruce-evans.co.uk.  
 
Finally, if you remain unhappy and wish to complain formally, you can contact the Chair of the University 
Research Ethics Committee, by phone, email or write a letter to: Professor Nicola Crichton 
London south Bank University 
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103 Borough Road 
London SE1 0AA 
phone 02078156742, email crichtnj@lsbu.ac.uk  
 
Participants can also contact the Patients Advisory Liaison Service (PALS) 02084532569. 
 
 
B. Participant Informed Consent 
 
Corneal RGP contact lenses Versus Scleral RGP contact lenses for the 
irregular cornea (e.g., keratoconus) 
 
Invitation to Participate 
You have been invited to participate in this study because you have keratoconus and habitually wear corneal 
rigid Gas Permeable (RGP) contact lenses (corneal lenses). If you are a suitable candidate it is up to you to 
decide whether or not to take part. If you do, you will be given this information sheet to keep and be asked to 
sign a consent form. You are still free to withdraw anytime without giving a reason up to the time when the 
dissertation is submitted. A decision to take part, withdraw or not to take part, will not affect the level of care 
and treatment you receive. Before you decide I would like you to understand why the research is being done and 
what it would involve for you. One of our team will go through the information sheet with you and answer any 
questions you may have. This should take no longer than 10-15 minutes. Please talk to others about the study if 
you wish.  
 
Part 1 tells you about the purpose of this study and what will happen to you if you choose to take part.  
 
Part 2 gives you more detailed information about the conduct of the study.  
After the verbal discussion please take time to read the information below and to contact Mr Levit (details 
below) if you have any further questions about this research. 
 
What is the purpose of the study?  
The aim is to investigate the visual quality and vision related quality of life whilst wearing scleral contact lenses 
compared with corneal lenses in participants with keratoconus (or a similar condition) who wear corneal lenses. 
Our objective is to discover whether modern scleral lenses should be considered not only as a problem solver 
but potentially as a lens of first choice in the management of keratoconus and related conditions.  
 
Why have I been invited?  
You have been invited because you have keratoconus and wear corneal lenses successfully.  
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Do I have to take part? 
It is up to you to decide whether to join the study. We will describe the study and go through this information 
sheet. If you agree to take part, we will then ask you to sign a consent form. You are free to withdraw at any 
time, without giving a reason. This would not affect the standard of care you receive. 
 
What will happen to me if I take part? 
If you are willing to participate your involvement in the study will last for approximately 8 months. The number 
of participants required to complete this research is 30. Please note that the frequency and nature of the check-
ups is similar to that required in the first 6 months of wearing a new type of contact lens. The differences are 
that the fitting appointments will last longer because two sorts of contact lens are being fitted and that additional 
measurements of visual quality of life will be performed. This will involve completing a form prior to the 
beginning of the study and at the end of the two lens wearing periods. This form takes 10-15 minutes to 
complete. 
You will be invited for contact lens fitting as well as the measurement of your vision with the contact lenses 
worn. The whole procedure will last approximately 40-60 minutes. Two types of lenses will be ordered, the 
corneal lens and the scleral lens. 
A few weeks later the new lenses and your vision with them will be checked and you will be instructed on how 
to insert, remove contact lenses and given one pair to wear. A review 3 weeks after this initial fitting 
appointment will be booked which will take approximately 30 minutes. 
Please note that this is a randomized experiment, which means that neither you nor the researcher will know 
which lenses you will be given to start with. If your practitioner needs to find out for clinical reasons he can do 
so. The type of lens given to you will be randomly allocated with a 50% chance of receiving the experimental 
scleral lens and 50% the control corneal lens. The reason for this way of researching is because sometimes we 
do not know which way of treating patients is best. To find out, we need to compare different treatments. We 
put people into groups and give each group a different treatment. The results are compared to see if one is better. 
To try to make sure the groups are the same to start with, each patient is put into a group by chance (randomly).  
After 8-12 weeks of wear you will be asked to return to wearing the contact lenses that you wore before starting 
in the research. About a month later you will be given the other research lenses to use for 8-12 weeks, this is the 
crossover stage. The reason for the break between the different types of lenses is so that any effects of the first 
type of lens are cleared before you start the new treatment. 
 
What are the possible disadvantages and risks of taking part? 
It is not anticipated that you will be at any disadvantage or suffer any risk specifically from taking part in this 
study, as the lenses used are of the highest quality and are CE marked. There is a slight risk of complications 
associated with contact lens wear, but as far as we know there is not any additional risk with the types of contact 
lenses used in the research compared with the contact lenses you already wear. The opportunity of trying two 
different types of lenses will allow you to choose which is better. But this opportunity involves more 
appointments and inconvenience for you and this is a disadvantage.   
What are the possible benefits of taking part? 
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If you prefer the comfort and vision of the experimental or the control lens you will be able to keep these lenses 
for your continued personal use. Otherwise it is unlikely that you will gain any personal benefit from 
participating in this research. However, the information gained from this research will help develop effective 
approaches for people who suffer from visual difficulties due to Keratoconus or similar conditions.  
 
What happens when the research study stops? 
If you wish you will be allowed to keep the lenses used in the research free of charge and will continue to be 
reviewed in the contact lens clinic in the regular manner. 
 
Will my taking part in the study be kept confidential? 
All information received from you will be handled in a confidential manner and stored in the hospital records 
and on a password protected computer in an environment locked when not occupied. Only the researcher and 
research supervisors will have direct access to the information. Any reference to you will be coded into a 
number and your name and contact details will not be taken away from the hospital. The research data will be 
held until the publication of the doctoral thesis, which is anticipated in 2017. 
This study is being completed as part of a Professional Doctorate degree in Optometry at London South Bank 
University and the Institute of Optometry. It has been reviewed and ethically approved by NHS Integrated 
Research Ethics Committee and the London South Bank University Research Ethics Committee. We will follow 
ethical and legal practice and all information about you will be handled in confidence. The details are included 
in Part 2. 
 
If you wish for any further information regarding this study or if you have a concern about any aspect of this 
study, you should ask to speak with the researcher who will do his best to answer your questions. 
 
Alex Levit Bsc. (Hons)  FCOptom (CL CVP)  
The Eye Department, 
Central Middlesex Hospital. 
Acton Lane 
London NW10 7NS 
Mobile 07813160631   
e mail: Alexander.Levit@nwlh.nhs.uk 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researcher who will do his 
best to answer your questions. 
Contact details: Alex Levit  (details above)  
If you have any complaints about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed by the researcher Mr A. Levit, you can also contact the academic supervisor of 
this research: Professor Bruce Evans on 0207 7407 4183. 
If you remain unhappy and wish to complain formally, you can contact the Chair of the University Research 
Ethics Committee.  Details can be obtained from the university website: 
http://www.lsbu.ac.uk/rbdo/external/index.shtml 
Participants can also contact the Patients Advisory Liaison Service (PALS) 02084532569 
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If the information in Part 1 has interested you and you are considering participation, please read the additional 
information in Part 2 before making any decision. 
 
 
Part 2 
What if relevant new information becomes available?  
Sometimes new information becomes available about the treatment being studied. If this happens, your research 
optometrist will tell you and discuss whether you should continue in the study. If you decide not to carry on, 
your research optometrist will make arrangements for your care to continue. If you decide to continue in the 
study, he may ask you to sign an agreement outlining the discussion he had with you.  
Or your research optometrist might consider you should withdraw from the study. He will explain the reasons 
and arrange for your care to continue.  
Or if the study is stopped for any other reason, we will tell you and arrange your continuing care. 
 
What will happen if I do not want to carry on with the study? 
You are free to withdraw from the study at any time up to the time of the completion of the dissertation. 
Information collected about you to the point when you decide to withdraw, will be retained and used by the 
researcher. The information collected will not identify you in any way, confidentiality and anonymity will be 
maintained at all times. You are free to withdraw at any time during the study without your normal standard of 
care being affected. 
 
Are there circumstances and/or reasons under which my participation in the trial may be terminated? 
Your participation is unlikely to be terminated unless you do not comply with the study protocol of the correct 
wear and care of your contact lenses and / or do not attend the required check up appointment without a good 
reason for non-attendance. You will be allowed to keep the contact lenses prescribed during the study even if 
your participation is terminated for any reason. 
 
Harm 
In the unlikely event that something does go wrong and you are harmed during the research and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation, but you may have to pay 
your legal costs. The normal National Health Service complaints mechanisms will still be available to you. 
 
Will my taking part in this study be kept confidential? 
During the approximately 9 months of your participation, the data of visual performance and visual quality of 
life will be collected during the consultations in the contact lens clinic.  
For the proper maintenance of anonymity and confidentiality all research information will be recorded on 
specially designed separate records which would be stored on a password protected computer. Hard copies 
would be kept in the Hospital in a locked cabinet, with no access except for the research personnel. These 
records will contain no personal data but only allocated research numbers. 
The clinical information contained in these research records may be later added to the patients Hospital records.  
257 
 
The data will be used for the writing of the doctoral thesis and in professional publications. The only details 
used will be the participants' gender, age and allocated research serial number. 
 
Involvement of the General Practitioner/Family doctor (GP) 
Your GP will be informed about the treatment you receive in the usual manner. 
 
What will happen to the results of the research study? 
The results of the research will be published in professional literature in a manner which does not in any way 
identify the participants. Should you wish, you may have access to copies of the publications relating to this 
research. 
 
Who is organizing and funding the research?   
This study is done as a part of professional doctorate in Optometry at the department of Allied Health Sciences 
at the School of Health and Social Care London South Bank University and the Institute of Optometry. The 
researcher and the Institutions involved have no conflicts of interests in this research. 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research Ethics Committee, to 
protect your interests.  
 
 
Further information and contact details 
1. General and specific information about research. Please see part 1 of this document or contact Mr A. Levit. 
 
2. Advice as to whether they should participate: see information of personnel below as well as your own GP. 
3. Emergency contact during the study: Mr A. Levit. Mobile 07813160631.  
4. Other personnel: Sister in charge 020 8963 7195 Mon - Fri 9-5 
Professor Bruce Evans on 0207 7407 4183. 
Chair of the University Research Ethics Committee: http://www.lsbu.ac.uk/rbdo/external/index.shtml 
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C. Consent form 
 
The Eye Department 
Central Middlesex Hospital 
Acton Lane 
London NW10 7NS 
   
    CONSENT FORM  
 
Title of Project: Corneal RGP vs. Scleral RGP contact lenses for the irregular cornea 
 
Name of Researcher: Mr A. Levit 
Ethics ref No:  11122014 
 
Please initial box  
 
1. I confirm that I have read and understand the information sheet dated 1/12/14 version 1, for the above study. I 
have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time without giving any 
reason, without my medical care or legal rights being affected.  
 
3. I understand that relevant sections of my medical notes and data collected during the study may be looked at 
by responsible individuals from the London South Bank University, the Ophthalmology department at Central 
Middlesex Hospital, from regulatory authorities or from the NHS Trust, and where it is relevant to my taking 
part in this research. I give permission for these individuals to have access to my records.  
 
 
4. I agree to my GP being informed of my participation in the study.       
 
                   
5. I agree to take part in the above study.             
 
                                  
Name of Patient   .....................................   Date.............. Signature............................  
 
Name of researcher.................................  Date................. Signature........................ 
CC copies to: 1. participant 2. participant's medical records. 
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D. Participant Information on Receipt of Contact Lenses 
In this research we aim to investigate the effect of contact lenses on your vision and visual quality of life. These 
lenses are of high quality and were fitted and manufactured with great precision to fit your eyes and correct their 
optical anomalies. 
If you are new to contact lenses or wore a different type of lenses, please note that a period of adaptation of 3-5 
days may be required. If no contraindications are found by your contact lens practitioner, you may be able to wear 
these lenses daily from 10-16 hours. 
Contact lens wear is safe and comfortable if proper hygiene and lens care are followed meticulously. However, in 
the unlikely event of developing any of the following symptoms;  
 -Eyes stinging, burning, itching (irritation), or other eye pain  
 -Lenses are less comfortable than when first placed on eye  
 -Feeling of something in the eye such as a foreign body or scratched area  
 -Excessive watering (tearing) of the eyes  
 -Unusual eye secretions  
 -Redness of the eyes  
 -Reduced sharpness of vision (poor visual acuity)  
 -Blurred vision, rainbows, or halos around objects  
 -Sensitivity to light (photophobia)  
 -Unusually dry eyes  
REMOVE YOUR LENSES IMMEDIATELY. 
If the discomfort or problem stops, then look closely at the lens. If the lens is in any way damaged, DO NOT put 
the lens back on your eye. Place the lens in the storage case and contact Mr Levit. If the lens has dirt, an eyelash, 
or other foreign objects on it, or the problem stops and the lens appears undamaged, you should thoroughly clean, 
rinse and disinfect the lens; then reinsert it. If the problem continues, you should IMMEDIATELY remove it and 
contact Mr Levit.  
If you have any questions regarding any aspect of contact lens wear contact Mr Levit at; The Ophthalmology 
Department, Central Middlesex Hospital, Acton Lane 
London NW10 7NS. Tel 07813160631, e mail Alexander.Levit@nwlh.nhs.uk 
Please read and learn the written contact lens handling instructions enclosed. Please view the video of contact lens 
handling and care on http://icdlens.com/icd-a&r-video.html 
 
 
E. Handling and Care of Scleral Contact Lenses 
You will be given full instruction by Alex Levit and plenty of time to practice handling under his supervision. 
This document is intended to reinforce the verbal instructions that you receive. 
As with all contact lenses, the maintenance of proper hygiene procedures is essential. The surface of gas permeable 
scleral lenses is subject to deterioration with use and handling. Please take good care of your lenses in order to 
maintain the optimal surface integrity as long as possible.  
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• Always wash your hands with antibacterial soap and dry your hands thoroughly with lint free towel or tissue, 
before inserting or removing your lenses.  
• Take care not to catch the lens or your eye with your fingernails – keep them short  
• Work over a clean, flat surface, put in the plug if you are working over a wash basin 
• Use saline solution to rinse your lenses – do not rinse them with tap water as this can cause serious eye infections.  
• Remember Contact lens case hygiene is important as infections can occur due to poor lens case cleaning. The 
rubber insert in the lens case and all rubber or plastic lens applicators should be scrubbed with a dedicated clean 
toothbrush on a weekly basis with cooled boiled water and then left to air dry. Do not use soap in case it is not 
fully rinsed away. The lens case should be replaced with a new one at least every six months  
• To minimise the possibility of mixing your lenses up, it is a good practice to always insert and remove the same 
lens first. 
• Prior to lens application, remove the lens from its soaking / conditioning solution, rinse it well with non-
preserved saline.  
• Fill the lens with non-preserved sterile saline and insert (see handling instructions below). 
 
Lens Application / Insertion 
• Rinse the lens well with preservative-free saline, never use tap water.  
• Place the lens, bowl side up, on the large plunger supplied with your lenses. 
 
 
 
• Fill the bowl of the lens completely with preservative-free sterile saline. It is important that the saline is non-
preserved and sterile as it will remain in contact with the cornea through the day. Tear circulation with a scleral 
lens is minimal therefore, preservatives or contaminants in the bowl of the lens remain in contact with the cornea 
for the duration of wear and this increases the chance of toxicity, infection and inflammation. 
• Lean forward with your face parallel to the floor. Hold both lids open wide.  
• Look at the hole in the plunger while guiding the lens on to the eye 
•  Apply the lens to the surface of the eye, take care to spill as little saline in the bowl of the lens as possible, in 
order to avoid trapping an air bubble.  
• If an air bubble gets under the lens, remove, rinse, refill with saline and reapply the lens as instructed above. 
 
Lens removal: 
Since the scleral lens is large, the capillary forces which hold the lens on the eye are powerful. Removal is always 
best done by first lifting the edge to eliminate this force. Attempting to pull the lens from the centre will create 
negative pressure and will rarely be successful. 
• First, moisten the small plunger with a few drops of saline solution. 
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• Place the small plunger on the lens at the lower edge at the 6 o’clock position. (Near the bottom),   so that the 
plunger is just inside the lens. 
• Lift or tilt the lens of the eye and remove. You may have to gently push on the eye or eyelid next to the lens to 
break the seal.  
 
Method 1. Plunger                                                        Method 2. Fingers 
             
 
Alternatively, the lens may be removed as follows (Method 2); 
Look down, but keep your chin upwards  
• Take your upper lid on the side nearest your nose with your index finger so that the lid is above the upper rim 
of the lens  
 
• Press downwards, then tighten the lid by drawing your finger towards the temple. This action will push the lid 
underneath the edge of the lens, relieving the suction. Now, look up to eject the lens from your eye and catch it 
with your other hand, or do this over a table covered with a towel to prevent the lens from falling onto the floor  
 
Lens Care and cleaning: 
Always use the care system recommended to you by your contact lens practitioner  
• Once the lens is removed from your eye, rinse the lens with saline  
• Apply your contact lens cleaning solution (Eyeye Crystal cleaner) to the front and back surfaces, while gently 
rubbing between your fingers  
• Rinse again with saline until all of the cleaning solution is removed  
• Store in fresh conditioning solution (Boston or Menicare plus) in the case provided taking care not to introduce 
any water or residual cleaning solution into the case. 
• Once every 2 weeks, after cleaning, soak in Progent (protein cleaner) for 30 minutes. Than in saline for 30-60 
seconds. Clean once again with cleaning solutions, rinse well and store overnight in the conditioning solution. 
 
General Information Regarding Scleral Lens Wear 
If you are new to contact lenses or wore a different type of lenses, please note that a period of adaptation of 3-5 
days may be required. If no contraindications are found by your contact lens practitioner, you may be able to wear 
these lenses daily from 10-16 hours. 
Contact lens wear is safe and comfortable if proper hygiene and lens care are followed meticulously. However, in 
the unlikely event of developing any of the following symptoms;  
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 -Eyes stinging, burning, itching (irritation), or other eye pain  
 -Lenses are less comfortable than when first placed on eye  
 -Feeling of something in the eye such as a foreign body or scratched area  
 -Excessive watering (tearing) of the eyes  
 -Unusual eye secretions  
 -Redness of the eyes  
 -Reduced sharpness of vision (poor visual acuity)  
 -Blurred vision, rainbows, or halos around objects  
 -Sensitivity to light (photophobia)  
 -Dry eyes  
 
REMOVE YOUR LENSES IMMEDIATELY  
If the discomfort or problem stops, then look closely at the lens. If the lens is in any way damaged, DO NOT put 
the lens back on your eye. Place the lens in the storage case and contact Mr Levit. If the lens has dirt, an eyelash, 
or other foreign objects on it, or the problem stops and the lens appears undamaged, you should thoroughly clean, 
rinse and disinfect the lens; then reinsert it. If the problem continues, you should IMMEDIATELY remove it and 
contact Mr Levit. 
Contact Details 
If you have any questions regarding any aspect of contact lens wear contact Mr Levit at; 
The Ophthalmology Department 
Central Middlesex Hospital 
Acton Lane London NW10 7NS 
Tel 07813160631, email; Alexander.Levit@nwlh.nhs.uk 
 
 
Appendix II 
Appendix II. A.  Baseline clinical information 
 
   Baseline information CRF 
      Scleral Vs Corneal RGP lenses 
Date:  Examiner: A. Levit 
General Information 
Participant's Serial Nr.  
DOB Age 
Gender  
Occupation  
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Race  
Condition Information 
Cornea 
irregularity type 
OD 
KC Nipple PMD Globus Post KC Graft DLK 
KC oval   Graft PK 
KC mixed INTACS 
Cornea 
irregularity type 
OS 
KC Nipple    Graft DLK  
KC oval Graft PK 
KC mixed INTACS 
Diagnosis age:  
Pachymetry: OD OS 
K max OD OS 
Surface Regularity Indices: OD OS 
Lens Information of participants own lens 
 OD OS 
Lens type Type 
 
 
Material 
 
Spherical 
 
toric quadrant Type 
 
 
Materi
al 
 
Spherical 
 
toric quadran
t 
Lens parameters OZR OZD TD BVP edge custom OZR OZD TD BVP edge custom 
Lens fit central bearing Alignment 
 
clearance bearing alignment clearance 
Lens fit periph inadequate Optimal 
 
excessive inadequate Optimal 
 
excessive 
Lens Condition 0-
10 
0-2 
unaccept
able 
3-4 Poor 5-6 
adequate 
 
7-8 
good 
9-10 
New 
1-2 
unaccep
table 
3-4 
Poor 
5-6 
adequat
e 
7-8 
good 
 
9-10 
New 
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Comfort 0-10 1 unbearable, 
10 cannot feel  
 1 unbearable, 
10 cannot feel 
 
Vision     0-10 1 very poor, 10 excellent  1 very poor, 10 excellent  
Visual Acuity   
Over refraction   
 sphere   
cyl   
axis   
VA   
 
Eye 
OD OS 
Visual Measures 1. 2. 3. Ø 1. 2. 3. Ø 
LogMAR BCVA         
CSF Row A 3cpd         
CSF Row B 6cpd         
CSF Row C 12cpd         
CSF Row D 18cpd         
Clinical findings on lens removal. Efron Scale from 0-5 in 0.1 steps 
Condition OD OS 
Blepharitis   
MGD   
SLK   
Corneal Infiltrates   
Corneal Ulcer   
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Endothelial Polymegathism   
Endothelial Blebs   
Corneal Distortion   
Conjunctival Redness 
Bulbar   
Limbal   
Conjunctival NaFl Staining 
Bulbar   
Limbal   
Tarsal Conjunctival Papillae   
Corneal NaFl Staining 
 
central   
Peripheral (limbal)   
Limbal Vascularisation   
Epithelial Microcysts   
Corneal Oedema   
 
Detail of QOL Questionnaire (1-10 scale in steps of 1) 
Question 
No 
Score 
Appendix 
Q No 
Score 
1   A1   
2   A2   
3   A3   
4   A4   
5   A5   
6   A6   
7   A7   
8   A8   
9   A9   
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10   A10   
11   A11a   
12   A11b   
13   A12   
14   A13   
15   Total   
15a   
15b   
15c   
16   
16a   
17   
18   
19   
20   
21   
22   
23   
24   
25   
Total   
  
 
 
 
Appendix II.B. Data collection CRF 
Data Collection (naive data collector) CRF 
    Scleral Vs Corneal RGP lenses 
Date: Examiner: 
Participant's Serial No  
  
Details 
Average Days per week:  Hours per day:  
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Eye OD OS 
Visual Acuity   
Over-Refraction  
Sphere   
Cylinder (-ve)   
Axis   
VA 
 
  
Comfort 0-10 1 unbearable, 
10 cannot feel  
 1 unbearable, 
10 cannot feel 
 
Vision     0-10 1 very poor, 10 
excellent (perfect) 
 1 very poor, 10 
excellent (perfect) 
 
 
 
Visual Quality Outcome Measures 
 
Eye OD OS 
 1. 2. 3. Ø 1. 2. 3. Ø 
LogMAR BCVA         
CSF A 3cpd         
CSF B 6cpd         
CSF C 12cpd         
CSF D 18cpd         
Clinical Findings on Lens Removal from 0-5 in 0.1 steps 
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Eye OD OS 
Blepharitis   
MGD   
SLK   
Corneal Infiltrates   
Corneal Ulcer   
Endothelial Polymegathism   
Endothelial Blebs   
Corneal Distortion   
Conjunctival Redness 
Bulbar   
Limbal   
Conjunctival Staining 
Bulbar   
Limbal   
Tarsal Conjunctival Papillae   
 
Corneal Staining 
central   
Peripheral (limbal)   
Limbal Vascularisation   
Epithelial Microcysts   
Corneal Oedema   
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Appendix II. C. Fitted Lens Information 
Patient Serial No                            Randomised to Fitter 
Corneal RGP Scleral RGP 
Lens Type RK2 date Material  Zenlens date Material 
                                            OD OS OD OS 
Type         
OZR         
OZR2 (toric)         
SAG         
Diameter         
Power (Sphere)         
Power (cyl)         
Axis (negative cyl)         
LCD (limbal sag)         
APS (edge spec)         
Edge lift         
Custom Quadrant fit         
Comfort 1-10         
Vision     1-10         
Over refract Sphere         
OR cylinder         
OR axis         
VA         
No fitted for best fit         
No exchanged          
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Appendix III 
Appendix III. A. Good clinical practice certificate 
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Appendix III.B. IRAS approval certificate 
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Appendix IV 
Appendix IV. A. Database Libre Office, data entry, extraction and analysis 
 
Data Entry Methodology  
Introduction 
The data generated by the experiments needs to be entered into a computer for statistical analysis, and it is 
important to use a tool that makes it as simple as possible to enter the data correctly. The best tool to use for this 
purpose is a database, using a graphical user interface to enter data into the underlying database tables. 
We developed a simple database using the open-source LibreOffice office productivity software suite 
(https://www.libreoffice.org/). This software provides a relational database (named ‘Base’), and includes tools 
to create forms and queries – these are respectively windows that can be used to view and enter data, and 
database commands that extract specific subsets of the data in the system.  The various forms in the database are 
managed by a small amount of programming using LibreOffice’s Basic macro language.  This is required to 
configure the forms to display the correct data when they are opened. 
LibreOffice Base is very flexible – it can be configured so that the underlying data and forms/queries are stored 
in separate files, and it can be used as the front-end to manipulate data stored in other vendors’ databases.  
However, in this case the scope of the database is small enough that it makes sense to keep everything in a 
single file – including the data, forms and queries.  The database can be opened simply by double-clicking on 
the file (provided the LibreOffice software is installed).   
The LibreOffice suite is available for a wide range of platforms, including all recent versions of Microsoft 
Windows, Apple Macintoshes, and common Linux distributions.  Therefore, the database file is portable 
between different systems simply by copying the file from one computer to another – and no special installation 
is required to configure the database on a new machine. 
Database Purpose 
The function of the database is to simplify data entry, not to analyse the data.  However, although visual acuity 
data is entered into the database in Snellen format, the data is stored in the underlying tables using its equivalent 
LogMAR value.  This allows the user to enter data in the more intuitive Snellen format, and automatically 
convert it to the LogMAR format which is more useful for statistical analysis. 
Where possible the database uses drop-down selection boxes and tick boxes for data entry rather than allowing 
manual typing.  This reduces as far as possible the opportunity for typographical errors in the entered data.  
Drop-down selections are used for fields such as Gender, Race, and lens fit information.  Tick boxes are used 
for all questions that are essentially Boolean in nature – i.e. yes/no or true/false data items. 
Database Workflow 
Data entry follows a simple workflow, starting from the main form used for entering data about each subject.  
The data entry fields are laid out to match the format of the raw data captured in the handwritten forms used 
during examinations. 
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The top-level form is shown below.  It contains basic data about the subject, including the condition of their 
eyes and their own contact lens parameters.  On the right-hand side the buttons can be clicked to open forms 
containing baseline data and results for each phase of the experiment. 
 
 
Figure 1.  Top-level data entry form. 
 
When the buttons on the right-hand side are clicked, the forms that open are set up to show data for the same 
subject as shown in the main form.  This is achieved using LibreOffice Basic macro programming that runs 
when buttons are pressed, and it ensures that data entered on linked forms refers to the correct individual, 
without any effort on the part of the database user.   
For example, when the button on the top right of the above form is clicked, the form shown below opens, 
displaying data for the same used as was selected in the main form.  
 
 
Figure 2.  Baseline Visual Data form. 
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Running Queries 
Queries are run using the SQL database query language.  Although this is fundamentally a text-based query 
language, LibreOffice Base provides a graphical tool to automatically create the SQL commands required to 
pull data out of the database.  Queries can contain parameters to be entered by the user when the query runs, so a 
single query can be used to extract equivalent data for different experimental phases, for example. 
The figure below shows an example of the graphical tool used to create queries.  The top half of the window 
contains tables defined in the database, and the lines drawn between them indicate the relationships between the 
tables (the key feature of this type of software, hence the name relational database).  The bottom half of the 
window shows the fields that will be present in the output data from this query, drawn from the three tables 
included in the query. The database will automatically collate the correct data from the linked fields in the tables 
to generate the result from the query. 
Although the fundamental purpose of queries is to extract subsets of data from the database, some basic data 
manipulation is also used.  This includes: 
splitting the date into separate day/month/year fields so that the date is not presented to analysis tools as a text 
string that has to be processed to pull out the individual fields 
Sorting the data in ascending order of participant ID. 
 
 
Figure 3.  Graphical tool for generating database queries. 
 
Data Analysis 
When a query is run the output is in the form of a table of data.  This is copied and pasted into Excel, for 
example, and it can then be saved to disk and/or used for basic analysis in Excel.  Although Excel is not the 
right tool for complex data analysis, some basic data manipulation is possible. 
Currently an Excel spreadsheet is used for processing VFQ-25 Quality-of-Life data.  An Excel template 
spreadsheet has been created, and raw data from a database query is pasted into the top-left of the first 
worksheet of this template.  Cell calculations then flow from this data and the last worksheet of the spreadsheet 
shows the average scores for each participant, with the raw answers recoded according to Version 2000 of the 
VFQ-25.  
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Appendix IV. B. NEI-VFQ Spreadsheet information 
QoL Spreadsheet Information 
Introduction 
The database contains raw data from the Quality-of-Life questionnaire, with individual answers scored in 
different ranges.  Reference [1] provides an algorithm for recoding these answers onto a scale of 0 to 100, and 
for grouping individual questions together into “sub-scales”. 
The Excel spreadsheet template “QoL Recode” is used to recode the results of Quality-of-Life questionnaire 
according to reference [1].  The steps involved are as follows: 
-Extract raw QoL data from the database and copy into the spreadsheet. 
-Recode individual answers onto a scale of 0 to 100 
-Count how many questions within each ‘sub-scale’ have been answered, so that missing answers can be 
accounted for. 
-Generate average scores for each ‘sub-scale’ 
 
Extracting Raw Data from the Database 
The database has a query called qryQualityOfLife which is used to extract QoL data from the database. Double-
click the query to run it, and enter the experiment for which QoL data is required – one of Baseline, 
Experimental_1, or Experimental_2.   
Copy all the data that appears in the query results window, then paste it into the top-left cell of the first 
worksheet of a new spreadsheet document created from the Excel template “QoL Recode”.  This first worksheet 
is called ‘Raw data’. It is important to paste the data correctly, as all calculations flow from this first page. 
Recoding Individual Answers 
Reference [1] defines how the scores from individual questions map onto the scale of 0 to 100. The second 
worksheet in the spreadsheet (called ‘Recoded data’) implements this recoding, for individual questions.   
The worksheet is split into two sections. The top section runs the recoding calculation for each question, setting 
the result to zero if the answer to the question is missing (this is required as part of the algorithm specified in [1]. 
Accounting for Missing Answers 
The lower section of the worksheet ‘Recoded data’ fills a table with one value for each question – a zero if the 
data is missing for that question, and a one if the data is present.  This data is used when calculating sub-scales, 
so that missing data is handled correctly.  The score for each sub-scale ignores missing data – i.e. the calculation 
has to keep count of how many valid answers are present in each sub-scale.   
Generating Average Scores 
Each sub-scale score is the average of a number of individual questions – i.e. the sum of those individual scores 
divided by the number of scores. The top section of the worksheet ‘Summed data’ contains the summed values, 
taken from the ‘Recoded data’ worksheet.   
Each cell in the top section of the worksheet contains the sum of the question scores for that sub-scale. If a 
question is missing its value is zero in ‘Recoded data’, so it doesn’t affect the average.  Therefore, there’s no 
need to check at this point which individual questions are present. 
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The lower section of the worksheet ‘Summed data’ contains the count of valid answers present for each sub-
scale.  This is done by summing the values for each sub-scale in the lower section of worksheet ‘Recoded data’ 
– where each cell contains a zero if the data is missing and a 1 if it’s present.  Therefore, this sum of ones and 
zeros adds up to the number of valid questions that make up the sub-scale. 
The worksheet ‘Processed data’ pulls all the information together to give the final scores for each sub-scale.  For 
each sub-scale score, the worksheet checks whether there are any valid data for the sub-scale. If not, the cell is 
left blank.  If there is at least one valid answer, the sub-scale is calculated as the sum of the valid answers 
divided by the number of valid answers. 
References 
[1] “The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25)”, Version 2000. 
 
Appendix IV.C. NEI-VFQ data entry, coding and analysis 
The scores from the NEI-VFQ questionnaire were entered into the specially prepared database 
software as raw data, with individual answers scored in different ranges. The NEI-VFQ manual 
(Mangione, 2000) provides an algorithm for recoding these answers onto a scale of 0-100, and 
for grouping individual questions together into “sub-scales”. 
The Excel spread sheet template “QoL Recode” was developed to recode the results of the 
NEI-VFQ questionnaire according to (Mangione, 2000) as follows: 
1. Extract raw QoL data from the database and copy into the spread-sheet. 
2. Recode individual answers onto a scale of 0-100 
3. Count how many questions within each ‘sub-scale’ have been answered, so that 
 missing answers can be accounted for. 
4. Generate average scores for each ‘sub-scale’. 
Data extraction 
The database has a query called qryQualityOfLife which is used to extract NEI-FVQ data from 
the database. The query is run by double-clicking it, entry of the required experimental QoL 
data; one of Baseline, Experimental_1 (first lens in sequence), or Experimental_2 (second lens 
in sequence).  The data that appears in the query results window is copied and pasted into the 
top-left cell of the first worksheet of a new spread sheet document created from the Excel 
template “QoL Recode”. This first worksheet is called ‘Raw data’.  
Recoding individual answers 
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Mangione (2000) defines how the scores from individual questions map onto the scale of 0-
100 (Mangione, 2000). The second worksheet in the spread-sheet (called ‘Recoded data’) 
implements this recoding, for individual questions. The worksheet is split into two sections. 
The top section runs the recoding calculation for each question, setting the result to zero if the 
answer to the question is missing (this is required as part of the algorithm specified in Mangione 
(2000).  
Accounting for missing answers 
The lower section of the worksheet ‘Recoded data’ fills a table with one value for each question 
– a zero if the data are missing for that question, and a one if the data are present.  These data 
are used when calculating sub-scales, so that missing data are handled correctly.  The score for 
each sub-scale ignores missing data – i.e. the calculation has to keep count of how many valid 
answers are present in each sub-scale.  
Generating average scores 
Each sub-scale score is the average of a number of individual questions (Table 4.6) – i.e., the 
sum of those individual scores divided by the number of scores. The top section of the 
worksheet ‘Summed data’ contains the summed values, taken from the ‘Recoded data’ 
worksheet.  Each cell in the top section of the worksheet contains the sum of the question scores 
for that sub-scale. If a question is missing its value is zero in ‘Recoded data’, so it doesn’t affect 
the average. The lower section of the worksheet ‘Summed data’ contains the count of valid 
answers present for each sub-scale. This is done by summing the values for each sub-scale in 
the lower section of worksheet ‘Recoded data’ – where each cell contains a zero if the data are 
missing and a 1 if it the data are present. Therefore, this sum of ones and zeros forms the 
number of valid questions that make up the sub-scale. The worksheet ‘Processed data’ pulls all 
the information together to give the final scores for each sub-scale.  For each sub-scale score, 
the worksheet checks whether there are any valid data for the sub-scale. If not, the cell is left 
blank. If there is at least one valid answer, the sub-scale is calculated as the sum of the valid 
answers divided by the number of valid answers.  
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Appendix IV. D. Table 4.7. The Efron grading scales contact lens complications (J&J 
vision care institute) 
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Appendix V 
Appendix V.A. Table 5.27.a OD/OS averages of the CS numerical scores for CRGPcl and 
SRGPcl 
  CRGPcl   SRGPcl 
SN 3 CPD 6 CPD 12 CPD 18 CPD   3 CPD 6 CPD 12 CPD 18 CPD 
1 5.34 5.00 5.67 5.17   4.34 3.67 4.50 4.67 
2 4.84 5.00 5.50 6.00   5.50 5.50 6.00 6.67 
3 5.34 5.17 4.67 5.34   3.17 3.50 3.17 3.00 
4 4.00 4.67 5.33 5.00   6.00 4.33 5.67 6.67 
5 4.00 4.00 3.67 4.67   3.00 3.67 3.33 3.00 
6 5.84 4.84 4.67 4.33   6.00 4.50 4.50 4.33 
7 5.00 5.34 4.67 5.50   4.84 5.17 5.50 5.50 
8 6.00 5.00 4.67 4.00   6.00 4.33 5.67 5.33 
9 5.84 6.50 4.00 3.50   5.50 4.50 3.83 4.50 
10 5.33 3.34 2.00 2.17   3.67 1.67 4.83 3.67 
11 3.84 3.84 4.50 2.50   4.67 5.00 3.50 3.33 
12 5.50 4.17 4.34 3.34   4.34 4.34 4.17 4.67 
13 4.67 4.67 5.50 5.84   5.00 5.17 3.17 5.34 
14 5.84 4.50 4.67 3.17   3.50 4.00 2.00 2.50 
15 7.00 7.17 6.34 7.50   6.17 6.33 6.34 6.34 
16 6.84 5.17 3.33 4.17   5.50 5.67 5.50 6.17 
17 6.84 7.33 7.84 7.84   5.67 5.84 6.17 7.17 
19 6.00 5.50 4.50 4.84   5.00 5.00 5.00 5.00 
20 5.33 5.84 5.50 5.84   5.50 4.50 5.00 5.00 
21 6.50 5.34 4.67 2.34   6.84 5.34 6.17 4.50 
23 3.84 2.84 3.00 3.00   3.50 3.17 1.00 2.00 
24 6.50 6.50 6.50 5.67   6.84 5.33 6.67 5.17 
26 6.00 5.67 6.00 7.00   6.00 6.33 6.33 7.33 
27 5.50 4.50 4.84 5.00   6.17 3.34 6.00 4.84 
28 6.17 4.67 4.17 4.00   6.00 4.33 4.00 4.34 
30 6.00 6.00 6.67 7.00   5.50 5.84 5.50 5.84 
31 6.50 5.17 7.00 5.00   6.50 5.34 7.17 5.34 
32 4.67 4.50 2.67 2.67   6.17 4.67 3.34 2.83 
33 4.84 3.17 3.34 2.84   5.17 3.17 4.17 3.50 
34 6.83 6.17 6.50 4.84   5.00 3.67 4.00 3.67 
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Appendix V. B. Table 5.35 Period sums and differences of means of all domains of NEI-
VFQ in group 1&2  
Group 1   Group 2 
SN P1 P2 P1+P2 P2-P1 A-B   SN P1 P2 P1+P2 P2-P1 A-B 
1 94.58 84.62 179.20 -9.97 9.97   3 88.40 90.35 178.75 1.94 1.94 
2 96.53 96.11 192.64 -0.42 0.42   4 83.13 96.32 179.44 13.19 13.19 
5 72.74 56.04 128.78 -16.70 16.70   6 94.31 88.47 182.78 -5.83 -5.83 
7 90.87 90.94 181.81 0.07 -0.07   8 94.83 90.49 185.31 -4.34 -4.34 
10 91.46 94.65 186.11 3.19 -3.19   9 82.80 48.14 130.95 -34.66 -34.66 
11 93.71 88.30 182.01 -5.42 5.42   12 78.61 80.10 158.72 1.49 1.49 
13 97.50 99.17 196.67 1.67 -1.67   15 76.84 88.68 165.52 11.84 11.84 
14 75.76 79.66 155.42 3.90 -3.90   16 94.10 88.26 182.36 -5.83 -5.83 
20 89.62 96.39 186.01 6.77 -6.77   17 89.93 94.79 184.72 4.86 4.86 
23 76.22 70.49 146.70 -5.73 5.73   19 97.36 97.95 195.32 0.59 0.59 
28 89.44 95.45 184.90 6.01 -6.01   21 80.98 76.67 157.65 -4.32 -4.32 
31 83.19 93.06 176.25 9.86 -9.86   24 85.66 92.47 178.13 6.81 6.81 
33 90.28 92.60 182.88 2.33 -2.33   26 81.18 62.57 143.75 -18.61 -18.61 
        27 86.18 86.04 172.22 -0.14 -0.14 
        30 96.32 94.58 190.90 -1.74 -1.74 
        32 69.77 55.23 125.00 -14.55 -14.55 
        34 74.41 69.51 143.92 -4.90 -4.90 
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Appendix V. C. Subjective comfort and vision of participants in group 1, period 1 vs period 2 
C  
Figure 5.43 Subjective comfort of each participant in group 1, period 1 vs period 2 
 
 
Figure 5.44 Subjective comfort of each participant in group 2, period 1 vs period 2 
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Figure 5.45 Subjective vision of each participant in group 1, period 1 vs period 2 
 
 
Figure 5.46 Subjective vision of each participant in group 2, period 1 vs period 2 
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Appendix V. D. Table 5.40 SPC and vision CRGPcl and final lens choice 
SN Comfort Vision Final lens choice 
1 8 10 CRGPcl 
2 8 8 SRGPcl 
3 7 7 CRGPcl 
4 8 7 CRGPcl 
5 9 8 CRGPcl 
6 4 9 SRGPcl 
7 7 7 CRGPcl 
8 9 9 CRGPcl 
9 5 6 SRGPcl 
10 7.5 9 SRGPcl 
11 8 6.5 SRGPcl 
12 7 7 SRGPcl 
13 9 10 CRGPcl 
14 9 7 CRGPcl 
15 9 4 CRGPcl 
16 6.5 6.5 SRGPcl 
17 10 9 CRGPcl 
19 10 9 CRGPcl 
20 7 10 SRGPcl 
21 6 9 SRGPcl 
23 7.5 7 SRGPcl 
24 8 9 CRGPcl 
26 6 8 SRGPcl 
27 7 8 CRGPcl 
28 7 10 CRGPcl 
30 9 9 CRGPcl 
31 9 9 SRGPcl 
32 7 8 SRGPcl 
33 10 6.5 SRGPcl 
34 9 6.5 CRGPcl 
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Appendix V. E Table 4.10. Randomisation order 
Number Randomised to Comments 
1 C  
2 C  
3 S  
4 S  
5 C  
6 S  
7 C  
8 S  
9 S  
10 C  
11 C  
12 S  
13 C  
14 C  
15 S  
16 S  
17 S  
18 C Lost to aftercare 
19 S  
20 C  
21 S  
22 C Lost to aftercare 
23 C  
24 S  
25 C Lost to aftercare 
26 S  
27 S  
28 C  
29 C Lost to aftercare 
30 S  
31 C Sequential  
32 S Sequential  
33 C Sequential  
34 S Sequential  
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Appendix V. F. Table 4.5. Item number translation from the 51-Item field test version to the 
VFQ 25 Mangione (2000). 
Field Test Sub-scale Status VFQ-25 Field Test Sub-scale Status VFQ-25 
1 General health S 1 29 Social Function ----- ----- 
2 General health A A1 30 Social Function A A9 
3 General vision S 2 31 Social Function S 13 
4 Expectations ----- ----- 32 Distance Vision A A8 
5 Wellbeing/distress S 3 33 Distance Vision A A7 
6 Wellbeing/distress ----- ----- 34 Distance Vision S 14 
7 Ocular pain S 19 35 Driving (filter item) S 15 
8 expectations ----- ----- 35a Driving (filter item) S 15a 
9 expectations ----- ----- 35b Driving (filter item) S 15b 
10 expectations ----- ----- 35c Driving  S 15c 
11 Wellbeing/distress S 25 36 Driving ----- ----- 
12 Ocular Pain S 4 37 Driving S 16 
13 Wellbeing/distress ----- ----- 38 Driving S 16a* 
14 General Vision A A2 39a Role limitations S 17 
15 Near Vision S 5 39b Role limitations A A11a 
16 Near Vision A A3 39c Well-being/distress ----- ----- 
17 Near Vision S 6 39d Role limitations ----- ----- 
18 Near Vision ----- ----- 39e Role limitations A A11b 
19 Near Vision S 7 39f Role limitations S 18 
20 Distance Vision S 8 40 Well-being/distress A A12 
21 Distance Vision ----- ----- 41 Dependency S 20 
22 Distance Vision S 9 42 Well-being/distress S 21 
23 Peripheral Vision S 10 43 Well-being/distress S 22 
24 Distance Vision A A6 44 Dependency ----- ----- 
25 Social Function S 11 45 Dependency A A13 
26 Near Vision A A4 46 Dependency S 23 
27 Colour Vision S 12 47 Dependency S 24 
28 Near Vision A A5         
 
Table 45. Terms: S=retained in the VFQ-25, A=retained in the appendix should be used for the 
VFQ-39, -----=deleted from the VFQ-25 & VFQ-39. *=VFQ-25 item 16a was listed in previous 
versions as part of the appendix of supplemental items (#A10). 
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Appendix V. G. Table 5.33 OD/OS logCS, 6CPD scores and period sums and differences 
group 1 and 2 
6 CPD Sums and Differences 
Group 1 (AB) CS 6 CPD   Group 2 (BA) CS 6 CPD  
P1(A) P2(B) P1+P2 P2-P1 A-B   P1(B) P2(A) P1+P2 P2-P1 A-B 
1.79 1.69 3.48 -0.10 0.10   1.80 1.70 3.50 -0.10 -0.10 
1.84 1.92 3.76 0.08 -0.08   1.75 1.79 3.54 0.04 0.04 
1.70 1.65 3.35 -0.05 0.05   1.77 1.82 3.59 0.05 0.05 
1.79 1.97 3.76 0.18 -0.18   1.74 1.84 3.58 0.10 0.10 
1.41 1.50 2.90 0.09 -0.09   1.84 1.99 3.83 0.15 0.15 
1.84 1.67 3.51 -0.17 0.17   1.77 1.70 3.47 -0.07 -0.07 
1.84 1.82 3.66 -0.02 0.02   2.12 2.09 4.21 -0.03 -0.03 
1.77 1.70 3.47 -0.08 0.08   1.82 1.99 3.81 0.17 0.17 
1.94 1.79 3.73 -0.15 0.15   2.07 2.09 4.16 0.02 0.02 
1.73 1.33 3.06 -0.40 0.40   1.85 1.92 3.76 0.07 0.07 
1.75 1.79 3.54 0.04 -0.04   1.87 1.92 3.78 0.05 0.05 
1.80 1.97 3.76 0.17 -0.17   1.99 1.97 3.96 -0.02 -0.02 
1.55 1.59 3.14 0.04 -0.04   2.04 1.94 3.98 -0.10 -0.10 
       1.48 1.87 3.34 0.39 0.39 
       1.99 1.97 3.96 -0.03 -0.03 
       1.78 1.79 3.57 0.02 0.02 
       1.64 2.02 3.65 0.38 0.38 
 
Appendix V. H. Table 5.26 Numeric CS scores of the research population 
 CSF Numeric Scale   Statistic Std. Error 
3 CPD Median 6.0  
Shapiro-Wilk (p<0.0001) Interquartile Range 1.0  
 Mean 5.48 0.12 
 95% CI for Mean 5.25-5.72  
  Std. Deviation 1.25  
  Skewness -0.59 0.23 (z=-2.59) 
  Kurtosis 1.67 0.45 (z=3.68) 
 6 CPD  Median 5.0  
Shapiro-Wilk (p<0.0001)  Interquartile Range 2.0  
 Mean 4.98 0.15 
 95% CI for Mean 4.70-5.27  
  Std. Deviation 1.53  
  Skewness -0.49 0.23 (z=-2.16) 
  Kurtosis 0.51 0.45 (z=1.12) 
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12 CPD Median 5.0  
Shapiro-Wilk (p=0.0001) Interquartile Range 2.0  
 Mean 4.89 0.18 
 95% CI for Mean 4.53-5.26  
  Std. Deviation 1.94  
  Skewness -0.38 0.23 (z=-1.68) 
  Kurtosis -0.37 0.45 (z=-0.83) 
18 CPD Median 5.0  
 Shapiro-Wilk (p=0.0002) Interquartile Range 2.0  
 Mean 4.79 0.18 
 95% CI for Mean 4.44-5.13  
  Std. Deviation 1.86  
  Skewness -0.23 0.23 (z=-1.01) 
  Kurtosis -0.57 0.45 (z=-1.26) 
 
 
Appendix V.I. Table 5.34 NEI-VFQ 12 domains measured in the research population 
NEI-VFQ Descriptive Statistics 
  Shapiro-Wilk   Median IQR Min Max Mean (StdDev) 
General health p < 0.0001 77.50 5.00 45.00 100.00 79.59 (±12.45) 
General vision p < 0.0001 80.00 20.00 30.00 100.00 82.45 (±14.37) 
Ocular pain p < 0.0001 87.50 37.50 37.00 100.00 77.55 (±21.19) 
Near activities p < 0.0001 91.67 18.75 50.00 100.00 87.84 (±12.89) 
Distance activities p < 0.0001 91.67 20.83 50.00 100.00 87.96 (±12.38) 
Social function p < 0.0001 100.00 8.33 66.67 100.00 94.56 (±9.40) 
Mental health p < 0.0001 90.00 20.00 40.00 100.00 82.25 (±16.04) 
Role difficulties P< 0.0001 93.75 21.88 43.75 100.00 87.88 (±14.51) 
Dependency p < 0.0001 100.00 6.25 50.00 100.00 95.54 (±9.11) 
Driving p < 0.0001 83.33 16.67 41.67 100.00 84.18 (±13.53) 
Colour vision p < 0.0001 100.00 0.00 50.00 100.00 97.96 (±8.60) 
Peripheral vision p < 0.0001 100.00 0.00 25.00 100.00 91.84 (±17.22) 
Total  91.29 14.60 44.09 100.00 87.47 (±6.53) 
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Appendix V.J. 
Table 5.43a Randomised demographics (*significant difference between the groups) 
Measure  Groups 
Difference 
p value  
  Group 1 Group 2   
 
  N Mean 
(StdDev) 
Median 
(IQR) 
N Mean 
(StdDev) 
Median 
(IQR) 
  
Gender  
Male 11   12  
 
0.109 
Female 2   5  
 
Age 
  
39.5 (14.2)   38.8 (9.3)  0.872 
Age at 
Diagnosis 
  
23.2 (5.0)    20.0 (8.0) 0.363 
Duration 
CRGPcl 
wear 
  10.0 (22.0)  16.47 (6.63)  0.363 
 
Black 
African 
3   2 
  
0.613 
Ethnicities Asian Indian 5 
  8 
  
 Black Afro 
Caribbean 
1   2 
  
 Caucasian 
white 
4   5 
  
Corneal 
metrics 
  
Kmax 
 
6.04 (0.47) 
  
6.31 (0.59) 
 
0.068 
*Pachymetry 
 
423.2 (45.1) 
  
462.8 (44.7) 
 
*0.002 
SRI 
 
1.59 (0.24) 
   
1.47 (0.48) 0.252 
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Appendix V. K 
Table 5.43b Inferential crossover statistics summary   
    Group 1   Group 2     
Measure  Mean (StdDev) Median (IQR) Mean (StdDev) Median (IQR)    P 
 
ETDRS logMAR 
Treatment effect  -0.01 (0.08)  0.00 (0.10) 
0.563 
 
Carryover effect  0.14 (0.27)  0.03 (0.17) 
0.281 
 
Period effect 0.0177 (0.08)  0.0006 (0.07)  
0.541 
 
CSF logCS all CPD 
Treatment effect crossover -0.035 (0.215)  0.03 (0.135)  
0.316 
 
Treatment effect P1 (G1) 1.46 (0.13)    0.070  
Treatment effect P1 (G2) 1.56 (0.51)     
Carryover effect 2.89 (0.31)  3.15 (0.25)  
0.019* 
 
Period effect  0.05 (0.24)  0.00 (0.12) 
0.711 
 
CSF logCS 6 CPD 
Treatment effect crossover -0.0285 (0.16)  0.0641 (0.14)  0.104  
Treatment effect P1 (G1) 1.75 (0.17)    0.110  
Treatment effect P1 (G2) 1.84 (0.16)     
NEI-VFQ all Domains 
Treatment effect  1.67 (10.53)  -1.74 (9.23) 0.483  
Carryover effect  182.0 (20.23)  178.1 (32.97) 0.245  
Period effect -0.92 (1.37)  -1.235 (1.98)  0.343  
NEI-VFQ Ocular pain 
Treatment effect  12.5 (37.5)  0.00 (25.0) 0.170  
Carryover effect  175 (56.25)  150.0 (75.0) 0.263  
Period effect  0.02 (0.21)  0.04 (0.16) 0.563  
LSCS Treatment effect  1.0 (2.25)  -1.0 (2.50) 0.002*  
 
Carryover effect  17.0 (1.50)  16.0 (4.0) 0.183  
 
Period effect -0.923 (±1.37)  -1.235 (1.98)  0.63  
LSVS 
Treatment effect  0.00 (0.50)  -0.50 (1.75) 0.213  
Carryover effect  16.0 (4.75)  16.0 (3.25) 0.592  
Period effect  0.00 (0.50)  -0.50 (1.75) 0.157  
Final lens choice 
CRGPcl  16 (53.3%)      
SRGPcl  14 (46.7%)      
LSCS CRGPcl 
CRGPcl chosen 16 (53%) Median (IQR) 9.0 (1.75) 
0.009*  
SRGPcl chosen 14 (46.7%) Median (IQR) 7.0 (1.54)  
 
*Statistically significant p<0.05 
